

CITATION REPORT

List of articles citing

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America

DOI: 10.1086/596757

Clinical Infectious Diseases, 2009, 48, 503-35.

Source: <https://exaly.com/paper-pdf/46632677/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2308	The vanB2 gene cluster of the majority of vancomycin-resistant <i>Enterococcus faecium</i> isolates from Taiwan is associated with the <i>pbp5</i> gene and is carried by Tn5382 containing a novel insertion sequence. 2005 , 49, 3937-9		13
2307	Anidulafungin and its role in candida infections. 2009 , 2, 51-60		3
2306	Current Status of Antifungal Susceptibility Testing: Methods and Clinical Application. 2009 , 12, 154		
2305	Pharmacotherapy of Candida Infections with Echinocandins. 2009 , 1, CMT.S2311		4
2304	Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1695-703	11.6	691
2303	Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for <i>Aspergillus</i> infections. 2009 , 64, 840-4		12
2302	Prevalence, distribution, and antifungal susceptibility profiles of <i>Candida parapsilosis</i> , <i>C. orthopsilosis</i> , and <i>C. metapsilosis</i> in a tertiary care hospital. 2009 , 47, 2392-7		94
2301	Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. 2009 , 64, 625-9		71
2300	In vitro activity of seven systemically active antifungal agents against a large global collection of rare <i>Candida</i> species as determined by CLSI broth microdilution methods. 2009 , 47, 3170-7		94
2299	Infectious Disease in the Aging. 2009 ,		
2298	Neonatal peritoneal candidiasis successfully treated with anidulafungin add-on therapy. 2009 , 43, 1907-10		13
2297	Report from the European Congress of Clinical Microbiology and Infectious Diseases. 2009 , 4, 783-7		
2296	[Infectiology and tropical medicine 2009]. 2009 , 134, 1343-8		0
2295	Ophthalmic manifestation of <i>Candida</i> : case report and review of the literature. 2009 , 19, 197-9		1
2294	Echinocandin-based initial therapy in fungemic patients with cancer: a focus on recent guidelines of the infectious diseases society of america. <i>Clinical Infectious Diseases</i> , 2009 , 49, 638-9; author reply 639-40	11.6	19
2293	<i>Candida albicans</i> meningitis with ventriculitis in a four-year-old child. 2009 , 57, 682-4		2
2292	Clinical outcomes of dialysis catheter-related candidemia in hemodialysis patients. 2009 , 4, 1102-5		17

2291	Reply to Kontoyiannis. <i>Clinical Infectious Diseases</i> , 2009 , 49, 639-640	11.6	2
2290	Variation in susceptibility of bloodstream isolates of <i>Candida glabrata</i> to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. 2009 , 47, 3185-90		97
2289	Cefepime and all-cause mortality. <i>Clinical Infectious Diseases</i> , 2009 , 49, 640-1; author reply 641-2	11.6	3
2288	Molecular identification and susceptibility of <i>Trichosporon</i> species isolated from clinical specimens in Qatar: isolation of <i>Trichosporon dohaense</i> Taj-Aldeen, Meis & Boekhout sp. nov. 2009 , 47, 1791-9		58
2287	Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Clinical Infectious Diseases</i> , 2009 , 49, 1226-36	11.6	44
2286	Invasive candidiasis and candidemia: from current opinions to future perspectives. 2009 , 18, 735-48		27
2285	<i>Candida</i> in solid organ transplant recipients. 2009 , 9 Suppl 4, S173-9		73
2284	[Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients]. 2009 , 26, 69-74		2
2283	[Micafungin in invasive candidiasis among oncohematological patients]. 2009 , 26, 75-7		1
2282	Antifungal prophylaxis in liver transplant recipients. 2009 , 15, 842-58		52
2281	Prophylaxis of invasive mycoses in solid organ transplantation. 2009 , 11, 427-34		3
2280	Optimal dosing of fluconazole for treatment of candidemia. 2009 , 3, 63-65		
2279	The role of adjuvant agents in treating fungal diseases. 2009 , 3, 117-126		
2278	Head-to-head comparison of micafungin versus caspofungin in the treatment of invasive candidiasis. 2009 , 3, 127-128		
2277	Fungemia associated with left ventricular assist device support. 2009 , 24, 763-5		36
2276	Abstracts of the 4th Trends in Medical Mycology. October 18-21, 2009. Athens, Greece. 2009 , 52 Suppl 1, 1-128		52
2275	Invasive fungal infections in the paediatric and neonatal population: diagnostics and management issues. 2009 , 15, 613-24		39
2274	Microbiological, clinical, and surgical features of fungal prosthetic joint infections: a multi-institutional experience. 2009 , 91 Suppl 6, 142-9		150

2273	Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1-45	11.6	2312
2272	Determinants of mortality in non-neutropenic ICU patients with candidaemia. 2009 , 13, R115		68
2271	Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. 2009 , 13, R159		43
2270	In vitro efficacy of 5 antifungal agents against <i>Candida parapsilosis</i> , <i>Candida orthopsilosis</i> , and <i>Candida metapsilosis</i> as determined by time-kill methodology. 2009 , 64, 283-8		14
2269	Time to positive culture and identification for <i>Candida</i> blood stream infections. 2009 , 64, 402-7		70
2268	[Antifungals for systemic use]. 2009 , 27, 353-62		5
2267	Echinocandins: the newest class of antifungals. 2009 , 43, 1647-57		137
2266	Consensus statement on the management of invasive candidiasis in Intensive Care Units in the Asia-Pacific Region. 2009 , 34, 205-9		39
2265	Efficacy of a new formulation of amphotericin B in murine disseminated infections by <i>Candida glabrata</i> or <i>Candida tropicalis</i> . 2009 , 34, 566-9		5
2264	[Combined antifungal therapy. Treatment success in a case of mural endocarditis due to <i>Candida glabrata</i>]. 2009 , 71, 368-9		1
2263	Short-course therapy for bloodstream infections in immunocompetent adults. 2009 , 34 Suppl 4, S47-51		14
2262	Antifungal activity of thymol against clinical isolates of fluconazole-sensitive and -resistant <i>Candida albicans</i> . 2009 , 58, 1074-1079		65
2261	Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. 2009 , 69, 361-92		219
2260	Overview of the changing epidemiology of candidemia. 2009 , 25, 1732-40		64
2259	Clinical aspects of invasive candidiasis in solid organ transplant recipients. 2009 , 69 Suppl 1, 15-20		23
2258	Clinical aspects of invasive candidiasis in critically ill patients. 2009 , 69 Suppl 1, 21-8		9
2257	Clinical aspects of invasive candidiasis in the surgical patient. 2009 , 69 Suppl 1, 29-32		7
2256	Candidaemia in patients with an inserted medical device. 2009 , 69 Suppl 1, 33-8		37

2255	Clinical aspects of invasive candidiasis: endocarditis and other localized infections. 2009 , 69 Suppl 1, 39-43	18
2254	Clinical aspects of invasive candidiasis in paediatric patients. 2009 , 69 Suppl 1, 45-50	10
2253	Treatment strategies for oropharyngeal candidiasis. 2009 , 10, 1413-21	17
2252	Caspofungin: in pediatric patients with fungal infections. 2009 , 11, 259-69	9
2251	The Infectious Diseases Society of America (IDSA) has updated its guidelines for the management of candidiasis. 2009 , 574, 3-3	
2250	Recent advances in antifungal prevention and treatment. 2009 , 46, 212-29	41
2249	Advances and challenges in infectious diseases supportive care of patients with hematologic malignancies, hematopoietic stem cell transplantation, and severe aplastic anemia. 2009 , 46, 191-7	5
2248	Fungal infections in hematopoietic stem cell transplantation and solid-organ transplantation--focus on aspergillosis. 2009 , 30, 295-306, vii	20
2247	Nephrotoxicity associated with amphotericin B deoxycholate in neonates. 2009 , 28, 1061-3	34
2246	Issues in the design and interpretation of antifungal drug trials in the critically ill. 2009 , 22, 564-7	5
2245	Invasive fungal infections in children. 2009 , 28, 734-7	37
2244	Current World Literature. 2009 , 22, 410-422	
2243	Prevention and treatment of invasive fungal diseases in neutropenic patients. 2009 , 22, 385-93	32
2242	Candidémie et candidose généralisée. 2010 , 7, 1-25	
2241	Antimicrobial resistance: consideration as an adverse drug event. 2010 , 38, S155-61	11
2240	Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. 2010 , 38, 826-30	38
2239	Prophylaxis, empirical and preemptive treatment of invasive candidiasis. 2010 , 16, 470-4	26
2238	Changing trends in the epidemiology of Candida blood stream infections: a matter for concern?. 2010 , 38, 990-2	13

2237	Recognition and prevention of nosocomial invasive fungal infections in the intensive care unit. 2010 , 38, S380-7	15
2236	Supportive care in children. 2010 , 22, 323-9	9
2235	<i>Pseudomonas aeruginosa</i> and <i>Candida</i> Species Interaction, an Approach for the Prevention of Nosocomial Pneumonia. 2010 , 17, 136-139	
2234	Early mannan detection in bronchoalveolar lavage fluid with preemptive treatment reduces the incidence of invasive <i>Candida</i> infections in preterm infants. 2010 , 29, 844-8	11
2233	Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: a prospective multicenter evaluation. 2010 , 29, 816-21	39
2232	Early antifungal intervention strategies in ICU patients. 2010 , 16, 465-9	21
2231	Invasive candidiasis in critically ill patients: does progressing knowledge improve clinical management and outcome?. 2010 , 16, 442-4	6
2230	Epidemiology of invasive candidiasis. 2010 , 16, 445-52	245
2229	Current world literature. 2010 , 16, 516-22	
2228	Th17 cells, Job's syndrome and HIV: opportunities for bacterial and fungal infections. 2010 , 5, 179-83	42
2227	Prophylaxis of invasive fungal diseases in patients with hematologic disorders. 2010 , 95, 1630-2	6
2226	Opportunistic fungi: a view to the future. 2010 , 340, 253-7	30
2225	Diagnostic challenges in native valve fungal endocarditis producing a massive septic pulmonary embolus. 2010 , 51, 207-10	7
2224	Fungal infections in leukemia patients: how do we prevent and treat them?. <i>Clinical Infectious Diseases</i> , 2010 , 50, 405-15	11.6 109
2223	<i>Candida tropicalis</i> in human disease. 2010 , 36, 282-98	71
2222	Invasive fungal infections in the ICU. 2010 , 25, 78-92	35
2221	[Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine]. 2010 , 59, 30-52	7
2220	[Results of studies in critical care medicine in the year 2009 : update]. 2010 , 59, 453-76	

2219	A systematic review of oral fungal infections in patients receiving cancer therapy. 2010 , 18, 985-92	146
2218	Prophylaxis Versus a Preemptive Approach for Invasive Aspergillosis. 2010 , 4, 30-37	
2217	Antifungal Therapy in Pregnancy and Breastfeeding. 2010 , 4, 62-69	5
2216	Antifungal Dosing in Critically Ill Patients. 2010 , 4, 78-86	3
2215	Antifungal Drug Resistance: Clinical Relevance and Impact of Antifungal Drug Use. 2010 , 4, 129-136	4
2214	Antifungal Dose Adjustment in Renal and Hepatic Dysfunction: Pharmacokinetic and Pharmacodynamic Considerations. 2010 , 4, 120-128	11
2213	Antifungal Distribution Into Cerebrospinal Fluid, Vitreous Humor, Bone, and Other Difficult Sites. 2010 , 4, 111-119	10
2212	Safety and Efficacy Data for High-Dose Caspofungin. 2010 , 4, 59-61	1
2211	Use of Antifungal Combination Therapy: Agents, Order, and Timing. 2010 , 4, 87-95	63
2210	Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and Candida: Time for New Clinical Breakpoints?. 2010 , 4, 168-174	11
2209	Antifungal Therapeutic Drug Monitoring. 2010 , 4, 158-167	20
2208	Yeast Infections of the Lower Urinary Tract: Recommendations for Diagnosis and Treatment. 2010 , 4, 175-178	2
2207	Nanosuspension formulation of itraconazole eliminates the negative inotropic effect of SPORANOX in dogs. 2010 , 6, 331-6	11
2206	Fungal infections after hematopoietic stem cell transplantation. 2010 , 91, 576-87	18
2205	Candida-Infektionen [Diagnose und Therapie. 2010 , 5, 19-30	
2204	Echinocandin antifungal drug resistance in Candida species: a cause for concern?. 2010 , 12, 437-43	10
2203	Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008. 2010 , 76, 46-51	36
2202	Continuing Medical Education Questionnaire. 2010 , 156, A1-S86	

2201 Evaluation Form. **2010**, 156, A1-S86

2200 Pediatric Fungal Infections: A Conundrum in Children. **2010**, 156, A1-S86

1

2199 Neonatal Candidiasis: Clinical Manifestations, Management, and Prevention Strategies. **2010**, 156, A1-S86

4

2198 Fungal Infections in Pediatric Immunocompromised Patients: Epidemiology, Principles of Treatment, and Promising Antifungal Agents. **2010**, 156, A1-S86

1

2197 Invasive Fungal Infections in Children with Cancer. **2010**, 156, A1-S86

6

2196 Anticandidal activity of the essential oils of *Thymus maroccanus* and *Thymus broussonetii* and their synergism with amphotericin B and fluconazol. **2010**, 17, 1057-60

57

2195 [Susceptibility to fluconazole and voriconazole of *Candida* species isolated from intensive care units patients in Medellin, Colombia (2001-2007)]. **2010**, 27, 125-9

15

2194 Comparative efficacy of echinocandins and nonechinocandins for the treatment of *Candida parapsilosis* Infections: a meta-analysis. **2010**, 30, 1207-13

26

2193 Hospital resource utilization and costs of inappropriate treatment of candidemia. **2010**, 30, 361-8

74

2192 Once-weekly liposomal amphotericin B as *Candida* prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study. **2010**, 32, 265-71

16

2191 Cost and resource utilization associated with fluconazole as first-line therapy for invasive candidiasis: a retrospective database analysis. **2010**, 32, 2467-77

9

2190 Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis. **2010**, 32, 2207-17

9

2189 Table of Contents. **2010**, 156, A1-S86

2188 Guidelines for Publication of Supplements. **2010**, 156, A1-S86

2187 Faculty Disclosures. **2010**, 156, A1-S86

2186 Invasive Fungal Infections in Pediatric Patients: Challenges to Optimal Management. **2010**, 156, A1-S86

2185 Diagnostic challenges and recent advances in the early management of invasive fungal infections. **2010**, 84, 281-90

32

2184 Nosocomial candidemia in adults: Risk and prognostic factors. **2010**, 20, 269-278

5

2183	Spectrométrie de masse MALDI-TOF, un nouvel outil que la mycologie médicale ne peut contourner. Exploration préliminaire d'une application concernant l'identification de levures isolées dans un CHU français. 2010 , 20, 263-267	0
2182	Micafungine. 2010 , 20, 194-205	1
2181	Caspofungine. 2010 , 20, 190-193	2
2180	Injectable in situ cross-linking hydrogels for local antifungal therapy. 2010 , 31, 1444-52	113
2179	Current therapeutic approaches to fungal infections in immunocompromised hematological patients. 2010 , 24, 51-61	43
2178	A focus on intra-abdominal infections. 2010 , 5, 9	104
2177	Oral candidiasis and angular cheilitis. 2010 , 23, 230-42	65
2176	Caspofungin for the treatment of candidaemia in patients with haematological malignancies. 2010 , 16, 298-301	4
2175	Eleven-year retrospective survey of candidaemia in a university hospital in southwestern Greece. 2010 , 16, 1378-81	15
2174	Epidemiology of invasive fungal infections in neonates and children. 2010 , 16, 1321-7	48
2173	Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy. 2010 , 34, 1063-75	36
2172	Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy. 2010 , 16, 774-80	104
2171	Potential impact of rapid diagnostic tests on improving antimicrobial use. 2010 , 1213, 70-80	25
2170	[Therapy of candidemia and invasive candidiasis according to guidelines]. 2010 , 53 Suppl 1, 30-5	2
2169	Fungal infections in burns: Diagnosis and management. 2010 , 43, S37-S42	11
2168	Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives. 2010 , 4, 121-35	98
2167	Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence. 2010 , 6, e1000753	42
2166	Rapid species diagnosis for invasive candidiasis using mass spectrometry. 2010 , 5, e8862	76

2165	Role of posaconazole in the treatment of oropharyngeal candidiasis. 2010 , 3, 45-51		4
2164	Canadian clinical practice guidelines for invasive candidiasis in adults. 2010 , 21, e122-50		41
2163	Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections. 2010 , 2, 27-38		10
2162	Current strategies for the prevention and management of central line-associated bloodstream infections. 2010 , 3, 147-63		21
2161	Interactions between human phagocytes and <i>Candida albicans</i> biofilms alone and in combination with antifungal agents. 2010 , 201, 1941-9		82
2160	Reply to Koh and Luong and to Shaked et al. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1348-1350	11.6	1
2159	Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid. 2010 , 54, 943-4		21
2158	Caspofungin-non-susceptible <i>Candida</i> isolates in cancer patients. 2010 , 65, 293-5		34
2157	Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1147-56	11.6	68
2156	Caspofungin use in patients with invasive candidiasis caused by common non- <i>albicans</i> <i>Candida</i> species: review of the caspofungin database. 2010 , 54, 1864-71		36
2155	A noninvasive renal fungus ball caused by <i>Rhizopus</i> --a previously unreported manifestation of zygomycosis. 2010 , 48, 866-9		8
2154	Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study. 2010 , 48, 3153-7		26
2153	Invasive candidiasis and the utility of antifungal susceptibility testing in the ICU. 2010 , 23, 33-7		1
2152	Fungicidal activity of anidulafungin in serum from patients does not correlate to its susceptible breakpoint against <i>Candida</i> spp. 2010 , 65, 374-6		3
2151	<i>Candida</i> meningitis post Gliadel wafer placement successfully treated with intrathecal and intravenous amphotericin B. 2010 , 44, 215-8		7
2150	Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and <i>Candida</i> spp. 2010 , 48, 52-6		136
2149	Antifungal susceptibility of 205 <i>Candida</i> spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods. 2010 , 48, 154-61		36
2148	Should the guidelines for management of central venous catheters in patients with candidemia be changed now?. <i>Clinical Infectious Diseases</i> , 2010 , 51, 304-6	11.6	13

2147	Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?. 2010 , 65, 1460-5	69
2146	A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. 2010 , 65, 1765-70	46
2145	Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. 2010 , 48, 1270-5	69
2144	Efficacy of posaconazole in a murine disseminated infection by Candida tropicalis. 2010 , 54, 530-2	7
2143	A clinical review of echinocandins in pediatric patients. 2010 , 44, 166-77	31
2142	Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates. 2010 , 54, 4041-3	3
2141	Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. 2010 , 54, 1360-2	89
2140	Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. 2010 , 54, 1347-50	13
2139	Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. 2010 , 54, 3432-41	43
2138	Recognition of yeast by murine macrophages requires mannan but not glucan. 2010 , 9, 1776-87	65
2137	Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. 2010 , 65, 1042-51	129
2136	Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. <i>Clinical Infectious Diseases</i> , 2010 , 51, 295-303	11.6 177
2135	Fungal infections in burns: Diagnosis and management. 2010 , 43, S37-42	29
2134	Catheter extraction does not improve survival in candidemia, or does it?. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1347-8; author reply 1348-50	11.6 2
2133	Fungal Infections of the Urinary Tract. 2010 , 649-653	
2132	Safety and efficacy of activated transfected killer cells for neutropenic fungal infections. 2010 , 201, 1708-17	15
2131	Coping with Candida infections. 2010 , 7, 197-203	19
2130	In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. 2010 , 54, 2497-506	173

2129	Candida spp. bloodstream infection: influence of antifungal treatment on outcome. 2010 , 65, 562-8	20
2128	Risk factors for fluconazole-resistant candidemia. 2010 , 54, 3149-54	83
2127	Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. 2010 , 48, 669-74	41
2126	Managing Infections in Patients With Hematological Malignancies. 2010 ,	1
2125	Combating Fungal Infections. 2010 ,	9
2124	Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. 2010 , 54, 426-39	126
2123	Candida infections of the genitourinary tract. 2010 , 23, 253-73	391
2122	Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. 2010 , 202, 171-5	193
2121	Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. 2010 , 54, 2409-19	114
2120	Candida bracarensis bloodstream infection in an immunocompromised patient. 2010 , 48, 4677-9	16
2119	Development and validation of an in vivo Candida albicans biofilm denture model. 2010 , 78, 3650-9	120
2118	Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. 2010 , 126, e865-73	244
2117	Recently tested strategies to reduce nosocomial infections in the neonatal intensive care unit. 2010 , 8, 235-42	7
2116	FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. 2010 , 54, 5042-7	111
2115	Breakthrough invasive candidiasis in patients on micafungin. 2010 , 48, 2373-80	157
2114	In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. 2010 , 54, 2194-7	57
2113	In vitro activity of antifungal combinations against Candida albicans biofilms. 2010 , 65, 271-4	72
2112	Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus. 2010 , 54, 597-601	47

2111	Flucytosine for treatment of Candida albicans in H1N1-positive patient. 2010 , 42, 318-9	
2110	Echinocandin pharmacodynamics: review and clinical implications. 2010 , 65, 1108-18	48
2109	Invasive candidiasis in the intensive care unit. 2010 , 38, 82-91	1
2108	Management of oropharyngeal and esophageal candidiasis in patients with HIV infection. 2010 , 4, 325-343	2
2107	Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriadfi efficacy and safety (SMILES). 2010 , 11, 186-96	37
2106	Candida infection and colonization among trauma patients. 2010 , 1, 367-75	40
2105	Candida infection in total knee arthroplasty with successful reimplantation. 2010 , 23, 169-74	21
2104	Invasive fungal infections in the intensive care unit. 2010 , 31, 79-86	30
2103	Pharmacoeconomics of voriconazole. 2010 , 11, 877-87	6
2102	Impact of education and an antifungal stewardship program for candidiasis at a Thai tertiary care center. 2010 , 31, 722-7	45
2101	Spondylodiscitis: update on diagnosis and management. 2010 , 65 Suppl 3, iii11-24	284
2100	Recommandations de stratégies thérapeutiques pour le traitement des candidoses et aspergilloses invasives chez l'adulte. 2010 , 12, 165-170	1
2099	Diagnostic et traitement des infections liées aux chambres implantables. 2010 , 12, 17-26	
2098	[Meningomyelorradiculitis in an immunocompetent patient]. 2010 , 166, 741-4	2
2097	Candidemia e candidosi generalizzata. 2010 , 15, 1-24	
2096	Neurologic presentations of fungal infections. 2010 , 28, 293-309	15
2095	Spondylodiscitis ^ Candida spp.. 2010 , 12, 61-65	1
2094	Fungal infections in transplant and oncology patients. 2010 , 24, 439-59	43

2093	Updated guidelines for managing fungal diseases in hematology patients. 2010 , 8, 1049-60	6
2092	Diagnosis and management of infectious complications in critically ill patients with cancer. 2010 , 26, 59-91	54
2091	Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs. 2010 , 6, e1000939	134
2090	Managing fungal and viral infections in pediatric leukemia. 2010 , 3, 603-24	1
2089	The echinocandins: three useful choices or three too many?. 2010 , 35, 13-8	46
2088	New antifungal agents for the treatment of candidaemia. 2010 , 36 Suppl 2, S63-9	7
2087	Management of Gram-negative and fungal endocarditis. 2010 , 36 Suppl 2, S40-5	53
2086	Management of invasive candidiasis in the intensive care unit. 2010 , 70, 823-39	21
2085	Traditional and emerging antifungal therapies. 2010 , 7, 222-8	35
2084	Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of <i>Candida</i> species. 2010 , 48, 1592-9	79
2083	Challenging issues in neonatal candidiasis. 2010 , 26, 1769-78	43
2082	Comparison of albicans vs. non-albicans candidemia in French intensive care units. 2010 , 14, R98	28
2081	Is routine autopsy in the intensive care unit viable? Authors' response. 2010 , 14, 433	
2080	The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. 2010 , 14, R222	198
2079	Treatment strategies for infective endocarditis. 2010 , 11, 345-60	10
2078	Epidemiology of invasive mycoses in North America. 2010 , 36, 1-53	669
2077	Pharmacology and clinical use of voriconazole. 2010 , 6, 83-94	35
2076	Nosocomial candidemia at a general hospital: prognostic factors and impact of early empiric treatment on outcome (2002-2005). 2010 , 134, 1-5	4

2075	[Nosocomial candidemias and invasive candidiasis]. 2010 , 134, 17-9	6
2074	[Antifungal prophylaxis in oncohematologic patients: Literature review and recommendations]. 2010 , 134, 222-33	0
2073	[Antifungal treatments of candidemia in non-neutropenic patients: evaluation of practice in intensive care units]. 2010 , 40, 644-9	0
2072	Antifungal therapy in invasive fungal infections. 2010 , 10, 522-30	78
2071	Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and <i>Aspergillus</i> spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. 2010 , 67, 56-60	24
2070	Variation in <i>Candida</i> spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). 2010 , 68, 278-83	115
2069	Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and <i>Candida</i> : time for harmonization of CLSI and EUCAST broth microdilution methods. 2010 , 13, 180-95	226
2068	Historical aspects of dermatomycoses. 2010 , 28, 125-32	24
2067	Candidosis, a new challenge. 2010 , 28, 178-84	89
2066	Central nervous system infectious complications early after liver transplantation. 2010 , 42, 1216-22	15
2065	Oropharyngeal candidiasis in the era of antiretroviral therapy. 2010 , 109, 488-95	100
2064	[Antifungal combination therapy in invasive fungal infections]. 2010 , 31, 72-81	5
2063	A <i>Candida albicans</i> strain with high MIC for caspofungin and no FKS1 mutations exhibits a high chitin content and mutations in two chitinase genes. 2011 , 49, 467-74	14
2062	Candidiasis in a 3-month-old vertically HIV-infected infant. 2010 , 9, 14-16	
2061	[<i>Candida</i> peritonitis]. 2010 , 28 Suppl 2, 42-8	3
2060	Protocolo terapéutico de la infección urinaria simple y con repercusión sistémica. 2010 , 10, 3526-3528	
2059	Infecciones por hongos. 2010 , 10, 3558-3568	
2058	Mujer de 32 años con fiebre y dolor lumbar. 2010 , 10, 3607.e1-3607.e3	

2057 Micosis pulmonares. **2010**, 10, 4597-4604

2056 Candidemia y candidiasis generalizada. **2010**, 36, 1-26

2055 Actualité thérapeutiques dans les infections fongiques. **2010**, 2, 125-131

1

2054 Pathogenic Yeasts. **2010**,

5

2053 How to Make Antimicrobial Stewardship Work: Practical Considerations for Hospitals of All Sizes. **2010**, 45, 10-21

7

2052 Antifungals to treat *Candida albicans*. **2010**, 11, 2037-48

50

2051 Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections. **2010**, 6, 1287-300

9

2050 Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. **2010**, 8, 127-35

14

2049 Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients. **2010**, 8, 1451-66

13

2048 Candidemia in children. **2010**, 26, 1761-8

73

2047 The gastrointestinal complications of oncologic therapy. **2010**, 39, 629-47

25

2046 *Candida* prosthetic infections: case series and literature review. **2010**, 42, 890-5

58

2045 Strategies to prevent invasive candidal infection in extremely preterm infants. **2010**, 37, 611-28

51

2044 Clinical review: What is the role for autopsy in the ICU?. **2010**, 14, 221

16

2043 Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. **2010**, 14, 244

40

2042 Approaches to the early treatment of invasive fungal infection. **2010**, 51, 1623-31

7

2041 Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clinical Infectious Diseases*, **2010**, 50, 625-63

11.6 1252

2040 Lack of standardization in the procedures for mycological examination of sputum samples from CF patients: a possible cause for variations in the prevalence of filamentous fungi. **2010**, 48 Suppl 1, S88-97

84

2039	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of <i>Candida</i> Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. 2010 , 48, 1366-77	432
2038	Optimization of antifungal therapy is crucial when treating adults with invasive candidiasis in the intensive care unit. 2010 , 26, 15-18	
2037	Efficacy and safety of caspofungin in obese patients. 2011 , 49, 748-54	11
2036	Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice. 2011 , 27, 335-42	
2035	Radiotracers for fungal infection imaging. 2011 , 49 Suppl 1, S62-9	21
2034	Treatment of candidemia in adult patients without neutropenia--an inconvenient truth. 2011 , 15, 114	8
2033	Evaluaci3n econ3mica de antimic3ticos en pacientes no neutrof3licos con candidiasis invasiva en M3xico. 2011 , 8, 16-28	1
2032	Improved identification of yeast species directly from positive blood culture media by combining Sepsityper specimen processing and Microflex analysis with the matrix-assisted laser desorption ionization Biotyper system. 2011 , 49, 2528-32	93
2031	Genetic relatedness and antifungal susceptibility profile of <i>Candida albicans</i> isolates from fungaemia patients. 2011 , 49, 248-52	7
2030	Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1->3)-D-glucan assay, <i>Candida</i> score, and colonization index. 2011 , 15, R249	129
2029	Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. 2011 , 15, R253	68
2028	Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. 2011 , 29, 705-17	16
2027	Infectious diseases and the liver. 2011 , 15, 111-30	54
2026	Treatment for recurrent vulvovaginal candidiasis (thrush). 2011 ,	1
2025	<i>Artemisia princeps</i> Pamp. Essential oil and its constituents eucalyptol and α -terpineol ameliorate bacterial vaginosis and vulvovaginal candidiasis in mice by inhibiting bacterial growth and NF- κ B activation. 2011 , 77, 1996-2002	42
2024	Micafungin. 2011 , 30, 329-33	
2023	Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. 2011 , 55, 4543-51	110
2022	Fungal sepsis: optimizing antifungal therapy in the critical care setting. 2011 , 27, 123-47	37

2021	Electronic memorandum decreases unnecessary antimicrobial use for asymptomatic bacteriuria and culture-negative pyuria. 2011 , 32, 644-8	37
2020	Common infections in the lung transplant recipient. 2011 , 32, 327-41	21
2019	Análisis del perfil proteico de aislamientos clínicos de <i>Candida guilliermondii</i> sensibles y resistentes al fluconazol. 2011 , 15, 20-24	
2018	[Recommendations of the Infectious Disease Committee of the French Association of Urology. Diagnosis, treatment and monitoring candiduria]. 2011 , 21, 314-21	9
2017	[The Spanish Society of Paediatric Infectious Diseases (SEIP) recommendations on the diagnosis and management of invasive candidiasis]. 2011 , 74, 337.e1-337.e17	5
2016	[Hepatosplenic candidiasis in paediatric haematology-oncology patients]. 2011 , 75, 26-32	1
2015	<i>Candida albicans</i> cervical lymphadenitis in patients who have acute myeloid leukemia. 2011 , 11, 375-7	5
2014	Possible role of azole and echinocandin lock solutions in the control of <i>Candida</i> biofilms associated with silicone. 2011 , 37, 380-4	39
2013	<i>Candida</i> bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). 2011 , 38, 65-9	178
2012	Activity of an Intralipid formulation of nystatin in murine systemic candidiasis. 2011 , 38, 336-40	15
2011	Candidiasis. 2011 , 167-206	14
2010	Antifungal Agents and Therapy. 2011 , 75-106	1
2009	European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. 2011 , 46, 709-18	359
2008	Hot Topics in Infection and Immunity in Children VII. 2011 ,	1
2007	Epidemiology and Evolution of Fungal Pathogens in Plants and Animals. 2011 , 59-132	11
2006	Molecular identification of closely related <i>Candida</i> species using two ribosomal intergenic spacer fingerprinting methods. 2011 , 13, 12-22	41
2005	Optimizing a <i>Candida</i> biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay. 2011 , 49, 1426-33	106
2004	Fungal infections in the critically ill. 2011 , 1, 210-218	1

2003	Echinocandin antifungal drugs in fungal infections: a comparison. 2011 , 71, 11-41	260
2002	Miconazole mucoadhesive tablet for oropharyngeal candidiasis. 2011 , 9, 13-7	22
2001	Hot Topics in Infection and Immunity in Children VIII. 2011 ,	
2000	Candida parapsilosis meningitis as the first manifestation of AIDS: case report. 2011 , 60, 1530-1533	2
1999	Amphotericin B use in children: conventional and lipid-based formulations. 2011 , 9, 357-67	4
1998	Invasive Candida infections in solid organ transplant recipient children. 2011 , 9, 317-24	2
1997	Fungal infections in transplant and oncology patients. 2011 , 25, 193-213	24
1996	An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. 2011 , 183, 96-128	388
1995	Candidiasis and Less Common Yeast Genera. 2011 , 249-301	1
1994	Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates. 2011 , 70, 54-9	6
1993	Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. 2011 , 70, 330-43	106
1992	Time-kill studies with micafungin and voriconazole against Candida glabrata intracellularly in human monocyte-derived macrophages and extracellularly in broth. 2011 , 70, 468-74	3
1991	Post-antifungal effects and time-kill studies of anidulafungin, caspofungin, and micafungin against Candida glabrata and Candida parapsilosis. 2011 , 71, 131-8	12
1990	Comparison of CLSI broth macrodilution and microdilution methods for echinocandin susceptibility testing of 5 Candida species. 2011 , 71, 320-2	1
1989	Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. 2011 , 14, 164-76	265
1988	[Candidemias: multicentre analysis in 16 hospitals in Andalusia (Spain)]. 2011 , 29, 328-33	20
1987	[Guidelines for the treatment of Invasive Candidiasis and other yeasts. Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2010 Update]. 2011 , 29, 345-61	31
1986	[Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update]. 2011 , 29, 435-54	24

1985	[Candidemia: impact of epidemiological studies on the treatment and prognosis of a serious infection]. 2011 , 29, 325-7	2
1984	(1B)-ED-Glucan Assay: A Review of its Laboratory and Clinical Application. 2011 , 42, 679-685	23
1983	Overview of treatment options for invasive fungal infections. 2011 , 49, 561-80	36
1982	The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective. 2011 , 37, 250-61	83
1981	Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents. 2011 , 64, 830-42	25
1980	[Assessment of adherence to Afssaps guidelines for the prescription of antifungals in pediatric hemato-oncology]. 2011 , 41, 25-32	3
1979	Clinical characteristics of hepatosplenic fungal infection in pediatric patients. 2011 , 44, 296-302	6
1978	Prognostic factors of candidemia among nonneutropenic adults with total parenteral nutrition. 2011 , 44, 461-6	7
1977	[Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-testfi]. 2011 , 59, 52-6	5
1976	Fungal eye disease at a tertiary care center: the utility of routine inpatient consultation. 2011 , 118, 1671-6	52
1975	[Management of candidemia and invasive candidiasis]. 2011 , 32, 173-80	6
1974	Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients. 2011 , 43, 2463-71	19
1973	[Fungal infections in children with malignant disease]. 2011 , 18 Suppl 1, S3-7	1
1972	[Invasive candidiasis in neonatal intensive care units]. 2011 , 18 Suppl 1, S22-32	6
1971	[Echinocandins in children]. 2011 , 18 Suppl 1, S33-41	0
1970	Emerging opportunistic yeast infections. 2011 , 11, 142-51	546
1969	Pharmacokinetic evaluation of fluconazole in critically ill patients. 2011 , 7, 1431-40	11
1968	Current perspectives on echinocandin class drugs. 2011 , 6, 441-57	176

1967 Systemic Antifungals. **2011**, 99-122

1966 Is (1->3)-D-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis?. **2011**, 15, 1017 11

1965 Echinocandins--first line in invasive candidiasis: how strong is this 'strong' evidence?. **2011**, 15, 461; author reply 461 2

1964 Risk factors for infections requiring hospitalization in renal transplant recipients: a cohort study. **2011**, 15, e188-96 13

1963 Invasive fungal infections in liver transplantation. **2011**, 15, e298-304 50

1962 Candidemic complications in patients with intravascular catheters colonized with *Candida* species: an indication for preemptive antifungal therapy?. **2011**, 15, e453-8 23

1961 In vitro activity of echinocandins against non-*Candida albicans*: is echinocandin antifungal activity the same?. **2011**, 29 Suppl 2, 3-9 8

1960 [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis]. **2011**, 29 Suppl 2, 15-22 2

1959 [Drug interactions in critically-ill patients. An important factor in the use of micafungin?]. **2011**, 29 Suppl 2, 33-7 1

1958 Update on fungemia in oncology and hematology. **2011**, 29 Suppl 4, 42-7 0

1957 [Antifungal therapy update: new drugs and medical uses]. **2011**, 29 Suppl 5, 38-44 4

1956 Candidemia in children after complex congenital heart defects surgery treated with caspofungin--our own experience and a review of literature. **2011**, 17, PH35-9 5

1955 Diagn stico y tratamiento de infecciones oportunistas en el paciente adulto con infecci n por VIH/SIDA. **2011**, 28, 440-460

1954 Diretrizes para tratamento da sepse grave/choque s ptico: abordagem do agente infeccioso - controle do foco infeccioso e tratamento antimicrobiano. **2011**, 23, 145-157 3

1953 Emerging fungal infections in immunocompromised patients. **2011**, 3, 14 169

1952 HealthCare-Associated Infections in the Nursery. **2011**, 1126-1143 3

1951 *Candida parapsilosis* complex water isolates from a haemodialysis unit: biofilm production and in vitro evaluation of the use of clinical antifungals. **2011**, 106, 646-54 28

1950 Equinocandinas. **2011**, 28, 529-536 3

1949	Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability. 2011 , 5, 369-74	21
1948	Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. 2011 , 26, 220-52	64
1947	Urinary tract infections in women: etiology and treatment options. 2011 , 4, 333-43	59
1946	Economic considerations of antifungal prophylaxis in patients undergoing surgical procedures. 2011 , 7, 13-20	5
1945	Update on the optimal use of voriconazole for invasive fungal infections. 2011 , 4, 43-53	52
1944	Epidemiology and treatment approaches in management of invasive fungal infections. 2011 , 3, 175-91	117
1943	Mucocutaneous and Deeply Invasive Candidiasis. 2011 , 589-596	1
1942	Evidence-based Guidelines for Empirical Therapy of Neutropenic Fever in Korea. 2011 , 43, 258	3
1941	Validation of the tetracycline regulatable gene expression system for the study of the pathogenesis of infectious disease. 2011 , 6, e20449	5
1940	Amino acid substitutions at the major insertion loop of <i>Candida albicans</i> sterol 14 α -demethylase are involved in fluconazole resistance. 2011 , 6, e21239	27
1939	Anidulafungin: Review of its Role in the Treatment of Invasive Candidiasis. 2011 , 3, CMT.S3153	1
1938	<i>Candida glabrata</i> spinal osteomyelitis. 2011 , 341, 78-82	14
1937	Current world literature. 2011 , 24, 172-5	
1936	<i>Candida</i> bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. 2011 , 39, 665-70	265
1935	Fluconazole loading dose pharmacokinetics and safety in infants. 2011 , 30, 375-8	82
1934	Critical care management of patients with end-stage liver disease. 2011 , 39, 1157-66	21
1933	Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice?. 2011 , 24, 163-71	23
1932	Antifungal azoles: old and new. 2011 , 30, 506-7	7

1931	Azoles: back to the future. 2011 , 24, S41-S58	3
1930	Candidemia in the intensive care unit: miles to go before we sleep. 2011 , 39, 884-5	12
1929	Mycoses de l'enfant. 2011 , 6, 1-23	
1928	Heat shock protein inhibitors for the treatment of fungal infections. 2011 , 6, 38-44	20
1927	Antifungal susceptibility testing of a 10-year collection of <i>Candida</i> spp. isolated from patients with candidemia. 2011 , 23, 92-6	16
1926	Austrian clinical practice with anidulafungin in 2008: a multicenter survey. 2011 , 23, 285-9	1
1925	Pharmacokinetic-pharmacodynamic optimization of triazole antifungal therapy. 2011 , 24, S14-S29	9
1924	<i>Candida</i> bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study. 2011 , 2011, 73-74	
1923	Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. 2011 , 16, 159-66	95
1922	Management of infectious complications in solid-organ transplant recipients. 2011 , 90, 333-42	13
1921	[Candidosis]. 2011 , 52, 15-8	
1920	[A case of micafungin-hyposensitive <i>Candida glabrata</i> due to FKS2 gene mutation]. 2011 , 85, 49-53	2
1919	Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin: review of the literature. 2011 , 16, 167-79	36
1918	Current evidence for the treatment of invasive fungal infections in immunocompromised patients. 2011 , 1, 447-457	2
1917	Best practice in treating infants and children with proven, probable or suspected invasive fungal infections. 2011 , 24, 225-9	17
1916	Infections in liver transplant recipients. 2011 , 3, 83-92	108
1915	Performance of the new Platelia <i>Candida</i> Plus assays for the diagnosis of invasive <i>Candida</i> infection in patients undergoing myeloablative therapy. 2011 , 49, 848-55	20
1914	Fungal endophthalmitis successfully treated with intravitreal voriconazole injection. 2011 , 50, 941	2

1913	Candiduria in those over 85 years old: a retrospective study of 73 patients. 2011 , 50, 1935-40	14
1912	Clinical analysis of 68 patients with pulmonary mycosis in China. 2011 , 6, 278-83	8
1911	[Level of evidence for therapeutic drug monitoring of fluconazole]. 2011 , 66, 97-101	
1910	Einsatz von Antibiotika und Antimykotika in Prophylaxe und Therapie bei großen viszeralkirurgischen Eingriffen. 2011 , 27, 50-57	2
1909	Microbiological findings of culture-positive preservation fluid in liver transplantation. 2011 , 13, 9-14	30
1908	Incidence and predictors of invasive candidiasis associated with candidaemia in children. 2011 , 54, 146-53	21
1907	Intraocular caspofungin: in vitro safety profile for human ocular cells. 2011 , 54, e110-21	11
1906	Candida endocarditis associated with cardiac rhythm management devices: review with current treatment guidelines. 2011 , 54, e168-74	22
1905	Fungal prosthetic valve endocarditis: Mayo Clinic experience with a clinicopathological analysis. 2011 , 54, 354-60	36
1904	Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients. 2011 , 54, 420-33	15
1903	The role of diagnostic imaging in the management of invasive fungal diseases--report from an interactive workshop. 2011 , 54 Suppl 1, 27-31	4
1902	Current issues in the clinical management of invasive candida infections--the AGIHO, DMykG, GMM and PEG web-based survey and expert consensus conference 2009. 2011 , 54, e546-56	11
1901	Epidemiology and management of candidaemia--a retrospective, multicentre study in five hospitals in the UK. 2011 , 54, e795-800	27
1900	Detection of characteristic metabolites of <i>Aspergillus fumigatus</i> and <i>Candida</i> species using ion mobility spectrometry-metabolic profiling by volatile organic compounds. 2011 , 54, e828-37	61
1899	Diagnosis and therapy of <i>Candida</i> infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. 2011 , 54, 279-310	91
1898	Fungal infections in immunocompromised patients. 2011 , 54 Suppl 4, 1-3	9
1897	Invasive candidiasis following liver transplantation and surgical complications. 2011 , 54 Suppl 4, 4-7	3
1896	Anidulafungin treatment in a kidney transplant recipient with hepatic damage. 2011 , 54 Suppl 4, 12-5	1

1895	Recurrent candidaemia and pacemaker wire infection with <i>Candida albicans</i> . 2011 , 54 Suppl 4, 20-3	4
1894	Getting it right first time in a patient with <i>Candida</i> peritonitis. 2011 , 54 Suppl 4, 24-7	1
1893	<i>Candida tropicalis</i> pylephlebitis with persistent fungaemia in a 72-year-old lady with severe pancreatitis. 2011 , 54 Suppl 4, 28-30	3
1892	Invasive fungal infections: therapeutic decision making in real life case studies. Discussion. 2011 , 54 Suppl 4, 31-3	
1891	How I manage haematology patients with septic shock. 2011 , 152, 380-91	9
1890	Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?. 2011 , 153, 681-97	33
1889	Improved clinical laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. 2011 , 17, 1359-65	165
1888	Decreasing candidaemia rate in abdominal surgery patients after introduction of fluconazole prophylaxis*. 2011 , 17, 1372-80	10
1887	Anidulafungin for the treatment of invasive candidiasis. 2011 , 17 Suppl 1, 1-12	15
1886	European expert opinion on the management of invasive candidiasis in adults. 2011 , 17 Suppl 5, 1-12	51
1885	Pharmacologic management of asymptomatic bacteriuria and urinary tract infections in women. 2011 , 56, 248-65	2
1884	Oral complications in the treatment of cancer patients. 2011 , 17, 550-9	69
1883	The value of amphotericin B in the treatment of invasive fungal infections. 2011 , 26, 225.e1-10	33
1882	Changes in the incidence of candidaemia during 2000-2008 in a tertiary medical centre in northern Taiwan. 2011 , 78, 50-3	26
1881	Fungal bloodstream infections in tertiary care hospitals in Colombia. 2011 , 28, 74-8	27
1880	[Changes in the epidemiology of fungaemia and fluconazole susceptibility of blood isolates during the last 10 years in Spain: results from the FUNGEMYCA study]. 2011 , 28, 91-9	21
1879	[Antifungal prophylaxis in HIV-seropositive liver transplant recipients]. 2011 , 28, 183-90	1
1878	[Candidiasis, aspergillosis and other invasive mycoses in recipients of solid organ transplants]. 2011 , 28, 110-9	6

1877	[Invasive candidiasis in liver transplant recipient: early rescue antifungal treatment]. 2011 , 28, 124-8	0
1876	Patient preferences and treatment safety for uncomplicated vulvovaginal candidiasis in primary health care. 2011 , 11, 63	9
1875	Epidemiological and clinico-mycological profile of fungal wound infection from largest burn centre in Asia. 2012 , 55, 181-8	18
1874	Efficacy and safety of antifungals in pediatric patients. 2011 , 87 Suppl 1, S71-4	1
1873	Synthesis and anticandidal activity of new triazolothiadiazine derivatives. 2011 , 46, 5562-6	23
1872	Update on invasive fungal disease. 2011 , 6, 985-9	4
1871	Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. 2011 , 12, 851-63	17
1870	Infectious diseases in the critically ill patients. 2011 , 24, 35-43	24
1869	Interface of <i>Candida albicans</i> biofilm matrix-associated drug resistance and cell wall integrity regulation. 2011 , 10, 1660-9	116
1868	<i>Candida</i> infections in non-neutropenic children after the neonatal period. 2011 , 9, 923-40	11
1867	A case of <i>Candida krusei</i> peritonitis secondary to duodenal perforation due to <i>Candida</i> duodenitis. 2011 , 171, 51-5	3
1866	The effect of cumulative length of hospital stay on the antifungal resistance of <i>Candida</i> strains isolated from critically ill surgical patients. 2011 , 171, 85-91	14
1865	Antifungal susceptibility of bloodstream <i>Candida</i> isolates in Sfax hospital: Tunisia. 2011 , 171, 417-22	18
1864	Fluconazole-, amphotericin-B-, caspofungin-, and anidulafungin-resistant <i>Candida ciferrii</i> : an unknown cause of systemic mycosis in a child. 2011 , 172, 237-9	11
1863	Oropharyngeal candidiasis in head and neck cancer patients treated with radiation: update 2011. 2011 , 19, 737-44	59
1862	Clinical practice: Obstructive renal candidiasis in infancy. 2011 , 170, 1227-35	15
1861	Therapie der posttraumatischen abdominalen Sepsis. 2011 , 48, 199-206	2
1860	Long-term follow-up of patients with candiduria. 2011 , 30, 137-40	9

- 1859 Candida infection of the central nervous system following neurosurgery: a 12-year review. **2011**, 153, 1347-50 48
- 1858 Rationale antimykotische Therapie bei Intensivpatienten. **2011**, 14, 24-27
- 1857 Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report. **2011**, 17, 622-32 17
- 1856 [Innovative antifungals for treatment of invasive fungal infections]. **2011**, 52, 1118-24, 1126 3
- 1855 Candida peritonitis: an update on the latest research and treatments. **2011**, 35, 2650-9 39
- 1854 Treatment of invasive fungal infections. **2011**, 4, 169-173 1
- 1853 Invasive Candidiasis in Patients with Implants. **2011**, 5, 12-17 1
- 1852 Candidemia in the Pediatric Intensive Care Unit: What's Different from Candidemia in Adults?. **2011**, 5, 49-55
- 1851 Invasive Candidiasis in the Neutropenic Cancer Patient. **2011**, 5, 34-41 4
- 1850 Fluconazole-Resistant Candida: Mechanisms and Risk Factor Identification. **2011**, 5, 23-28 7
- 1849 Antifungal Pharmacokinetics and Dosing Considerations in Burn Patients. **2011**, 5, 67-74
- 1848 Update on Antifungal Drug Dosing and Therapeutic Drug Monitoring. **2011**, 5, 92-102 3
- 1847 Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans. **2011**, 5, 59-66 1
- 1846 Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins. **2011**, 5, 120-127 3
- 1845 Polymerase Chain Reaction (PCR)Based Diagnostic Assays for Invasive Candidiasis. **2011**, 5, 135-140
- 1844 An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB). **2011**, 7, 12-5 35
- 1843 When and how to cover for fungal infections in patients with severe sepsis and septic shock. **2011**, 13, 426-32 8
- 1842 Update in adult urinary tract infection. **2011**, 13, 552-60 17

1841	Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients. 2011 , 11, 130	16
1840	Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by <i>Candida albicans</i> : a multivariate analysis of factors associated with improved outcome. 2011 , 11, 261	61
1839	WSES consensus conference: Guidelines for first-line management of intra-abdominal infections. 2011 , 6, 2	51
1838	Diagnosis of invasive candidiasis in the ICU. 2011 , 1, 37	84
1837	Evaluation of "Candida score" in critically ill patients: a prospective, multicenter, observational, cohort study. 2011 , 1, 50	53
1836	A novel assay of biofilm antifungal activity reveals that amphotericin B and caspofungin lyse <i>Candida albicans</i> cells in biofilms. 2011 , 28, 561-8	28
1835	Fungal endocarditis involving rheumatic mitral valve in a young man. 2011 , 4, e55-e57	
1834	Strategies to manage antifungal drug resistance. 2011 , 12, 241-56	6
1833	New-generation triazole antifungal drugs: review of the Phase II and III trials. 2011 , 1, 1577-1594	13
1832	Rational use of antimicrobials in patients with severe acute pancreatitis. 2011 , 32, 174-80	15
1831	<i>Candida</i> prophylaxis and therapy in the ICU. 2011 , 32, 159-73	11
1830	Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey. 2011 , 49, 4158-63	47
1829	Management of invasive fungal infections: a role for polyenes. 2011 , 66, 457-65	53
1828	Fungal infections in pediatric intensive care units. 2011 , 24 Suppl 2, 21-3	3
1827	Intraocular penetration of micafungin in patient with <i>Candida albicans</i> endophthalmitis. 2011 , 27, 531-3	15
1826	Fungal endophthalmitis. 2011 , 9, 1191-201	55
1825	FKS2 mutations associated with decreased echinocandin susceptibility of <i>Candida glabrata</i> following anidulafungin therapy. 2011 , 55, 1312-4	27
1824	Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. 2011 , 55, 532-8	245

1823	Caspofungin dose escalation for invasive candidiasis due to resistant <i>Candida albicans</i> . 2011 , 55, 3254-60	51
1822	Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. 2011 , 49, 3300-8	125
1821	Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. 2011 , 55, 3491-7	18
1820	Comparison of BD Bactec Plus Aerobic/F medium to VersaTREK Redox 1 blood culture medium for detection of <i>Candida</i> spp. in seeded blood culture specimens containing therapeutic levels of antifungal agents. 2011 , 49, 1524-9	26
1819	Quantitation of <i>Candida</i> CFU in initial positive blood cultures. 2011 , 49, 2879-83	96
1818	Invasive fungal infections in acute leukemia. 2011 , 2, 231-47	41
1817	Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against <i>Candida</i> spp. 2011 , 49, 1765-71	25
1816	Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. 2011 , 55, 2113-21	84
1815	Efficacy of a single 6 mg/kg versus two 3 mg/kg caspofungin doses for treatment of disseminated candidiasis caused by <i>Candida albicans</i> in a neutropenic mouse model. 2011 , 23, 107-9	3
1814	New Fks hot spot for acquired echinocandin resistance in <i>Saccharomyces cerevisiae</i> and its contribution to intrinsic resistance of <i>Scedosporium</i> species. 2011 , 55, 3774-81	62
1813	Paradoxical effect of caspofungin against <i>Candida</i> bloodstream isolates is mediated by multiple pathways but eliminated in human serum. 2011 , 55, 2641-7	60
1812	Disseminated Candidiasis caused by <i>Candida albicans</i> with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. 2011 , 55, 3075-83	47
1811	Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in <i>Candida</i> strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone. 2011 , 55, 1629-37	5
1810	Osteoarticular infection by <i>Candida albicans</i> in an infant with cystic fibrosis. 2011 , 60, 1542-1545	4
1809	Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global <i>Candida</i> antifungal surveillance program. 2011 , 49, 1274-9	25
1808	Comparative evaluation of three commercial identification systems using common and rare bloodstream yeast isolates. 2011 , 49, 2722-7	37
1807	At what cost echinocandin resistance?. 2011 , 204, 499-501	7
1806	Optimizing management of invasive mould diseases. 2011 , 66 Suppl 1, i45-53	32

1805	Activities of triazole-echinocandin combinations against <i>Candida</i> species in biofilms and as planktonic cells. 2011 , 55, 1968-74		42
1804	Pharmacotherapy of Invasive Fungal Infections with Voriconazole. 2011 , 3, 83-95		
1803	Development of an HPLC method for the determination of anidulafungin in human plasma and saline. 2011 , 49, 397-400		7
1802	Anidulafungin in treatment of experimental invasive infection by <i>Candida parapsilosis</i> : in vitro activity, (1-->3)-beta-D-glucan and mannan serum levels, histopathological findings, and in vivo efficacy. 2011 , 55, 4985-9		6
1801	<i>Candida</i> bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. 2011 , 55, 561-6		172
1800	Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with <i>Candida</i> empyema. 2011 , 55, 2478-80		11
1799	Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method. 2011 , 49, 4322-5		11
1798	Antifungal use influences <i>Candida</i> species distribution and susceptibility in the intensive care unit. 2011 , 66, 2880-6		57
1797	What should we be doing about fungal infections in intensive care?. 2011 , 107, 299-302		
1796	<i>Aspergillus</i> vertebral osteomyelitis in immunocompetent hosts: role of triazole antifungal therapy. <i>Clinical Infectious Diseases</i> , 2011 , 52, e1-6	11.6	31
1795	Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. 2011 , 66, 1906-15		23
1794	Effectiveness of antibiotic-lock therapy for long-term catheter-related bacteremia due to Gram-negative bacilli: a prospective observational study. <i>Clinical Infectious Diseases</i> , 2011 , 53, e129-32	11.6	29
1793	Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi. 2011 , 66, 1447-66		35
1792	Micafungin therapy in a critically ill, morbidly obese patient. 2011 , 66, 2678-80		13
1791	Management of fungal infections in the intensive care unit: a survey of UK practice. 2011 , 106, 827-31		12
1790	Comparative in vitro susceptibility of clinical isolates of <i>Candida parapsilosis</i> complex and other <i>Candida</i> species to caspofungin and anidulafungin by Etest. 2011 , 23, 97-101		1
1789	The role of azoles in the treatment of invasive mycoses: review of the Infectious Diseases Society of America guidelines. 2011 , 24, S1-S13		9
1788	Antimicrobial treatment of "complicated" intra-abdominal infections and the new IDSA guidelines ? a commentary and an alternative European approach according to clinical definitions. 2011 , 16, 115-26		48

1787 Fungal Infections in Humans. **2011**,

1786 Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections. **2011**, 68, 1207-20 21

1785 Pharmacodynamics of echinocandins against *Candida glabrata*: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. **2011**, 55, 4880-7 37

1784 Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. **2011**, 55, 5868-73 38

1783 Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. **2011**, 66, 2146-51 62

1782 Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections. **2011**, 55, 184-9 15

1781 *Candida glabrata* mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility. **2011**, 55, 3947-9 23

1780 Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant *Aspergillus fumigatus*. **2011**, 66, 1324-31 15

1779 Use of epidemiological cutoff values to examine 9-year trends in susceptibility of *Candida* species to anidulafungin, caspofungin, and micafungin. **2011**, 49, 624-9 48

1778 Epidemiology of candidaemia in critically ill trauma patients: experiences of a level I trauma centre in North India. **2011**, 60, 342-348 20

1777 Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in *Candida* spp.: a case-control study in Paris, France. **2011**, 55, 5358-61 37

1776 *Candida* urinary tract infections--epidemiology, pathogenesis, diagnosis, and treatment: executive summary. *Clinical Infectious Diseases*, **2011**, 52 Suppl 6, S429-32 11.6 23

1775 *Candida* urinary tract infections--treatment. *Clinical Infectious Diseases*, **2011**, 52 Suppl 6, S457-66 11.6 124

1774 Invasive fungal disease: better survival through early diagnosis and therapeutic intervention. **2011**, 9, 279-81 6

1773 Ocular manifestations of candidemia. *Clinical Infectious Diseases*, **2011**, 53, 262-8 11.6 136

1772 Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. *Clinical Infectious Diseases*, **2011**, 52, 648-53 11.6 152

1771 *Candida pelliculosa* meningitis as an opportunistic infection in HIV: the first reported case. **2011**, 22, 54-6 4

1770 Successful treatment of chronic mucocutaneous candidiasis caused by azole-resistant *Candida albicans* with posaconazole. **2011**, 2011, 283239 14

1769	Candida glabrata perinephric abscess. 2011 , 43, 63-5	4
1768	Acute Cystitis. 2011 , 339-344	
1767	Practices of Lebanese gynecologists regarding treatment of recurrent vulvovaginal candidiasis. 2011 , 3, 406-10	4
1766	Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. 2011 , 204, 626-35	106
1765	Case-control study of risk factors and outcomes associated with neonatal candidiasis. 2011 , 4, 39-43	
1764	Candida albicans Als3, a multifunctional adhesin and invasin. 2011 , 10, 168-73	206
1763	Invasive candidiasis in non-hematological patients. 2011 , 3, e2011007	17
1762	Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei. 2011 , 66, 375-80	17
1761	Blutkulturdiagnostik Standards und aktuelle Entwicklungen/Blood culture diagnostics: standards and recent developments. 2012 , 36,	
1760	Invasive candidiasis: a review of nonculture-based laboratory diagnostic methods. 2012 , 30, 264-9	39
1759	A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. 2012 , 8, e1002848	190
1758	Candida spp. with acquired echinocandin resistance, France, 2004-2010. 2012 , 18, 86-90	103
1757	Infectious complications after orthotopic liver transplantation. 2012 , 33, 111-24	22
1756	Combined use of nonculture-based lab techniques in the diagnosis and management of critically ill patients with invasive fungal infections. 2012 , 10, 1321-30	15
1755	A review of Candida species causing blood stream infection. 2012 , 30, 270-8	63
1754	Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. 2012 , 67, 707-14	77
1753	A 32-Year-Old Man With Ulcerative Mucositis, Skin Lesions, and Nail Dystrophy. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1035-1036	11.6 11
1752	Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. 2012 , 56, 5303-8	22

1751	Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. 2012 , 67, 269-89	316
1750	Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. 2012 , 50, 2509-12	16
1749	Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and <i>Candida</i> spp. as determined by CLSI broth microdilution. 2012 , 50, 2040-6	98
1748	The case for antifungal stewardship. 2012 , 25, 107-15	102
1747	Fungal peri-prosthetic joint infection after primary total knee replacement. 2012 , 94, 656-9	59
1746	Utilization Patterns of Caspofungin and Micafungin for Treatment of Invasive Fungal Infections. 2012 , 20, 53-57	
1745	Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United kingdom. 2012 , 50, 2639-44	14
1744	<i>Candida</i> osteomyelitis: analysis of 207 pediatric and adult cases (1970-2011). <i>Clinical Infectious Diseases</i> , 2012 , 55, 1338-51	11.6 113
1743	Recurrent episodes of candidemia due to <i>Candida glabrata</i> with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin. 2012 , 56, 3417-9	24
1742	Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). 2012 , 23, 823-33	88
1741	Differential in vivo activities of anidulafungin, caspofungin, and micafungin against <i>Candida glabrata</i> isolates with and without FKS resistance mutations. 2012 , 56, 2435-42	98
1740	Azole resistance by loss of function of the sterol 14-desaturase gene (ERG3) in <i>Candida albicans</i> does not necessarily decrease virulence. 2012 , 56, 1960-8	68
1739	Rapid redistribution of phosphatidylinositol-(4,5)-biphosphate and septins during the <i>Candida albicans</i> response to caspofungin. 2012 , 56, 4614-24	25
1738	Invasive fungal infections in solid organ transplant recipients. 2012 , 7, 639-55	108
1737	Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. 2012 , 32 Suppl 2, S32-86	168
1736	Fluconazole-resistant <i>Candida</i> : collateral damage associated with prior antibacterial exposure?. 2012 , 7, 1029-31	3
1735	Prevention and management of central line-associated bloodstream infections in hospital practice. 2012 , 40, 106-18	3
1734	The potential impact of antifungal drug resistance mechanisms on the host immune response to <i>Candida</i> . 2012 , 3, 368-76	31

1733	Voriconazole in clinical practice. 2012 , 24, 311-27	41
1732	Progress in antifungal susceptibility testing of <i>Candida</i> spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. 2012 , 50, 2846-56	323
1731	Candidal thrombophlebitis of central veins: case report and review. 2012 , 50, 299-304	8
1730	Trends in <i>Candida</i> central line-associated bloodstream infections among NICUs, 1999-2009. 2012 , 130, e46-52	53
1729	Treatment of candidemia with echinocandins: data on hospital resource use from a real world setting. 2012 , 15, 1130-8	2
1728	Distribution and antifungal susceptibility of <i>Candida</i> species causing nosocomial candiduria. 2012 , 50, 529-32	25
1727	Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1352-61 ^{11.6}	258
1726	Antibiotic exposure as a risk factor for fluconazole-resistant <i>Candida</i> bloodstream infection. 2012 , 56, 2518-23	110
1725	Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review. 2012 , 67, 1493-5	21
1724	Management of Invasive Candidiasis in the Critically Ill. 2012 , 324-336	1
1723	Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the <i>Candida parapsilosis</i> complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model. 2012 , 58, 159-64	10
1722	The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to <i>Candida glabrata</i> . 2012 , 56, 4862-9	133
1721	Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. 2012 , 67, 2506-13	50
1720	Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six <i>Candida</i> species as determined by the colorimetric Sensititre YeastOne method. 2012 , 50, 3921-6	40
1719	Declining incidence of candidemia in a tertiary inpatient pediatric population. 2012 , 50, 1048-50	19
1718	Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, <i>Candida glabrata</i> . 2012 , 56, 1215-22	28
1717	Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. 2012 , 67, 2731-8	37
1716	In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. 2012 , 50, 3952-9	75

1715	Voriconazole inhibits biofilm formation in different species of the genus <i>Candida</i> . 2012 , 67, 2418-23	23
1714	Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible <i>Candida</i> species in hospitalized patients with candidemia. 2012 , 56, 3239-43	38
1713	A 37-year-old man with a chronic cough. 2012 , 79, 141-50	
1712	Recurrent vulvovaginal candidosis among young women in south eastern Nigeria: the role of lifestyle and health-care practices. 2012 , 23, 704-9	14
1711	Risk factors for persistent candidemia infection in a neonatal intensive care unit and its effect on mortality and length of hospitalization. 2012 , 32, 621-5	14
1710	In the Literature. <i>Clinical Infectious Diseases</i> , 2012 , 55, iii-iv	11.6
1709	Diagnostik invasiver Pilzinfektionen/Diagnosis of invasive fungal infections. 2012 , 36,	
1708	Impact of a rapid peptide nucleic acid fluorescence in situ hybridization assay on treatment of <i>Candida</i> infections. 2012 , 69, 1910-4	50
1707	Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. 2012 , 3, 120	158
1706	Reduced acquisition and overgrowth of vancomycin-resistant enterococci and <i>Candida</i> species in patients treated with fidaxomicin versus vancomycin for <i>Clostridium difficile</i> infection. <i>Clinical Infectious Diseases</i> , 2012 , 55 Suppl 2, S121-6	11.6 87
1705	Septic shock attributed to <i>Candida</i> infection: importance of empiric therapy and source control. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1739-46	11.6 302
1704	Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients. 2012 , 4, e9	20
1703	The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy. 2012 , 2012, 262471	48
1702	Fks1 and Fks2 are functionally redundant but differentially regulated in <i>Candida glabrata</i> : implications for echinocandin resistance. 2012 , 56, 6304-9	80
1701	Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections. 2012 , 6, 19-31	2
1700	Disseminated candidiasis 18 years after renal transplantation. 2012 , 22, 462-5	1
1699	Reply to Anaissie and Nucci and to Cisneros et al. <i>Clinical Infectious Diseases</i> , 2012 , 55, 894-895	11.6
1698	Anidulafungin for <i>Candida glabrata</i> infective endocarditis. 2012 , 56, 4552-3	16

1697	Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against <i>Candida glabrata</i> with and without fks mutations. 2012 , 56, 5875-82	36
1696	Correlation of clinical outcomes with β -glucan levels in patients with invasive candidiasis. 2012 , 50, 2104-6	48
1695	Species identification and antifungal susceptibility testing of <i>Candida</i> bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. 2012 , 50, 3435-42	191
1694	Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of <i>Candida glabrata</i> . 2012 , 50, 1199-203	284
1693	Therapeutic drug monitoring of voriconazole in children. 2012 , 34, 77-84	29
1692	Echinocandin resistance due to simultaneous FKS mutation and increased cell wall chitin in a <i>Candida albicans</i> bloodstream isolate following brief exposure to caspofungin. 2012 , 61, 1330-1334	30
1691	Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against <i>Candida</i> species using time-kill methodology. 2012 , 24, 18-25	15
1690	Influence of fungicidal activity against <i>Candida tropicalis</i> on the efficacy of micafungin and liposomal amphotericin B in a neutropenic murine lethal infection model. 2012 , 90, 133-45	3
1689	Population pharmacokinetics of voriconazole in adults. 2012 , 56, 526-31	76
1688	Failure of echinocandin therapy in the treatment of <i>Candida glabrata</i> chorioretinitis. 2012 , 343, 98-100	2
1687	Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. 2012 , 97, 464-71	30
1686	Systemic antifungal therapy in critically ill patients without invasive fungal infection*. 2012 , 40, 813-22	95
1685	In vitro synergy testing of anidulafungin with fluconazole, tioconazole, 5-flucytosine and amphotericin B against some <i>Candida</i> spp. 2012 , 8, 690-8	7
1684	<i>Candida</i> and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. 2012 , 26, 1457-72	103
1683	<i>Penicillium</i> pneumonia in a patient with newly diagnosed Franklin disease. 2012 , 344, 69-71	2
1682	Impact of 4.0% chlorhexidine cord cleansing on the bacteriologic profile of the newborn umbilical stump in rural Sylhet District, Bangladesh: a community-based, cluster-randomized trial. 2012 , 31, 444-50	23
1681	Antifungal therapy and outcomes in infants with invasive <i>Candida</i> infections. 2012 , 31, 439-43	43
1680	Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. 2012 , 46 Suppl, S73-80	49

1679	Rapidly progressive kidney failure induced by fungal mycelia obstructing indwelling ureteral stents. 2012 , 2012,	1
1678	Infectious complications in leukemia. 772-793	
1677	[Recent trend in subacute meningitides]. 2012 , 52, 885-8	
1676	Primary retroperitoneal abscess caused by <i>Candida glabrata</i> . 2012 , 344, 332-4	4
1675	Fatal community-acquired primary <i>Candida</i> pneumonia in an alcoholic patient. 2012 , 51, 3159-61	4
1674	Otras esofagitis. Etiología infecciosa y tóxica/crónica. Esfagitis eosinofílica. 2012 , 11, 13-25	
1673	Fungal infection in solid organ recipients. 2012 , 30 Suppl 2, 49-56	9
1672	Cardiac emergencies: infective endocarditis, pericarditis, and myocarditis. 2012 , 96, 1149-69	12
1671	Antifungal effect of 4-arylthiosemicarbazides against <i>Candida</i> species. Search for molecular basis of antifungal activity of thiosemicarbazide derivatives. 2012 , 18, 4159-70	38
1670	Opportunistic fungal infections in the Asia-Pacific region. 2012 , 50, 18-25	36
1669	CRS-MIS in <i>Candida glabrata</i> : sphingolipids modulate echinocandin-Fks interaction. 2012 , 86, 303-13	45
1668	Chronic vulvovaginal candidiasis: what we know and what we have yet to learn. 2012 , 53, 247-54	22
1667	Echinocandin resistance in <i>Candida</i> species: mechanisms of reduced susceptibility and therapeutic approaches. 2012 , 46, 1086-96	77
1666	Sepsis and Infection. 2012 , 393-404	
1665	Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomised clinical trial. 2012 , 16, R57	16
1664	A survey on infection management practices in Italian ICUs. 2012 , 16, R221	7
1663	ESCMID* guideline for the diagnosis and management of <i>Candida</i> diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). 2012 , 18 Suppl 7, 53-67	241
1662	Comparison of the Bactec Fx Plus, Mycosis IC/F, Mycosis/F Lytic blood culture media and the BacT/Alert 3D FA media for detection of <i>Candida</i> species in seeded blood culture specimens containing therapeutic peak levels of fluconazole. 2012 , 26, 412-9	11

1661	Antifungal susceptibility testing: a primer for clinicians. 2012 , 32, 1112-22	8
1660	Discrepancy of in-vitro data and clinical efficacy of micafungin against <i>Candida tropicalis</i> endophthalmitis. 2012 , 18, 786-9	7
1659	Clinical efficacy and safety of intravenous itraconazole in the management of invasive candidiasis in patients of surgery and critical care. 2012 , 18, 515-21	2
1658	Comparison of in vitro and vivo efficacy of caspofungin against <i>Candida parapsilosis</i> , <i>C. orthopsilosis</i> , <i>C. metapsilosis</i> and <i>C. albicans</i> . 2012 , 174, 311-8	16
1657	Ten-year study of species distribution and antifungal susceptibilities of <i>Candida</i> bloodstream isolates at a Brazilian tertiary hospital. 2012 , 174, 389-96	21
1656	Bilateral polymicrobial osteomyelitis with <i>Candida tropicalis</i> and <i>Candida krusei</i> : a case report and an updated literature review. 2012 , 16, e16-22	12
1655	Epidemiology and predictors of a poor outcome in elderly patients with candidemia. 2012 , 16, e442-7	42
1654	Successful management of fungal pericarditis and endocarditis in a neonate: A case report. 2012 , 24, 195-9	6
1653	Constrictive pericarditis due to <i>Candida albicans</i> : an unexpected cause of pericardial effusion after heart transplantation. 2012 , 212, 551-2	2
1652	Iliac bone <i>Candida albicans</i> osteomyelitis in a patient with iliac crest bone autograft: a case report and review of the literature. 2012 , 40, 445-9	6
1651	Uso actual de los antifúngicos triazoles en niños. 2012 , 16, 82-93	
1650	Protocolo de estudio y manejo de pacientes con candidiasis sistémica en adultos. 2012 , 16, 118-122	1
1649	Zasady postępowania w zakażeniach wirusem Epsteina-Barr w hematologii, onkologii i transplantologii. Zalecenia grupy roboczej Polskiej Federacji Onkologów Transplantacji Szpiku. 2012 , 43, 48-53	1
1648	Surgeon cataract volume and endophthalmitis. 2012 , 119, 2415; author reply 2416	1
1647	[Cost analysis of 3 candins in the treatment of invasive candidiasis in adult non-neutropaenic patients in Spain]. 2012 , 36, 207-15	1
1646	Combination Antifungal Therapy: Is it for everyone and every mycosis?. 2012 , 16, 11-22	
1645	The Pro-debate: How can we improve the outcome of invasive fungal infection? The case for combination therapy. 2012 , 16, 3-10	
1644	[Fungal endocarditis with central and peripheral embolization: case report]. 2012 , 31, 449-53	7

1643	Brazilian guidelines for the management of candidiasis: a joint meeting report of three medical societies [Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia, Sociedade Brasileira de Medicina Tropical. 2012 , 16, S1-S34			1
1642	Voriconazole for Candida endophthalmitis. 2012 , 119, 2414-2415.e4			6
1641	[Ruptured cerebral aneurysm after a Candida parapsilosis prosthetic valve endocarditis]. 2012 , 59, 521-2			0
1640	Empirical antifungal treatment in the critically ill patients: how does it impact on the outcome?. 2012 , 16,			78
1639	Fungal arthritis of the wrist caused by Candida parapsilosis during infliximab therapy for rheumatoid arthritis. 2012 , 22, 903-906			10
1638	Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients. 2012 , 50, 439-45			23
1637	Invasive fungal infections during the neonatal period: diagnosis, treatment and prophylaxis. 2012 , 13, 193-205			8
1636	Miconazole mucoadhesive tablets: a novel delivery system. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1480-4	11.6		25
1635	Far-reaching conclusions based on weak and missing data. <i>Clinical Infectious Diseases</i> , 2012 , 55, 890-3; author reply 894-5	11.6		1
1634	Echinocandin use in the neonatal intensive care unit. 2012 , 46, 108-16			22
1633	Fungal endocarditis with central and peripheral embolization: Case report. 2012 , 31, 449-453			4
1632	Prevalence, distribution and antifungal susceptibility profiles of Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis bloodstream isolates. 2012 , 61, 1003-1008			32
1631	Outcomes following candiduria in extremely low birth weight infants. <i>Clinical Infectious Diseases</i> , 2012 , 54, 331-9	11.6		37
1630	Diagnosis, management and outcome of Candida endocarditis. 2012 , 18, E99-E109			74
1629	Antifungal prophylaxis in haematology patients: the role of voriconazole. 2012 , 18 Suppl 2, 1-15			23
1628	Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. 2012 , 18, 680-7			37
1627	Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000-2007. 2012 , 18, E185-7			31
1626	Direct maldi-tof mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. 2012 , 50, 176-9			155

1625	The end of an era in defining the optimal treatment of invasive candidiasis. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1123-5	11.6	20
1624	Invasive mycoses: diagnostic challenges. 2012 , 125, S14-24		148
1623	Invasive mycoses: strategies for effective management. 2012 , 125, S25-38		62
1622	Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. 2012 , 125, S3-13		632
1621	Disseminated candidemia refractory to caspofungin therapy in an infant with extremely low birth weight. 2012 , 111, 46-50		3
1620	Lactobacillus helveticus HY7801 ameliorates vulvovaginal candidiasis in mice by inhibiting fungal growth and NF- κ B activation. 2012 , 14, 39-46		24
1619	Pga13 in Candida albicans is localized in the cell wall and influences cell surface properties, morphogenesis and virulence. 2012 , 49, 322-31		37
1618	Changing pattern of fungal infection in burn patients. 2012 , 38, 520-8		39
1617	Effects of echinocandins on cytokine/chemokine production by human monocytes activated by infection with Candida glabrata or by lipopolysaccharide. 2012 , 72, 226-33		8
1616	The preanalytical optimization of blood cultures: a review and the clinical importance of benchmarking in 5 Belgian hospitals. 2012 , 73, 1-8		42
1615	Evaluation of the MALDI TOF-MS method for identification of Candida strains isolated from blood cultures. 2012 , 73, 65-7		40
1614	The changing epidemiology of healthcare-associated candidemia over three decades. 2012 , 73, 45-8		234
1613	Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature. 2012 , 73, 89-93		52
1612	Clinical characteristics and risk factors of ocular candidiasis. 2012 , 73, 149-52		30
1611	Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology. 2012 , 73, 338-42		13
1610	The PATH (Prospective Antifungal Therapy) Alliancefi registry and invasive fungal infections: update 2012. 2012 , 73, 293-300		173
1609	[Invasive fungal infection in critically ill patients]. 2012 , 30, 338-43		7
1608	Routine identification of medical fungi by the new Vitek MS matrix-assisted laser desorption ionization-time of flight system with a new time-effective strategy. 2012 , 50, 2107-10		77

1607	Using rapid diagnostic tests to optimize antimicrobial selection in antimicrobial stewardship programs. 2012 , 32, 677-87	51
1606	Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant <i>Candida parapsilosis</i> (2003-2007). 2012 , 18, 1100-9	50
1605	Therapeutic use of a cationic antimicrobial peptide from the spider <i>Acanthoscurria gomesiana</i> in the control of experimental candidiasis. 2012 , 12, 28	25
1604	<i>Candida parapsilosis</i> and the neonate: epidemiology, virulence and host defense in a unique patient setting. 2012 , 10, 935-46	29
1603	Optimizing drug therapy in the surgical intensive care unit. 2012 , 92, 1573-620	2
1602	ESCMID* guideline for the diagnosis and management of <i>Candida</i> diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. 2012 , 18 Suppl 7, 1-8	67
1601	ESCMID* guideline for the diagnosis and management of <i>Candida</i> diseases 2012: non-neutropenic adult patients. 2012 , 18 Suppl 7, 19-37	774
1600	Micafungin: a review of its use in the prophylaxis and treatment of invasive <i>Candida</i> infections. 2012 , 72, 2141-65	26
1599	Essentials for selecting antimicrobial therapy for intra-abdominal infections. 2012 , 72, e17-32	59
1598	Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. 2012 , 96, 748-57	85
1597	The postantifungal and paradoxical effects of echinocandins against <i>Candida</i> spp. 2012 , 7, 565-9	11
1596	Occurrence, presentation and treatment of candidemia. 2012 , 8, 755-65	41
1595	Antimicrobial Agents. 2012 , 379-402	1
1594	Treatment and prophylaxis of invasive candidiasis. 2012 , 36, 416-23	21
1593	Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. 2012 , 39, 1-10	37
1592	Invasive fungal infections in patients with cancer in the Intensive Care Unit. 2012 , 39, 464-71	45
1591	Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive <i>Candida</i> infections: a post hoc analysis. 2012 , 40, 521-6	12
1590	Mendelian traits causing susceptibility to mucocutaneous fungal infections in human subjects. 2012 , 129, 294-305; quiz 306-7	62

1589	Epidemiology of fungal infection in burns: therapeutic implications. 2012 , 38, 942-3; author reply 943-4	4
1588	Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance) registry, 2004-2008. 2012 , 74, 323-31	271
1587	[Candidemia and invasive candidiasis in the adult: clinical forms and treatment]. 2012 , 30, 483-91	5
1586	[Invasive fungal infection in haematology patients]. 2012 , 30, 572-9	6
1585	[Invasive fungal infection in solid organ transplant]. 2012 , 30, 645-53	3
1584	Impact of Port-A-Cath device management in cancer patients with candidaemia. 2012 , 82, 281-5	5
1583	Fluconazole exposure rather than clonal spreading is correlated with the emergence of <i>Candida glabrata</i> with cross-resistance to triazole antifungal agents. 2012 , 28, 306-15	16
1582	[Disseminated infection due to <i>Geotrichum capitatum</i>]. 2012 , 42, 574-5	2
1581	Epidemiology and prevalence of oropharyngeal candidiasis in Spanish patients with head and neck tumors undergoing radiotherapy treatment alone or in combination with chemotherapy. 2012 , 14, 740-6	10
1580	<i>Candida glabrata</i> : Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen. 2012 , 6, 154-164	7
1579	Advances in Antifungal Susceptibility Testing of <i>Candida</i> , 2010-2012. 2012 , 6, 141-153	2
1578	Healthcare-Associated Candidemia: Is It a Distinct Syndrome?. 2012 , 6, 165-169	
1577	Update on Amphotericin B Pharmacology and Dosing for Common Systemic Mycoses. 2012 , 6, 349-357	2
1576	A practical critique of antifungal treatment guidelines for haemato-oncologists. 2012 , 38, 203-16	9
1575	Encyclopedia of Intensive Care Medicine. 2012 , 1400-1404	
1574	ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. 2012 , 47, 1030-45	70
1573	Leukemia and Related Disorders. 2012 ,	3
1572	Mouse model of oropharyngeal candidiasis. 2012 , 7, 637-42	128

1571	Interactions of Yeasts, Moulds, and Antifungal Agents. 2012,	10
1570	Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. 2012, 7, e33705	146
1569	[Could antifungal lock be useful in the management of candidiasis linked with catheters?]. 2012, 28, 740-5	0
1568	Candidiasis. 2012, 1986-1990	
1567	[Prophylaxis against fungal infections in solid organ and hematopoietic stem cells transplantation]. 2012, 29 Suppl 1, S11-8	2
1566	Dysregulation of ion homeostasis by antifungal agents. 2012, 3, 133	16
1565	Posaconazole for the Treatment of Oropharyngeal Candidiasis, Including Triazole-Resistant Disease, in HIV-positive patients. 2012, 4, CMT.S5434	1
1564	[Advantages and drawbacks of amphotericin formulations in children: literature review]. 2012, 110, 46-51	6
1563	Antimicrobial management of intra-abdominal infections: literature's guidelines. 2012, 18, 865-71	29
1562	Fungal Infections in Patients of Paediatric Age. 2012,	
1561	Sepsis: Antimicrobial Therapy. 2012,	
1560	The Mycoses. 2012, 531-544	
1559	Post-Cardiac Surgery Fungal Endocarditis. 2012,	1
1558	Recurrent Candida parapsilosis infective endocarditis aortic root replacement. 2012, 73, 468-9	3
1557	Fungal Infections in Immunosuppressed Patients. 2012,	7
1556	Candida spp. isolated from inpatients, the environment, and health practitioners in the Pediatric Unit at the Universitary Hospital of the Jundiaí Medical College, State of São Paulo, Brazil. 2012, 45, 225-31	15
1555	Pathogens in Severe Sepsis: New Paradigms for Fungi Treatment. 2012, 149-170	
1554	Candida colonization in urine samples of ICU patients: determination of etiology, antifungal susceptibility testing and evaluation of associated risk factors. 2012, 174, 149-55	24

1553	Fatal candidemia caused by azole-resistant <i>Candida tropicalis</i> in patients with hematological malignancies. 2012 , 18, 741-6	23
1552	Insights into <i>Candida tropicalis</i> nosocomial infections and virulence factors. 2012 , 31, 1399-412	72
1551	Favorable outcome of chronic disseminated candidiasis in four pediatric patients with hematological malignancies. 2012 , 50, 315-9	5
1550	Impact of first-line antifungal agents on the outcomes and costs of candidemia. 2012 , 56, 3950-6	21
1549	Detection of yeasts in blood cultures by the Luminex xTAG fungal assay. 2012 , 50, 492-4	32
1548	[Antimicrobial treatment in burn injury patients]. 2012 , 61, 249-51, 254-6, 258	8
1547	Antifungal activities of different extracts of marine macroalgae against dermatophytes and <i>Candida</i> species. 2012 , 174, 223-32	21
1546	Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions. 2012 , 34, 611-7	11
1545	Is There Still a Place for Conventional Amphotericin B in the Treatment of Neonatal Fungal Infections?. 2012 , 6, 81-94	
1544	Medical Mycology for the Hospital Epidemiologist. 2012 , 6, 74-80	
1543	Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins. 2012 , 6, 95-106	
1542	Clinical Relevance of In Vitro Resistance of Echinocandins: a Focus on <i>Candida parapsilosis</i> . 2012 , 6, 107-112	1
1541	Comparison of the Etest and a rapid flow cytometry-based method with the reference CLSI broth microdilution protocol M27-A3 for the echinocandin susceptibility testing of <i>Candida</i> spp. 2012 , 31, 941-6	13
1540	Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy. 2012 , 55, 2-16	27
1539	Caspofungin: when and how? The microbiologist's view. 2012 , 55, 27-35	8
1538	Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008). 2012 , 55, 73-9	83
1537	Anidulafungin: when and how? The clinician's view. 2012 , 55, 36-44	10
1536	Infections in Heart and Lung Transplant Recipients. 2012 , 34, 19-25	5

1535	Fluconazole use and safety in the nursery. 2012 , 88 Suppl 2, S11-5	14
1534	Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice. 2012 , 12, 2414-28	111
1533	An alternative respiratory pathway on <i>Candida krusei</i> : implications on susceptibility profile and oxidative stress. 2012 , 12, 423-9	18
1532	[Fungemia in hospitals of the city of Buenos Aires, Argentina]. 2012 , 29, 144-9	10
1531	[Persistent candidemia in a renal-pancreatic transplant patient]. 2012 , 29, 76-80	1
1530	[<i>Candida</i> peritonitis in a haemodynamically stable patient. First choice of antifungal treatment □ fluconazole?]. 2012 , 29, 81-4	0
1529	[Echinocandins in a critically ill patient during continuous venovenous renal replacement]. 2012 , 29, 85-9	1
1528	[Clinical features of critically ill patients with invasive fungal infection]. 2012 , 29, 102-7	0
1527	[Antifungal treatment options in the critically ill patient]. 2012 , 29, 108-13	4
1526	[Invasive candidiasis in severely ill burned patients]. 2012 , 29, 93-6	1
1525	Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. 2012 , 161, 264-9.e2	41
1524	Emerging trends in candidemia: a higher incidence but a similar outcome. 2012 , 65, 64-70	55
1523	Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety. 2012 , 26, 87-96	21
1522	A scoring model of factors associated with <i>Candida glabrata</i> candidemia among critically ill patients. 2012 , 55, 228-36	14
1521	Antifungal susceptibility of <i>Candida albicans</i> in biofilms. 2012 , 55, 199-204	104
1520	Micafungin for candidiasis. 2012 , 55, 8-12	9
1519	Clinical utility of micafungin: pharmacokinetics, dosing, use in special populations and drug interactions. 2012 , 55, 33-38	2
1518	Azole-resistant <i>Candida</i> spp. [emerging pathogens?]. 2012 , 55, 24-32	43

1517	Invasive Candida infections in the ICU. 2012 , 55, 65-72	6
1516	Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study. 2012 , 55, e124-37	39
1515	Evaluation of the peptide nucleic acid fluorescence in situ hybridisation technology for yeast identification directly from positive blood cultures: an Italian experience. 2012 , 55, 388-92	21
1514	[Ambulatory therapy of aspergillosis in hematological and oncological patients]. 2012 , 55 Suppl 2, 30-4	
1513	New insights into hepatosplenic candidosis, a manifestation of chronic disseminated candidosis. 2012 , 55, e74-84	64
1512	Invasive fungal disease in PICU: epidemiology and risk factors. 2012 , 2, 6	51
1511	Traitements anti-infectieux. 2012 , 21, 206-211	
1510	Compendium of national guidelines for imaging of the pediatric patient. 2012 , 42, 82-94	5
1509	Neonatal intensive care unit candidemia: epidemiology, risk factors, outcome, and critical review of published case series. 2012 , 173, 219-28	30
1508	Evaluation of the commercial rapid trehalose test (GLABRATA RTT) for the point of isolation identification of Candida glabrata isolates in primary cultures. 2012 , 173, 259-64	10
1507	Use of antifungal agents in pediatric and adult high-risk areas. 2012 , 31, 337-47	6
1506	European survey on the use of prophylactic fluconazole in neonatal intensive care units. 2012 , 171, 439-45	25
1505	Outcomes associated with amphotericin B lipid complex (ABLC) prophylaxis in high-risk liver transplant patients. 2013 , 51, 155-63	10
1504	Diagnosis and inflammatory response of patients with candiduria. 2013 , 56, 61-9	10
1503	Practical considerations on current guidelines for the management of non-neutropenic adult patients with candidaemia. 2013 , 56, 11-20	14
1502	Orofacial diseases in solid organ and hematopoietic stem cell transplant recipients. 2013 , 19, 18-36	23
1501	Evaluation of the correlation of caspofungin MICs and treatment outcome in murine infections by wild type strains of Candida parapsilosis. 2013 , 77, 41-5	3
1500	How low can you go? Use of low- and standard-dose liposomal amphotericin B for treatment of invasive fungal infections. 2013 , 17, e615-20	6

1499	A 6-year antifungal stewardship programme in a teaching hospital. 2013 , 41, 621-8	63
1498	Duration of treatment for candidemia and risk for late-onset ocular candidiasis. 2013 , 41, 129-34	19
1497	Antifungal activity of geldanamycin alone or in combination with fluconazole against <i>Candida</i> species. 2013 , 175, 273-9	21
1496	Utilization of fluconazole in an intensive care unit at a university hospital in Brazil. 2013 , 35, 176-80	5
1495	A matched-control evaluation of an antifungal bundle in the intensive care unit at a university teaching hospital. 2013 , 35, 145-8	26
1494	Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections. 2013 , 69, 1031-6	13
1493	Echinocandins: production and applications. 2013 , 97, 3267-84	62
1492	What is the success of treatment of hip and knee candidal periprosthetic joint infection?. 2013 , 471, 3002-9	62
1491	Infection in neutropenic patients with cancer. 2013 , 29, 411-41	22
1490	Contemporary drug treatment of infective endocarditis. 2013 , 13, 251-8	9
1489	Complications of Fungal Cystitis. 2013 , 8, 212-216	
1488	Antifungal Prophylaxis in the Pediatric Intensive Care Unit. 2013 , 7, 361-371	1
1487	Update on Antifungal Resistance and its Clinical Impact. 2013 , 7, 224-234	4
1486	Treatment of Invasive <i>Candida</i> Infections in the Neonatal Intensive Care Unit. 2013 , 7, 96-109	
1485	Aerosolized Antifungals for the Prevention and Treatment of Invasive Fungal Infections. 2013 , 7, 110-118	2
1484	EUCAST and CLSI: Working Together Towards a Harmonized Method for Antifungal Susceptibility Testing. 2013 , 7, 59-67	23
1483	Are Echinocandins Better Than Azoles for Invasive Candidiasis?. 2013 , 7, 79-82	2
1482	Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer. 2013 , 3, 229-233	12

1481	Recommendations for the management of candidemia in neonates in Latin America. Latin America Invasive Mycosis Network. 2013 , 30, 158-70	3
1480	Invasive fungal infections in newborns and current management strategies. 2013 , 11, 709-21	20
1479	Candida cerebral abscesses: a case report and review of the literature. 2013 , 51, 779-84	20
1478	Biofilm formation by oral clinical isolates of Candida species. 2013 , 58, 1318-26	37
1477	BICO project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients. 2013 , 60, e1-e18	1
1476	Newer antifungals. 2013 , 5, 78-82	
1475	Candidaemia in the non-neutropenic patient: a critique of the guidelines. 2013 , 42, 294-300	15
1474	[Recommendations for the management of candidemia in adults in Latin America. Grupo Proyecto Bico]. 2013 , 30, 179-88	3
1473	Zakażenia grzybami Candida [Wyżwanie medycyny XXI wieku. 2013 , 88, 561-566	
1472	Management and diagnostic guidelines for fungal diseases in infectious diseases and clinical microbiology: critical appraisal. 2013 , 19, 1115-21	26
1471	Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. 2013 , 57, 4559-61	78
1470	Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. 2013 , 51, 2571-81	174
1469	Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications. 2013 , 57, 4769-81	70
1468	Fundamentals of Pharmaceutical Nanoscience. 2013 ,	13
1467	Infectiologie en ranimation. 2013 ,	
1466	Associated clinical characteristics of patients with candidemia among different Candida species. 2013 , 46, 463-8	15
1465	Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011. 2013 , 13, 353	19
1464	Pretransplant model for end stage liver disease score predicts posttransplant incidence of fungal infections after liver transplantation. 2013 , 56, 350-7	22

1463	Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. 2014 , 57, 342-50	28
1462	[Candida albicans endocarditis after treatment of complete atrioventricular canal]. 2013 , 23, 185-8	1
1461	Inhibitory effect of chromogenic culture media on the growth of Rhodotorula: relevance to the diagnosis of Rhodotorula spp. infections. 2013 , 121, 1109-17	
1460	Guidelines in infectious diseases: how reliable are they?. 2013 , 19, 1093-5	1
1459	Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA. 2013 , 11, 169	52
1458	Time to blood culture positivity as a predictor of clinical outcome in patients with Candida albicans bloodstream infection. 2013 , 13, 486	20
1457	Cyclooxygenase inhibitors reduce biofilm formation and yeast-hypha conversion of fluconazole resistant Candida albicans. 2013 , 51, 598-604	28
1456	Iatrogenic fungal infections of central nervous system. 2013 , 13, 399	7
1455	Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan. 2013 , 19, 946-50	4
1454	Efficacy and safety of liposomal amphotericin B for deep mycosis in patients with connective tissue disease. 2013 , 19, 691-7	3
1453	Acid suppression therapy as a risk factor for Candida esophagitis. 2013 , 58, 1282-6	13
1452	[Invasive candidiasis in non-neutropenic adults : Guideline-based management in the intensive care unit]. 2013 , 62, 1003-9	1
1451	Distribution and drug susceptibilities of Candida species causing candidemia from a medical center in central Taiwan. 2013 , 19, 1065-71	18
1450	EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial. 2013 , 14, 399	14
1449	Epidemiology of Candida Endocarditis. 2013 , 7, 306-310	1
1448	Infectious Complications of Mechanical Circulatory Support (MCS) Devices. 2013 , 15, 472	6
1447	Rare Invasive Fungal Infections: Epidemiology, Diagnosis and Management. 2013 , 7, 351-360	24
1446	Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis. 2013 , 39, 2226-30	38

1445	Invasive candidiasis in pediatric intensive care in Greece: a nationwide study. 2013 , 39, 2188-95	29
1444	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. 2013 , 39, 2092-106	138
1443	Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. 2013 , 89 Suppl 1, S25-7	6
1442	How to select an antifungal agent in critically ill patients. 2013 , 28, 717-27	19
1441	Invasive fungal infections: biomarkers and molecular approaches to diagnosis. 2013 , 33, 505-25	22
1440	Infections in the Adult Intensive Care Unit. 2013 ,	
1439	The evolving role of antifungal susceptibility testing. 2013 , 33, 465-75	20
1438	Urinary tract infection. 2013 , 29, 699-715	54
1437	Infective endocarditis in the intensive care unit. 2013 , 29, 923-51	13
1436	Résistance des Candida aux antifongiques : détection et mécanismes. 2013 , 2013, 71-77	
1435	Once weekly fluconazole for antifungal prophylaxis post-liver transplantation. 2013 , 15, 541-7	4
1434	Mechanisms of Candida biofilm drug resistance. 2013 , 8, 1325-37	233
1433	Fluconazole treatment hyperpolarizes the plasma membrane of Candida cells. 2013 , 51, 785-94	10
1432	Early fungal infection in an aortic prosthesis with probable cerebral metastasis: the success of a conservative strategy. 2013 , 33 Suppl 1, S41-5	
1431	Antimicrobial photodynamic inactivation inhibits Candida albicans virulence factors and reduces in vivo pathogenicity. 2013 , 57, 445-51	62
1430	Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients. 2013 , 11, 989-97	7
1429	Cardiac effects of echinocandin preparations - three case reports. 2013 , 38, 429-31	23
1428	Recent advances in the treatment of life-threatening, invasive fungal infections. 2013 , 14, 2361-74	16

1427	2-stage revision recommended for treatment of fungal hip and knee prosthetic joint infections. 2013 , 84, 517-23	82
1426	β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. 2013 , 188, 1100-9	151
1425	Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. 2013 , 168, 1059-73	300
1424	Incidence and outcome of early <i>Candida</i> peritonitis after liver and pancreas transplantation. 2013 , 56, 162-7	11
1423	Performance of matrix-assisted laser desorption-time of flight mass spectrometry for identification of clinical yeast isolates. 2013 , 56, 229-35	43
1422	Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials. 2013 , 54, 1479-87	10
1421	Micafungin for <i>Candida albicans</i> pacemaker-associated endocarditis: a case report and review of the literature. 2013 , 175, 129-34	15
1420	Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. 2013 , 39, 165-228	2975
1419	Intracellular pH homeostasis in <i>Candida glabrata</i> in infection-associated conditions. 2013 , 159, 803-813	22
1418	Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. 2013 , 17, 283-312	78
1417	Endogenous candida endophthalmitis in South Taiwan: A 10-year retrospective study. 2013 , 3, 146-150	2
1416	Do all candidemic patients need an ophthalmic examination?. 2013 , 17, e146-8	22
1415	Clinical study on anti-fungal drug activity against clinically isolated strains of oral <i>Candida</i> species. 2013 , 10, 87-94	2
1414	Rapid and reliable MALDI-TOF mass spectrometry identification of <i>Candida</i> non- <i>albicans</i> isolates from bloodstream infections. 2013 , 94, 262-6	51
1413	<i>Candida lipolytica</i> candidemia as a rare infectious complication of acute pancreatitis: a case report and literature review. 2013 , 46, 393-6	13
1412	Infections in intestinal and multivisceral transplant recipients. 2013 , 27, 359-77	26
1411	<i>Candida parapsilosis</i> meningitis in a patient with AIDS. Report of a case and review of the literature. 2013 , 30, 122-4	6
1410	Species distribution and drug susceptibilities of <i>Candida</i> isolates in TSARY 2010. 2013 , 76, 182-6	13

1409	[Epidemiological profile and sensitivity pattern of isolates causing invasive fungal infection vs. colonizing isolates in non-neutropenic critically ill patients]. 2013 , 30, 14-20	1
1408	PCR diagnosis of candidemia. 2013 , 28, 524	1
1407	Emergence of Antifungal Resistance and Resistant Candida Species in Health-care Setups. 2013 , 1, 22-24	
1406	Best laboratory practices for respiratory cultures. 2013 , 35, 35-43	1
1405	Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects. 2013 , 68 Suppl 3, iii5-16	24
1404	Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. 2013 , 16, 81-95	98
1403	Use of isothermal microcalorimetry to quantify the influence of glucose and antifungals on the growth of Candida albicans in urine. 2013 , 115, 1186-93	14
1402	Les Échinocandines : mise au point. 2013 , 15, 83-94	
1401	Ten Years of Experience with Peptide Nucleic Acid Fluorescent in Situ Hybridization in the Clinical Microbiology Laboratory. 2013 , 35, 79-83	1
1400	[Píco project: Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients. Grupo Proyecto Píco]. 2013 , 30, 135-49	
1399	[Recommendations for the management of candidemia in children in Latin America. Grupo Proyecto Píco]. 2013 , 30, 171-8	1
1398	Surveillance of bacterial and fungal infections in the postoperative period following liver transplantation: a series from 2005-2011. 2013 , 45, 2718-21	15
1397	[Epidemiology and prevention of nosocomial invasive infections by filamentous fungi and yeasts]. 2013 , 31, 328-41	4
1396	Recommendations for the management of candidemia in adults in Latin America. Latin America Invasive Mycosis Network. 2013 , 30, 179-88	22
1395	Píco Project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients. 2013 , 30, 135-49	9
1394	[Recommendations for the management of candidemia in neonates in Latin America. Grupo Proyecto Píco]. 2013 , 30, 158-70	12
1393	[Non-antibiotic anti-infectious treatments in urology]. 2013 , 23, 1342-56	
1392	Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain. 2013 , 23, 155-63	6

1391	[Venous catheter-related infections]. 2013 , 60, 215-25	1
1390	Recommendations for the management of candidemia in children in Latin America. Latin America Invasive Mycosis Network. 2013 , 30, 171-8	8
1389	A risk factor analysis of healthcare-associated fungal infections in an intensive care unit: a retrospective cohort study. 2013 , 13, 10	39
1388	The use of ciprofloxacin and fluconazole in Italian neonatal intensive care units: a nationwide survey. 2013 , 13, 5	6
1387	2013 WSES guidelines for management of intra-abdominal infections. 2013 , 8, 3	184
1386	Candida infections in solid organ transplantation. 2013 , 13 Suppl 4, 220-7	78
1385	Expanding the reach of antimicrobial stewardship. 2013 , 33, 118-21	2
1384	Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC). 2013 , 56, 532-42	8
1383	Neonatal infectious diseases: evaluation of neonatal sepsis. 2013 , 60, 367-89	245
1382	Candiduria in haematologic malignancy patients without a urinary catheter: nothing more than a frailty marker?. 2013 , 56, 311-4	16
1381	Principles of Treatment: Decision Making. 2013 , 55-81	
1380	Abdominal Infections. 2013 , 113-144	
1379	Evaluation and Management of Bacterial and Fungal Infections Occurring in Patients with a Hematological Malignancy: A 2011 Update. 2013 , 1165-1191	
1378	Combination antifungal therapy for invasive fungal infections in children and adults. 2013 , 11, 523-35	38
1377	Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. 2013 , 9, 911-26	68
1376	Safety of fluconazole in paediatrics: a systematic review. 2013 , 69, 1211-21	30
1375	Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. 2013 , 167, 132-6	30
1374	Invasive candidiasis: update on current pharmacotherapy options and future perspectives. 2013 , 14, 1515-28	22

1373	Management of candidaemia and invasive candidiasis in critically ill patients. 2013 , 42 Suppl, S29-35	11
1372	Infective Endocarditis. 2013 , 521-542	
1371	Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis. 2013 , 11, 347-58	18
1370	Echinocandins in invasive candidiasis. 2013 , 56, 601-9	6
1369	Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. 2013 , 75, 1381-95	26
1368	Short-course therapy for severe infections. 2013 , 42 Suppl, S22-4	9
1367	Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. 2013 , 8, 1117-26	99
1366	Candida urinary tract infection and Candida species susceptibilities to antifungal agents. 2013 , 66, 651-4	6
1365	Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis. 2013 , 43, 668-77	4
1364	Nystatin nanosizing enhances in vitro and in vivo antifungal activity against <i>Candida albicans</i> . 2013 , 68, 2099-105	22
1363	[<i>Candida peritonitis</i> : Prevalence and risk factors]. 2013 , 30, 189-92	1
1362	Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B. 2013 , 33 Suppl 1, S5-14	9
1361	Intraocular penetration of itraconazole in patient with fungal endophthalmitis. 2013 , 33, 579-81	8
1360	Single-center retrospective study of the incidence of, and risk factors for, non- <i>C. albicans</i> invasive candidiasis in hospitalized patients in China. 2014 , 52, 115-22	5
1359	Evaluation of MALDI-TOF mass spectrometry for the identification of medically-important yeasts in the clinical laboratories of Dijon and Lille hospitals. 2013 , 51, 25-32	60
1358	Antifungal lock therapy. 2013 , 57, 1-8	101
1357	Effect of alkylphospholipids on <i>Candida albicans</i> biofilm formation and maturation. 2013 , 68, 113-25	56
1356	Ocular manifestations of candidemia in children. 2013 , 32, 84-6	15

1355	Antimicrobial Drug Interactions in the Critically Ill Patients. 2013 , 8, 25-38	
1354	Amphotericin B deoxycholate for candidiasis in intensive care unit patients revisited: medical, ethical, and financial implications. 2013 , 187, 661-3	8
1353	Caspofungin MICs correlate with treatment outcomes among patients with <i>Candida glabrata</i> invasive candidiasis and prior echinocandin exposure. 2013 , 57, 3528-35	83
1352	Caspofungin benefit on phagocytes from patients with renal dysfunction infected with multidrug-resistant <i>Candida glabrata</i> . 2013 , 8, 1091-6	2
1351	Association of high levels of α -defensins and S100A proteins with <i>Candida</i> mannan detection in bronchoalveolar lavage fluid of preterm neonates. 2013 , 74, 19-25	12
1350	Treatment of fungal disease in the setting of neutropenia. 2013 , 2013, 423-7	45
1349	Amphotericin B in severe fungal infections: a critical reappraisal of the evidence. 2013 , 188, 1032	2
1348	De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic <i>Candida</i> infections. 2013 , 16, 1344-56	8
1347	Mixed bloodstream infections involving bacteria and <i>Candida</i> spp. 2013 , 68, 1881-8	46
1346	Successful management of <i>Candida krusei</i> monoarthritis after allo-SCT. 2013 , 48, 1585-6	0
1345	Genital mycotic infections in patients with diabetes. 2013 , 125, 33-46	51
1344	Isavuconazole pharmacodynamic target determination for <i>Candida</i> species in an in vivo murine disseminated candidiasis model. 2013 , 57, 5642-8	47
1343	Recent developments and current issues in the epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis. 2013 , 30, 131-41	90
1342	Epidemiology of <i>Candida</i> blood stream infections: experience of a tertiary care centre in North India. 2013 , 7, 670-5	39
1341	<i>Candida albicans</i> endocarditis in a child with acute lymphoblastic leukemia: A dreaded complication of intensive chemotherapy. 2013 , 34, 28-30	2
1340	The molecular mimicry and its possible role in origin of false-positive results in HCV-infection testing. 2013 , 29, 406-412	
1339	Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six <i>Candida</i> species as determined by the colorimetric Sensititre YeastOne method. 2013 , 51, 2691-5	33
1338	Advances in identification of clinical yeast isolates by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry. 2013 , 51, 1359-66	62

1337	Increasing echinocandin resistance in <i>Candida glabrata</i> : clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1724-32	11.6	530
1336	<i>Candida</i> Infections. 2013 , 32, E1-E15		
1335	Endocarditis caused by <i>Candida dubliniensis</i> . 2013 , 346, 237-9		10
1334	<i>Candida albicans</i> osteomyelitis in an infant: a case report and literature review. 2013 , 22, 491-7		5
1333	Examination of the in vitro fungicidal activity of echinocandins against <i>Candida lusitanae</i> by time-killing methods. 2013 , 68, 864-8		19
1332	Pharmacokinetics and pharmacodynamics of anidulafungin for experimental <i>Candida</i> endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection. 2013 , 57, 281-8		14
1331	Intra-abdominal fungal infections. 2013 , 26, 441-6		15
1330	Azole resistance in <i>Aspergillus fumigatus</i> : a growing public health concern. 2013 , 26, 493-500		154
1329	Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011. 2013 , 51, 841-8		63
1328	New antifungal antibiotics. 2013 , 26, 168-74		26
1327	Flucytosine antagonism of azole activity versus <i>Candida glabrata</i> : role of transcription factor Pdr1 and multidrug transporter Cdr1. 2013 , 57, 5543-7		7
1326	Activity of MK-3118, a new oral glucan synthase inhibitor, tested against <i>Candida</i> spp. by two international methods (CLSI and EUCAST). 2013 , 68, 858-63		77
1325	Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis. 2013 , 57, 1672-6		46
1324	Fluconazole versus an echinocandin for <i>Candida glabrata</i> fungaemia: a retrospective cohort study. 2013 , 68, 922-6		39
1323	T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. 2013 , 5, 182ra54		196
1322	Accuracy of species-level identification of yeast isolates from blood cultures from 10 university hospitals in South Korea by use of the matrix-assisted laser desorption ionization-time of flight mass spectrometry-based Vitek MS system. 2013 , 51, 3063-5		18
1321	Management of chemotherapy-induced neutropenic fever. 2013 , 41, 96-108		3
1320	Antifungal activity of azole compounds CPA18 and CPA109 against azole-susceptible and -resistant strains of <i>Candida albicans</i> . 2013 , 68, 1111-9		16

1319	Activities of systemically administered echinocandins against in vivo mature <i>Candida albicans</i> biofilms developed in a rat subcutaneous model. 2013 , 57, 2365-8	36
1318	Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. 2013 , 57, 4999-5004	43
1317	Blood culture diagnostics [standards and recent developments ¹). 2013 , 36,	
1316	Invasive fungal infections in patients with chronic granulomatous disease. 2013 , 764, 27-55	64
1315	Adjuvanticity of a recombinant calreticulin fragment in assisting anti- β -glucan IgG responses in T cell-deficient mice. 2013 , 20, 582-9	10
1314	Invasive fungal infections in transplant recipients. 2013 , 1, 85-105	37
1313	Impact on hospital mortality of catheter removal and adequate antifungal therapy in <i>Candida</i> spp. bloodstream infections. 2013 , 68, 206-13	81
1312	Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. 2013 ,	35
1311	Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis. 2013 , 32, e419-25	17
1310	Glycerophosphocholine utilization by <i>Candida albicans</i> : role of the Git3 transporter in virulence. 2013 , 288, 33939-33952	17
1309	Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. 2013 , 57, 4053-7	46
1308	Interlaboratory variability of Caspofungin MICs for <i>Candida</i> spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?. 2013 , 57, 5836-42	172
1307	Editorial Board. 2013 , 57, A1-A1	42
1306	Evaluation of bactec mycosis IC/F and Plus Aerobic/F blood culture bottles for detection of <i>Candida</i> in the presence of antifungal agents. 2013 , 51, 3683-7	16
1305	Reply to "Why should we monitor (1-3)- β -D-glucan levels during invasive candidiasis? Just ask your ophthalmologist!". 2013 , 51, 1647	
1304	Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients. 2013 , 13, 37	9
1303	Usefulness of time-to-positivity in aerobic and anaerobic vials to predict the presence of <i>Candida glabrata</i> in patients with candidaemia. 2013 , 68, 2839-41	11
1302	Multicenter study evaluating the Vitek MS system for identification of medically important yeasts. 2013 , 51, 2267-72	73

1301	Aspergillus tracheobronchitis causing subtotal tracheal stenosis in a liver transplant recipient. 2013 , 2013, 928289	2
1300	Invasive fungal infections in infants-focus on anidulafungin. 2013 , 7, 7-11	5
1299	Prise en charge des infections chez les adultes transplantés d'organe(s). 2013 , 503-521	
1298	Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era. 2013 , 27, E454-61	66
1297	Antifungal drug usage in haematologic patients during a 4-year period in an Asian university teaching hospital. 2013 , 43, 541-6	4
1296	Metabolic and toxicological considerations for sepsis drug treatments. 2013 , 9, 79-89	2
1295	Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. 2013 , 19, E343-53	151
1294	Impact of an antimicrobial stewardship program comprehensive care bundle on management of candidemia. 2013 , 33, 137-43	65
1293	Candida albicans and non-Candida albicans fungemia in an institutional hospital during a decade. 2013 , 51, 33-7	38
1292	Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs. 2013 , 51, 117-24	79
1291	Candida albicans pathogenicity mechanisms. 2013 , 4, 119-28	977
1290	Time to initiation of antifungal therapy for neonatal candidiasis. 2013 , 57, 2550-5	4
1289	In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. 2013 , 51, 2608-16	66
1288	Clinical impact of time to positivity for Candida species on mortality in patients with candidaemia. 2013 , 68, 2890-7	44
1287	In the Literature. <i>Clinical Infectious Diseases</i> , 2013 , 56, iii-iv	11.6
1286	Intraocular penetration of intravenous micafungin in inflamed human eyes. 2013 , 57, 4027-30	25
1285	Candida glabrata sepsis associated with chorioamnionitis in an in vitro fertilization pregnancy: case report and review. <i>Clinical Infectious Diseases</i> , 2013 , 56, 555-8	11.6 17
1284	Infections fongiques sévères en réanimation. 2013 , 273-304	

1283	[JSMM clinical practice guidelines for diagnosis and treatment of invasive candidiasis]. 2013 , 54, 147-251	8
1282	Bibliographical investigation (domestic and overseas) on the treatment of endogenous Candida endophthalmitis over an 11-year period. 2013 , 54, 53-67	2
1281	Using Galleria mellonella-Candida albicans infection model to evaluate antifungal agents. 2013 , 36, 1482-7	53
1280	Probiotics for vulvovaginal candidiasis in non-pregnant women. 2013 ,	4
1279	The management of infection in myeloma. 276-287	
1278	Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. 2013 , 41, 580-637	4914
1277	Incidence, classification, and risk stratification for Candida central line-associated bloodstream infections in pediatric patients at a tertiary care children's hospital, 2000-2010. 2013 , 34, 1266-71	5
1276	Update on antifungal resistance in children: epidemiology and recommendations. 2013 , 32, 556-7	1
1275	Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH. 2013 , 25, 376-8	9
1274	Carriage-associated Streptococcus pneumoniae serotype 1 in Brussels, Belgium. 2013 , 32, 86-7	5
1273	Candidemia in ICU patients with sepsis. 2013 , 41, e385	6
1272	Association of maternal smoking during pregnancy with infant hospitalization and mortality due to infectious diseases. 2013 , 32, e1-7	32
1271	Candida krusei arthritis in an adolescent with acute myelogenous leukemia. 2013 , 32, 1142-4	3
1270	2B or not 2B for selective decontamination of the digestive tract in the surviving sepsis campaign guidelines. 2013 , 41, e385-6	5
1269	The epidemiology of neonatal and pediatric candidemia in England and Wales, 2000-2009. 2013 , 32, 23-6	31
1268	Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients. 2013 , 96, 573-8	39
1267	The BMT/SCT pharmacopoeia. 411-508	
1266	Candida tropicalis: diagnostic dilemmas for an unusual prosthetic hip infection. 2013 , 159, 123-5	8

1265	[Diagnosis, treatment and prevention of infectious diseases. Topics: III. Various problems in antimicrobial agents; 2. Progresses and appropriate use of anti-fungal agents]. 2013 , 102, 2915-21	
1264	Successful treatment of recurrent candidemia due to candidal thrombophlebitis associated with a central venous catheter using a combination of fosfluconazole and micafungin. 2013 , 52, 2139-43	1
1263	Invasive candidosis: contrasting the perceptions of infectious disease physicians and intensive care physicians. 2013 , 46, 466-71	1
1262	Treatment of invasive candidiasis in the elderly: a review. 2013 , 8, 1199-208	51
1261	Intensive care unit-related fluconazole use in Spain and Germany: patient characteristics and outcomes of a prospective multicenter longitudinal observational study. 2013 , 6, 15-25	5
1260	[Candida esophagitis in an immunocompetent women. A case report]. 2013 , 36, 551-6	3
1259	Outcomes associated with conventional versus lipid-based formulations of amphotericin B in propensity-matched groups. 2013 , 5, 507-17	1
1258	[Endogenous endophthalmitis: case report and brief review of a serious ocular disease]. 2013 , 30, 516-21	
1257	Epidemiology of cryptococcal meningitis in the US: 1997-2009. 2013 , 8, e56269	197
1256	Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis. 2013 , 8, 31-4	22
1255	Etiology, diagnosis and treatment of infectious esophagitis. 2013 , 8, 333-7	36
1254	Optimizing Containment and Control of Candida parapsilosis Fungemia among Neonates in the Outbreak Setting Using a Mathematical Modeling Approach. 2013 , 2013, 1-11	
1253	Appropriateness and cost-effectiveness in the treatment of invasive candidiasis in Internal Medicine Wards. 2014 , 8, 221	
1252	Invasive candidiasis in critical care setting, updated recommendations from "Invasive Fungal Infections-Clinical Forum", Iran. 2014 , 3, 102-12	1
1251	[Invasive candidiasis in newborns: diagnosis, treatment and prophylaxis]. 2014 , 31, 73-83	9
1250	Surveillance of Candida spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitals. 2014 , 9, e97325	21
1249	Nosocomial candidemia; risk factors and prognosis revisited; 11 years experience from a Norwegian secondary hospital. 2014 , 9, e103916	26
1248	The widely used ATB FUNGUS 3 automated readings in China and its misleading high MICs of Candida spp. to azoles: challenges for developing countries' clinical microbiology labs. 2014 , 9, e114004	12

1247	Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study. 2014 , 25, 299-304	3
1246	Oral complications and management strategies for patients undergoing cancer therapy. 2014 , 2014, 581795	47
1245	Susceptibility of <i>Candida</i> spp. isolated from blood cultures as evaluated using the M27-A3 and new M27-S4 approved breakpoints. 2014 , 56, 477-82	29
1244	Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study. 2014 , 6, 39-47	24
1243	<i>Candida Albicans</i> Infections. 2014 ,	
1242	Antifungal susceptibility testing: current role from the clinical laboratory perspective. 2014 , 6, e2014030	16
1241	[Characterization of azole resistance mechanisms in Chilean clinical isolates of <i>Candida albicans</i>]. 2014 , 31, 511-7	3
1240	Management of <i>Candida</i> infections in liver transplant recipients: current perspectives. 2014 , 45	
1239	Total Parenteral Nutrition Changes Species Distribution in Patients with Fungemia. 2014 , 80, 278-280	
1238	<i>Candida parapsilosis</i> osteomyelitis. 2014 , 2014,	5
1237	8.12 Invasive Pilzinfektionen. 2014 ,	
1236	In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates. 2014 , 63, 1638-1643	19
1235	Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs. 2014 , 145, 867-73	90
1234	Unusual case of an elbow mass caused by <i>Candida</i> arthritis in a patient with systemic lupus erythematosus. 2014 , 19, 409-11	1
1233	Fluconazole affects the alkali-metal-cation homeostasis and susceptibility to cationic toxic compounds of <i>Candida glabrata</i> . 2014 , 160, 1705-1713	13
1232	Applied Antifungal Pharmacometrics: Fluconazole and Echinocandins in the Treatment of Candidemia and Invasive Candidiasis. 2014 , 297-323	
1231	Esophageal Disorders Related to Medication, Trauma, and Infection. 2014 , 143-155	
1230	<i>Candida</i> Endophthalmitis. 2014 , 8, 271-276	

1229	Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children. 2014 , 58, 6742-6	9
1228	Invasive candidiasis as a cause of sepsis in the critically ill patient. 2014 , 5, 161-9	181
1227	Tackling candidemia in pediatric intensive care units: a global concern!. 2014 , 81, 1139-40	2
1226	Low but sufficient anidulafungin exposure in critically ill patients. 2014 , 58, 304-8	21
1225	Rare infection of implantable cardioverter-defibrillator lead with <i>Candida albicans</i> : case report and literature review. 2014 , 8, 193-201	13
1224	Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. 2014 , 44, 1315-32	50
1223	Maintenance of therapeutic concentrations of micafungin administered 5 days/week in a leukemic adolescent with invasive candidiasis. 2014 , 20, O975-6	0
1222	Contribution of the Slt2-regulated transcription factors to echinocandin tolerance in <i>Candida glabrata</i> . 2014 , 14, 1128-31	9
1221	Successful treatment of an infant infected with refractory <i>C. parapsilosis</i> with caspofungin. 2014 , 60, 329-30	3
1220	<i>Candida glabrata</i> Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen?. 2014 , 2014, 371631	11
1219	A virtual infection model quantifies innate effector mechanisms and <i>Candida albicans</i> immune escape in human blood. 2014 , 10, e1003479	54
1218	Clinical and microbiological characteristics of <i>Rhodotorula mucilaginosa</i> infections in a tertiary-care facility. 2014 , 32, 304-9	20
1217	Septic coronary artery embolism treated with aspiration thrombectomy: case report and review of literature. 2014 , 41, 437-9	15
1216	Nosocomial candiduria in chronic liver disease patients at a hepatobiliary center. 2014 , 18, 639-40	1
1215	Management of candidemia: getting better, but not there yet. 2014 , 42, 1554-6	1
1214	Micafungin: an evidence-based review of its place in therapy. 2014 , 9, 27-39	15
1213	Evaluation of treatment of invasive fungal infections. 2014 , 5, 47-52	4
1212	Invasive candidiasis in intensive care unit; consensus statement from an Iranian panel of experts, July 2013. 2014 , 5, 2042533313517689	8

1211	Drug-resistant <i>Candida glabrata</i> infection in cancer patients. 2014 , 20, 1833-40		116
1210	Normvarianten und Veränderungen der Zungenoberseite. 2014 , 8, 339-358		
1209	Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible <i>Candida parapsilosis</i> isolates with different degrees of caspofungin susceptibility. 2014 , 58, 229-36		10
1208	The adaptor CARD9 is required for adaptive but not innate immunity to oral mucosal <i>Candida albicans</i> infections. 2014 , 82, 1173-80		49
1207	<i>Candida utilis</i> catheter-related bloodstream infection. 2014 , 6, 70-2		8
1206	Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. 2014 , 61, 393-400		67
1205	Editorial commentary: Is the debate about treatment of <i>Candida parapsilosis</i> complex infections with echinocandins much ado about nothing?. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1422-3	11.6	5
1204	Cardiac toxicity of some echinocandin antifungals. 2014 , 13, 5-14		25
1203	An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America. 2014 , 57, 12-8		14
1202	State of the Art in the Laboratory Methods for the Diagnosis of Invasive Fungal Diseases. 2014 , 281-297		
1201	Serum albumin promotes ATP-binding cassette transporter-dependent sterol uptake in yeast. 2014 , 14, 1223-33		16
1200	Outcomes, impact on management, and costs of fungal eye disease consults in a tertiary care setting. 2014 , 121, 2334-9		20
1199	Identification of immunogenic proteins of <i>Candida parapsilosis</i> by serological proteome analysis. 2014 , 116, 999-1009		12
1198	Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: a single centre experience. 2014 , 68, 20-7		22
1197	Role of FKS Mutations in <i>Candida glabrata</i> : MIC values, echinocandin resistance, and multidrug resistance. 2014 , 58, 4690-6		154
1196	Problems related to antifungal prescription: a qualitative study of the views of intensivists. 2014 , 20, 460-6		1
1195	Caspofungin exposure-response relationships in adult patients with mucosal or invasive candidiasis. 2014 , 3, 43-50		1
1194	Trailing or paradoxical growth of <i>Aspergillus flavus</i> exposed to caspofungin is independent of genotype. 2014 , 63, 1584-1589		7

1193	Synergistic effect of amphotericin B and tyrosol on biofilm formed by <i>Candida krusei</i> and <i>Candida tropicalis</i> from intrauterine device users. 2014 , 52, 853-61	20
1192	Epidemiology, clinical characteristics, and outcome of invasive aspergillosis in renal transplant patients. 2014 , 16, 951-7	24
1191	Expressed Breast Milk as a Predictor of Neonatal Yeast Colonization in an Intensive Care Setting. 2014 , 3, 213-20	4
1190	Management of invasive candidiasis in nonneutropenic ICU patients. 2014 , 2, 105-15	5
1189	Interpretation of Fungal Culture Results. 2014 , 8, 312-321	11
1188	How to treat severe infections in critically ill neutropenic patients?. 2014 , 14, 512	6
1187	<i>Candida albicans</i> brain abscesses in an injection drug user patient: a case report. 2014 , 7, 837	12
1186	Presence of <i>Candida</i> cell wall derived polysaccharides in the sera of intensive care unit patients: relation with candidaemia and <i>Candida</i> colonisation. 2014 , 18, R135	31
1185	Isolated pulmonary valve infective endocarditis in a middle aged man caused by <i>Candida albicans</i> : a case report. 2014 , 14, 557	7
1184	Catheter-related <i>Candida</i> bloodstream infection in intensive care unit patients: a subgroup analysis of the China-SCAN study. 2014 , 14, 594	12
1183	Relationship of fluconazole prophylaxis with fungal microbiology in hospitalized intra-abdominal surgery patients: a descriptive cohort study. 2014 , 18, 590	12
1182	Impact of targeted antifungal prophylaxis in heart transplant recipients at high risk for early invasive fungal infection. 2014 , 97, 1192-7	24
1181	Characteristics of surgical patients receiving inappropriate empiric antimicrobial therapy. 2014 , 77, 546-54	3
1180	Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting. 2014 , 33, e198-206	14
1179	Positions and numbers of FKS mutations in <i>Candida albicans</i> selectively influence in vitro and in vivo susceptibilities to echinocandin treatment. 2014 , 58, 3626-35	48
1178	Fluconazole prophylaxis for prevention of invasive candidiasis in infants. 2014 , 26, 151-6	15
1177	Current concepts in the management of periprosthetic fungal joint infection using antifungal bone cement. 2014 , 25, 169-174	4
1176	Impact of therapeutic strategies on the prognosis of candidemia in the ICU. 2014 , 42, 1423-32	108

1175	Evaluation of a positive yeast-in-blood service. 2014 , 348, 43-6	2
1174	Micafungin Use. 2014 , 22, 38-41	
1173	Echinocandin resistance: an emerging clinical problem?. 2014 , 27, 484-92	213
1172	Antifungal resistance does not necessarily affect <i>Candida glabrata</i> fitness. 2014 , 26, 32-6	14
1171	Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. 2014 , 58, 1529-37	89
1170	Multidrug resistance in fungi: regulation of transporter-encoding gene expression. 2014 , 5, 143	79
1169	From the case records of KKCTH [An infant with failure to thrive and candidial sepsis. 2014 , 6, 153-158	
1168	Micosis del sistema nervioso central. 2014 , 233-251	
1167	Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. 2014 , 311, 1742-9	79
1166	Failed Reverse Total Shoulder Arthroplasty Caused by Recurrent <i>Candida glabrata</i> Infection with Prior <i>Serratia marcescens</i> Coinfection. 2014 , 2014, 142428	10
1165	An Observational Study on Early Empiric versus Culture-Directed Antifungal Therapy in Critically Ill with Intra-Abdominal Sepsis. 2014 , 2014, 479413	4
1164	Incidence and clinical predictors of ocular candidiasis in patients with <i>Candida</i> fungemia. 2014 , 2014, 650235	18
1163	Cervical Bone Graft <i>Candida albicans</i> Osteomyelitis: Management Strategies for an Uncommon Infection. 2014 , 2014, 986393	1
1162	Future directions for anti-biofilm therapeutics targeting <i>Candida</i> . 2014 , 12, 375-82	58
1161	Update on Vaginitis. 2014 , 34, 1-5	
1160	<i>Candida glabrata</i> vertebral osteomyelitis in an immunosuppressed patient. 2014 , 17, 229-31	5
1159	Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant <i>Candida</i> Species and <i>Aspergillus</i> species isolates. 2014 , 58, 1248-51	78
1158	Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to Echinocandins in <i>Candida glabrata</i> . 2014 , 52, 790-5	36

1157	Improving the management of candidemia through antimicrobial stewardship interventions. 2014 , 78, 157-61	43
1156	Acute limb ischemia due to <i>Candida lusitanae</i> aortic valve endocarditis. 2014 , 43, 338-40	6
1155	Evidence-based protocol: diagnosis and treatment of catheter-associated urinary tract infection within adult neurocritical care patient population. 2014 , 49, 29-43	5
1154	Successful caspofungin treatment of persistent candidemia in extreme prematurity at 23 and 24 weeks' gestation. 2014 , 113, 191-4	6
1153	Systemic fungal infections. 2014 , 42, 26-30	3
1152	Characterization of a lysophospholipid acyltransferase involved in membrane remodeling in <i>Candida albicans</i> . 2014 , 1841, 505-13	7
1151	[Bilateral endogenous ophthalmitis due to <i>Candida glabrata</i> after complicated bariatric surgery]. 2014 , 89, 282-5	3
1150	[Antifungal treatment for suspected or proved candidiasis in the critically ill]. 2014 , 33, 232-9	3
1149	Photodynamic fungicidal efficacy of hypericin and dimethyl methylene blue against azole-resistant <i>Candida albicans</i> strains. 2014 , 57, 35-42	36
1148	Atlas of Geriatric Dermatology. 2014 ,	2
1147	A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. 2014 , 20, O50-7	67
1146	Candidal psoas abscess following persistent pyuria in a renal transplant recipient. 2014 , 46, 269-73	4
1145	Is empiric therapy with fluconazole appropriate for esophageal candidiasis?. 2014 , 33, 165-8	
1144	Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of <i>Aspergillus</i> and <i>Candida</i> species. 2014 , 33, 7-21	73
1143	Treatment and outcomes of <i>Candida</i> osteomyelitis: review of 53 cases from the PATH Allianceefi registry. 2014 , 33, 135-41	19
1142	Pediatric Hematology-Oncology in Countries with Limited Resources. 2014 ,	6
1141	Clinical practice guidelines for the management of invasive <i>Candida</i> infections in adults in the Middle East region: Expert panel recommendations. 2014 , 7, 6-19	22
1140	Periprosthetic Joint Infection of the Hip and Knee. 2014 ,	1

1139	Infectious Complications in Cancer Patients. 2014 ,	4
1138	Fluconazole prophylaxis in preterm infants: a multicenter case-controlled analysis of efficacy and safety. 2014 , 90 Suppl 1, S87-90	17
1137	Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. 2014 , 53, 429-54	29
1136	Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia. 2014 , 47, 245-53	5
1135	Invasive fungal infections in the ICU: how to approach, how to treat. 2014 , 19, 1085-119	95
1134	[Neonatal renal candidiasis: a case report]. 2014 , 21, 287-90	4
1133	Candida Biofilm: Clinical Implications of Recent Advances in Research. 2014 , 8, 72-80	1
1132	Recent Studies on Invasive Fungal Diseases in Children and Adolescents: an Update. 2014 , 8, 56-66	1
1131	Procalcitonin as a marker of Candida species detection by blood culture and polymerase chain reaction in septic patients. 2014 , 14, 9	26
1130	Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013. 2014 , 14, 14	13
1129	Follow guidance to individualize antibacterial regimens when treating infective endocarditis. 2014 , 30, 100-104	
1128	Assessment of caspofungin susceptibility of Candida glabrata by the Etestfi , CLSI, and EUCAST methods, and detection of FKS1 and FKS2 mutations. 2014 , 33, 1247-52	18
1127	Effects of echinocandin preparations on adult rat ventricular cardiomyocytes. Preliminary results of an in vitro study. 2014 , 63, 129-34	8
1126	Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. 2014 , 33, 259-64	58
1125	Qu'apportent les recommandations 2012 de l'European Society of Clinical Microbiology and Infectious Diseases sur la prise en charge des candidoses invasives chez les patients non neutrophiques ?. 2014 , 23, 243-244	
1124	Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives. 2014 , 43, 207-14	20
1123	Clinical characteristics of septic pulmonary embolism in adults: a systematic review. 2014 , 108, 1-8	94
1122	Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. 2014 , 20, O245-54	185

1121	MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1219-26	11.6	117
1120	Clinical features of Candidiasis in patients with inherited interleukin 12 receptor β deficiency. <i>Clinical Infectious Diseases</i> , 2014 , 58, 204-13	11.6	81
1119	Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight <i>Candida</i> species and the CLSI M27-A3 broth microdilution method. 2014 , 58, 916-22		35
1118	Diagnosis, management, and prevention of catheter-associated urinary tract infections. 2014 , 28, 105-19		86
1117	Diseases of the mouth. 2014 , 41, 75-90		34
1116	Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. 2014 , 69, 1993-9		84
1115	Invasive fungal infections in solid organ transplant recipients. 2014 , 20 Suppl 7, 27-48		125
1114	Antifungal stewardship in invasive <i>Candida</i> infections. 2014 , 20 Suppl 6, 11-8		56
1113	Inhibition of Fungal Biofilms. 2014 , 273-289		1
1112	Changes in the incidence of candidiasis in neonatal intensive care units. 2014 , 133, 236-42		90
1111	Antibiofilm Agents. 2014 ,		6
1110	What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. 2014 , 40, 808-19		75
1109	Current Antifungal Agents for Treatment of Central Nervous System Infections. 2014 , 8, 146-152		6
1108	CNS Infections. 2014 ,		
1107	Sulfone derivatives reduce growth, adhesion and aspartic protease SAP2 gene expression. 2014 , 30, 2511-21		9
1106	Effects of azole treatments on the physical properties of <i>Candida albicans</i> plasma membrane: a spin probe EPR study. 2014 , 1838, 465-73		9
1105	Fungal infections and critically ill adults. 2014 , 14, 262-267		4
1104	Intraabdominal infections in the intensive care unit. 2014 , 29, 247-54		10

1103	Neonatal sepsis: progress towards improved outcomes. 2014 , 68 Suppl 1, S24-32	172
1102	Fungal infections of the central nervous system. 2014 , 121, 1383-401	35
1101	Management of infections related to totally implantable venous-access ports: challenges and perspectives. 2014 , 14, 146-59	106
1100	Catheter-Related Bloodstream Infections Review. 2014 , 3, e32-e49	4
1099	Pediatric and Adolescent Urologic Imaging. 2014 ,	3
1098	Multilaboratory study of epidemiological cutoff values for detection of resistance in eight <i>Candida</i> species to fluconazole, posaconazole, and voriconazole. 2014 , 58, 2006-12	87
1097	An Italian consensus for invasive candidiasis management (ITALIC). 2014 , 42, 263-79	34
1096	Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). 2014 , 93, 13-32	94
1095	Fungal infections associated with long-term mechanical circulatory support-diagnosis and management. 2014 , 29, 95-100	12
1094	Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of <i>Candida</i> by use of CLSI methods and interpretive criteria. 2014 , 52, 108-14	42
1093	Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis. 2014 , 120, 1255-62	42
1092	Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration. 2014 , 34, e162-8	9
1091	Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole. 2014 , 103, 3843-3858	19
1090	Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. 2014 , 14, 2758-64	74
1089	Evaluation of anticandidal and antioxidant activities of phenolic compounds from <i>Pyrostegia venusta</i> (Ker Gawl.) Miers. 2014 , 224, 136-41	14
1088	Antifungal prophylaxis in liver transplantation: a systematic review and network meta-analysis. 2014 , 14, 2765-76	28
1087	Oral administration of the broad-spectrum antibiofilm compound toremifene inhibits <i>Candida albicans</i> and <i>Staphylococcus aureus</i> biofilm formation in vivo. 2014 , 58, 7606-10	19
1086	Third case of <i>Candida dubliniensis</i> endogenous endophthalmitis in North America: case report and review of the literature. 2014 , 34, 945-50	8

1085	Interaction between caspofungin or voriconazole and cefoperazone-sulbactam or piperacillin-tazobactam by in vitro and in vivo methods. 2014 , 122, 412-7	5
1084	Antifungal clinical trials and guidelines: what we know and do not know. 2014 , 4, a019745	7
1083	In vitro susceptibility profile of 200 recent clinical isolates of <i>Candida</i> spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents. 2014 , 24, 303-7	23
1082	Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. 2014 , 48, 683-90	33
1081	Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1527-33	11.6 22
1080	Regional data analysis of <i>Candida</i> non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. 2014 , 57, 602-11	67
1079	Positive tip culture with <i>Candida</i> and negative blood culture: to treat or not to treat? A systematic review with meta-analysis. 2014 , 46, 854-61	4
1078	Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of <i>Candida</i> by using CLSI methods and interpretive criteria. 2014 , 52, 3223-9	41
1077	Vertebral infection with <i>Candida albicans</i> failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine. 2014 , 6, 6-9	9
1076	Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. 2014 , 74, 1573-85	71
1075	Treatment with echinocandins during continuous renal replacement therapy. 2014 , 18, 218	13
1074	Pharmacokinetics of caspofungin in ICU patients. 2014 , 69, 3294-9	52
1073	Bilateral endogenous ophthalmitis due to <i>Candida glabrata</i> after complicated bariatric surgery. 2014 , 89, 282-285	
1072	Echinocandin failure case due to a previously unreported FKS1 mutation in <i>Candida krusei</i> . 2014 , 58, 3550-2	24
1071	Current Epidemiology of <i>Candida</i> Infection. 2014 , 36, 131-136	44
1070	Intérêt de la cartographie fongique en transplantation hépatique. 2014 , 33, A112	
1069	Real-world experience with echinocandin MICs against <i>Candida</i> species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. 2014 , 58, 1897-906	55
1068	Initial use of echinocandins does not negatively influence outcome in <i>Candida parapsilosis</i> bloodstream infection: a propensity score analysis. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1413-21	11.6 80

1067	Prospective assessment of FilmArrayfi technology for the rapid identification of yeast isolated from blood cultures. 2014 , 106, 119-122	3
1066	Breakthrough invasive <i>Candida glabrata</i> in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC. 2014 , 52, 2709-12	17
1065	Is biofilm production a predictor of catheter-related candidemia?. 2014 , 52, 407-10	12
1064	Species distribution and antifungal susceptibility profile of <i>Candida</i> isolates from bloodstream infections in Lima, Peru. 2014 , 63, 855-860	16
1063	Effects of empiric antifungal therapy for septic shock on time to appropriate therapy for <i>Candida</i> infection: a pilot study. 2014 , 36, 1226-32	8
1062	[Nosocomial infection in patients receiving a solid organ transplant or haematopoietic stem cell transplant]. 2014 , 32, 386-95	4
1061	Liver cirrhosis as a predisposing risk factor for esophageal candidiasis: Bystander or culprit?. 2014 , 1, 72-73	
1060	[Meningitis to <i>Candida albicans</i> at the adult, use of the new diagnosis methods]. 2014 , 33, 533-5	
1059	Resistance of <i>Candida</i> spp. to antifungal drugs in the ICU: where are we now?. 2014 , 40, 1241-55	90
1058	Distribution of <i>Candida</i> species isolated from blood cultures in hospitals in Osaka, Japan. 2014 , 20, 558-62	17
1057	Synthesis and antimicrobial activity of novel 5-aminoimidazole-4-carboxamidrazones. 2014 , 24, 4699-4702	13
1056	Micafungin is more active against <i>Candida albicans</i> biofilms with high metabolic activity. 2014 , 69, 2984-7	13
1055	EUCAST technical note on <i>Candida</i> and micafungin, anidulafungin and fluconazole. 2014 , 57, 377-9	33
1054	Rat indwelling urinary catheter model of <i>Candida albicans</i> biofilm infection. 2014 , 82, 4931-40	31
1053	Neonatal invasive fungal infection in England 2004-2010. 2014 , 20, 936-41	36
1052	Emerging drugs and vaccines for candidemia. 2014 , 57, 718-33	27
1051	Glucose directly promotes antifungal resistance in the fungal pathogen, <i>Candida</i> spp. 2014 , 289, 25468-73	20
1050	Invasive candidiasis in low birth weight preterm infants: risk factors, clinical course and outcome in a prospective multicenter study of cases and their matched controls. 2014 , 14, 327	41

1049	Empirical antifungal therapy with an echinocandin in critically-ill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU. 2014 , 14, 385		20
1048	Yeast central nervous system infection in a critically ill patient: a case report. 2014 , 8, 253		
1047	Fungal infections after liver transplantation: incidence and outcome. 2014 , 46, 2314-8		21
1046	Fungal endocarditis: current challenges. 2014 , 44, 290-4		56
1045	Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). 2014 , 40, 1303-12		223
1044	Fungal endocarditis observed over an 8-year period and a review of the literature. 2014 , 178, 37-51		32
1043	Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. 2014 , 40, 1429-48		84
1042	Performance of two MALDI-TOF MS systems for the identification of yeasts isolated from bloodstream infections and cerebrospinal fluids using a time-saving direct transfer protocol. 2014 , 203, 93-9		34
1041	Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?. 2014 , 33, 1489-96		56
1040	Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. 2014 , 178, 1-9		34
1039	Diagnosis and management of fungal urinary tract infection. 2014 , 28, 61-74		61
1038	Epidemiology and antifungal susceptibilities of yeasts causing vulvovaginitis in a teaching hospital. 2014 , 178, 251-8		31
1037	Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. <i>Clinical Infectious Diseases</i> , 2014 , 59, 147-59	11.6	1194
1036	Diagnosis and Management of Fungal Urinary Tract Infections. 2014 , 9, 161-166		1
1035	Niche Specialization: Features That Distinguish Biofilm Cells from Commensal Cells. 2014 , 8, 179-184		15
1034	Amphotericin B: How Much Is Enough?. 2014 , 8, 119-128		
1033	Nouveaux marqueurs pour le diagnostic de la maladie fongique invasive. 2014 , 23, 298-308		1
1032	Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants. 2014 , 53, 581-610		29

1031	Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. 2014 , 14, 166	147
1030	Isolation of cholesterol-dependent, multidrug-resistant <i>Candida glabrata</i> strains from blood cultures of a candidemia patient in Kuwait. 2014 , 14, 188	11
1029	Epidemiology, species distribution and outcome of nosocomial <i>Candida</i> spp. bloodstream infection in Shanghai. 2014 , 14, 241	48
1028	Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. 2014 , 14, 97	63
1027	Killing rates exerted by caspofungin in 50 % serum and its correlation with in vivo efficacy in a neutropenic murine model against <i>Candida krusei</i> and <i>Candida inconspicua</i> . 2014 , 63, 186-194	15
1026	Micafungin at physiological serum concentrations shows antifungal activity against <i>Candida albicans</i> and <i>Candida parapsilosis</i> biofilms. 2014 , 58, 5581-4	14
1025	Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre YeastOne for <i>Candida albicans</i> : a prospective observational cohort study. 2014 , 69, 2210-4	21
1024	Infecciones por hongos en sujetos no inmunocomprometidos. 2014 , 11, 3426-3434	
1023	Diagnostic usefulness of differential time to positivity for catheter-related candidemia. 2014 , 52, 2566-72	31
1022	EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations. 2014 , 31, 157-75	10
1021	[Adequacy of antifungal agents in a teaching hospital: too many inappropriate prescriptions despite training]. 2014 , 43, e241-50	1
1020	Hampered by historical paradigms--echinocandins and the treatment of <i>Candida</i> endocarditis. 2014 , 57, 316-9	7
1019	Neonatal candidiasis: diagnosis, prevention, and treatment. 2014 , 69 Suppl 1, S19-22	38
1018	Breakthrough candidemia due to multidrug-resistant <i>Candida glabrata</i> during prophylaxis with a low dose of micafungin. 2014 , 58, 2438-40	53
1017	A case of <i>Candida glabrata</i> severe urinary sepsis successfully treated with micafungin. 2014 , 5, 1-3	10
1016	Risk management strategies for reducing oral adverse drug events. 2014 , 14 Suppl, 87-94.e1	8
1015	Systemic Infection Due to in a Domestic Ferret (). 2014 , 23, 85-90	3
1014	Diagnosis and Management of Ophthalmic Emergencies in the Hospital. 2014 , 3, e409-e429	

1013	The impact of new epidemiological cutoff values on <i>Candida glabrata</i> resistance rates and concordance between testing methods. 2014 , 79, 209-13	11
1012	[Venous catheter-related infections]. 2014 , 32, 115-24	24
1011	Polymerase chain reaction melting profiles of <i>Candida glabrata</i> clinical isolates in solid organ transplant recipients in comparison to the other group of surgical patients. 2014 , 46, 1366-70	1
1010	Does the current treatment of invasive fungal infection need to be reviewed?. 2014 , 32, 523-8	4
1009	Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. 2014 , 58, 4565-72	37
1008	In vitro antifungal susceptibility of <i>Candida glabrata</i> to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection. 2014 , 58, 3646-9	8
1007	A single center's experience with <i>Candida parapsilosis</i> related long-term central venous access device infections: the port removal decision and its outcomes. 2014 , 31, 435-41	8
1006	Fungal osteomyelitis and septic arthritis. 2014 , 22, 390-401	72
1005	Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer. 2014 , 58, 3526-9	7
1004	Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. 2014 , 74, 891-909	37
1003	Decreasing rates of invasive candidiasis in pediatric hospitals across the United States. <i>Clinical Infectious Diseases</i> , 2014 , 58, 74-7	11.6 21
1002	<i>Candida dubliniensis</i> spondylodiscitis in an immunocompetent patient. Case report and review of the literature. 2014 , 3, 4-7	14
1001	A case of rib fungal osteomyelitis. 2014 , 67, e81-3	4
1000	Concurrent subcutaneous candidal abscesses and pulmonary cryptococcosis in a patient with diabetes mellitus and a history of corticosteroid therapy. 2014 , 53, 1385-90	5
999	[Relationship between the effectiveness and dose of micafungin in the treatment of candidemia]. 2014 , 134, 433-8	1
998	Oxygen delivery, cardiac function and monitoring. 1-12	
997	Early state research on antifungal natural products. 2014 , 19, 2925-56	55
996	<i>Pimenta pseudocaryophyllus</i> inhibits virulence factors and promotes metabolic changes in <i>Candida</i> yeast. 2014 , 47, 618-23	3

- 995 Guideline for diagnosis, prophylaxis and treatment of invasive fungal infection post burn injury in China 2013. **2014**, 2, 45-52 11
- 994 Central venous catheter (CVC) removal for adult patients with candidaemia. **2014**, 1
- 993 Optimizing antimicrobial therapy in the ICU. 173-186
- 992 Conservative oxygen therapy in mechanically ventilated patients. **2014**, 42, e630-1 6
- 991 The authors reply. **2014**, 42, e629-30
- 990 FEATURES. **2014**, 18, 25-68 1
- 989 Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study. **2014**, 33, 1294-6 22
- 988 Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection. **2014**, 56, 834-837
- 987 A study of cardiovascular miRNA biomarkers for Kawasaki disease. **2014**, 33, 1296-9 21
- 986 Antifungal Treatment is Not Required for Immunocompetent Individuals With Asymptomatic Esophageal Candidiasis. **2015**, 94, e1969 4
- 985 Epidemiology and Outcome of Trichosporon Fungemia: A Review of 185 Reported Cases From 1975 to 2014. **2015**, 2, ofv141 56
- 984 Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases. **2015**, 21, 204-12 55
- 983 Burden of serious fungal infections in Mexico. **2015**, 58 Suppl 5, 34-44 29
- 982 Yeasts. **2015**, 268-276
- 981 Mechanisms of Action of Antifungal Agents. **2015**, 183-196
- 980 Interventions for the management of esophageal candidiasis in immunocompromised patients. **2015**,
- 979 Candida albicans: Clinical Relevance, Pathogenesis, and Host Immunity. **2015**, 929-952 1
- 978 Esophageal Candidiasis as the Initial Manifestation of Acute Myeloid Leukemia. **2015**, 54, 3087-92 3

977	Early surgical intervention and optimal medical treatment for Candida parapsilosis endocarditis. 2015 , 54, 411-3	6
976	The Differences in the Epidemiology and Predictors of Death between Candidemia Acquired in Intensive Care Units and Other Hospital Settings. 2015 , 54, 3009-16	16
975	Candidemia from an upper urinary tract infection complicated by candida endophthalmitis. 2015 , 54, 2693-8	2
974	16. Diagnosis and Treatment of Deep-seated Mycoses in Daily Clinical Practice. 2015 , 104, 2025-2030	
973	Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs. 2015 , 3,	45
972	A sensitive liquid chromatography-tandem mass spectrometry method for monitoring the caspofungin trough plasma concentration and its association with caspofungin efficacy in intensive-care-unit patients. 2015 , 5, 104806-104814	3
971	Pacemaker lead Candida endocarditis: Is medical treatment possible?. 2015 , 67 Suppl 3, S100-2	7
970	Epidemiology of invasive candidiasis in a surgical intensive care unit: an observational study. 2015 , 8, 491	22
969	Leberfunktionsstörungen in der Intensivmedizin. 2015 , 18, 174-181	
968	T cells from patients with Candida sepsis display a suppressive immunophenotype. 2016 , 20, 15	66
967	Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015. 2015 , 22, 405-32	235
966	Author's Response. 2015 , 61, e24-5	2
965	Clinical perspectives on echinocandin resistance among Candida species. 2015 , 28, 514-22	53
964	Candida glabrata--unique features and challenges in the clinical management of invasive infections. 2015 , 58, 445-50	34
963	Evaluation of paper gradient concentration strips for antifungal combination testing of Candida spp. 2015 , 58, 679-87	2
962	Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis. 2015 , 15, 463	9
961	Recurrent candida prosthetic endocarditis over fifteen years managed with medical therapy and four valvular surgeries: a case report and review of literature. 2015 , 10, 105	3
960	Comparative antifungal susceptibility analysis of Candida albicans versus non-albicans Candida corneal isolates. 2015 , 34, 576-9	13

959	Author's Response. 2015 , 61, e26	1
958	Darier disease can be complicated by generalized cutaneous candidiasis: a case report. 2015 , 172, 837-9	
957	Treatment of neonatal fungal infective endocarditis with recombinant tissue plasminogen: activator in a low birth weight infant case report and review of the literature. 2015 , 58, 578-81	4
956	Management of Invasive Fungal Infections after Hematopoietic Stem Cell Transplantation. 2015 , 4, 91-100	
955	Management of oropharyngeal mycosis in head and neck cancer occurring during (chemo) radiotherapy: an Italian radio-oncologist survey. 2015 , 101, 312-7	2
954	Candidiasis. 1104-1112	
953	Antifungal prescribing pattern and attitude towards the treatment of oral candidiasis among dentists in Jordan. 2015 , 65, 216-26	11
952	Candida and cardiovascular implantable electronic devices: a case of lead and native aortic valve endocarditis and literature review. 2015 , 58, 637-41	11
951	Fungal infections in the ICU: advances in treatment and diagnosis. 2015 , 21, 421-9	23
950	Fatal <i>Yarrowia lipolytica</i> Intra-abdominal Abscess With Persistent Fungemia in a Liver Transplant Recipient. 2015 , 23, 273-275	2
949	Severe infections in neutropenic patients. 2015 , 21, 586-92	5
948	Fungal infections in intestinal and multivisceral transplant recipients. 2015 , 20, 295-302	13
947	Invasive fungal infections in children with hematologic and malignant diseases. 2015 , 37, e69-72	14
946	<i>Candida parapsilosis</i> Endocarditis Presenting on Native Valve With Cerebrovascular Accident and Myocardial Infarction. 2015 , 23, 235-242	1
945	Successful Eradication of <i>Candida</i> Central Venous Catheter Infection With Ambisome Line Lock in Factitious Illness. 2015 , 61, e24	2
944	Relevance of <i>Candida</i> and other mycoses for morbidity and mortality in severe sepsis and septic shock due to peritonitis. 2015 , 58, 399-407	14
943	In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos. 2015 , 97, 292-7	16
942	What's new in antifungals: an update on the in-vitro activity and in-vivo efficacy of new and investigational antifungal agents. 2015 , 28, 539-45	15

941	Experience with anidulafungin in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease. 2015 , 17, 761-7	4
940	Fungal Infections of the Spine. 2015 , 40, E719-28	17
939	The Role of Biomarkers for Starting Antifungals in the Intensive Care Unit. 2015 , 22, 286-293	1
938	Sirolimus is a Successful Treatment for Recurrent Iron Deficiency Anaemia in Blue Rubber Bleb Naevus Syndrome. 2015 , 61, e24	3
937	Severe Liver Disease in Children With α 1 Antitrypsin Deficiency in France (DEFI-ALPHA Cohort). 2015 , 61, e25	4
936	Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation. 2015 , 37, e45-50	7
935	Performance Characteristics of Galactomannan and β -D-Glucan in High-Risk Liver Transplant Recipients. 2015 , 99, 2543-50	31
934	. 2015 ,	
933	The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia. 2014 , 4, 1-17	28
932	TUBERCULOSIS INFECTION MIGHT INCREASE THE RISK OF INVASIVE CANDIDIASIS IN AN IMMUNOCOMPETENT PATIENT. 2015 , 57, 273-5	8
931	From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. 2015 , 3,	20
930	Posologies des anti-infectieux (antibiotiques, antifongiques, antiviraux). 2015 , 235-242	
929	FREQUENCY OF Candida SPECIES IN A TERTIARY CARE HOSPITAL IN TRIANGULO MINEIRO, MINAS GERAIS STATE, BRAZIL. 2015 , 57, 185-91	5
928	Retrospective analysis of mortality and Candida isolates of 75 patients with candidemia: a single hospital experience. 2015 , 8, 199-205	31
927	Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients. 2015 , 7, 527-35	5
926	Nosocomial Urinary Tract Infections. 2015 , 3334-3346.e3	
925	Prevalence and factors predictive of intraocular fungal infection in patients with fungemia at an academic urban tertiary care center. 2015 , 9, 1853-8	8
924	Infectious Arthritis of Native Joints. 2015 , 1302-1317.e5	2

923	Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs. 2015 , 33-49	2
922	From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. 2015 , 373-388	1
921	Successful Treatment of Fungemia Caused by <i>Cyberlindnera fabianii</i> with Anidulafungin: A Case Report. 2015 , 18, 94	7
920	Application of Culture-Independent Rapid Diagnostic Tests in the Management of Invasive Candidiasis and Cryptococcosis. 2015 , 1, 217-251	7
919	Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations. 2015 , 1, 345-366	9
918	Posaconazole: An Update of Its Clinical Use. 2015 , 3, 210-268	10
917	Clinical Appearance of Oral Candida Infection and Therapeutic Strategies. 2015 , 6, 1391	120
916	An outbreak of Candida parapsilosis fungemia among preterm infants. 2015 , 14, 18259-67	10
915	The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected]. 2015 , 10, e0125149	29
914	Long-Term Trends in Esophageal Candidiasis Prevalence and Associated Risk Factors with or without HIV Infection: Lessons from an Endoscopic Study of 80,219 Patients. 2015 , 10, e0133589	33
913	Validation of High Resolution Melting Analysis (HRM) of the Amplified ITS2 Region for the Detection and Identification of Yeasts from Clinical Samples: Comparison with Culture and MALDI-TOF Based Identification. 2015 , 10, e0132149	12
912	Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis. 2015 , 10, e0141872	2
911	Synergistic effects of tacrolimus and azole antifungal compounds in fluconazole-susceptible and fluconazole-resistant Candida glabrata isolates. 2015 , 46, 125-9	22
910	Potent and Synergistic Extract Combinations from and Against Pathogenic Yeasts. 2015 , 2, 220-235	16
909	Infections mycosiques: Fungal infections. 2015 , 127-138	
908	Trichosporon asahii infection after total knee arthroplasty: A case report and review of the literature. 2015 , 26, 47-51	15
907	Recurrent Candida albicans Ventriculitis Treated with Intraventricular Liposomal Amphotericin B. 2015 , 2015, 340725	2
906	Successful Treatment of Candida parapsilosis Fungemia in Two Preterms with Voriconazole. 2015 , 2015, 402137	5

905	First Report of Ventriculoperitoneal Shunt Infection due to <i>Cyberlindnera fabianii</i> . 2015 , 2015, 630816	7
904	Recurring Events of <i>Candida krusei</i> Septicaemia: First Report from an ICU. 2015 , 2015, 1-6	2
903	Clinical Features of Fungal Peritonitis with <i>Candida Albicans</i> Infection after Gastric and Duodenal Perforation. 2015 , 05,	
902	Antifungal therapy. 1344-1352	
901	Esophageal infections. 324-333	
900	Candiduria. 430-433	
899	<i>Candida</i> Species. 2015 , 2879-2894.e3	8
898	Radiotherapy and Chemotherapy Treatments in Head and Neck Cancer Patients [Protocol for Management Before, During and After RTP. 2015 ,	
897	The incidence of ocular candidiasis and evaluation of routine ophthalmic examination in critically ill patients with candidaemia. 2015 , 43, 693-7	7
896	Short-term Fluconazole Therapy for the Treatment of Candiduria in ICU and ICU Step-down Patients. 2015 , 6, CMTIM.S20140	
895	Identificaci3n de <i>Candida glabrata</i> y otras especies comunes del g3nero <i>Candida</i> mediante el uso secuencial del medio de cultivo crom3geno y la prueba del tubo germinal. 2015 , 28,	
894	Successful medical treatment of infective endocarditis caused by <i>Candida parapsilosis</i> in an immunocompromised patient. 2015 , 2015,	3
893	Fungal endophthalmitis: an unusual complication of GI surgery and endoluminal vacuum therapy. 2015 , 2015,	3
892	Management bundles for candidaemia: the impact of compliance on clinical outcomes. 2015 , 70, 587-93	52
891	Candidaemia in a paediatric centre and importance of central venous catheter removal. 2015 , 58, 140-8	10
890	The search for endocarditis in patients with candidemia: a systematic recommendation for echocardiography? A prospective cohort. 2015 , 34, 1543-9	35
889	Antifungal design: The toxicity-resistance yin-yang. 2015 , 11, 453-4	5
888	Oncologic emergencies in critical care. 2015 , 167-200	

887	Candidiasis. 2015 , 101-117		1
886	Systemic review of published literature on Candida infection following total hip arthroplasty. 2015 , 179, 173-85		13
885	A case of Candida albicans fungus balls in the urinary tract appeared during the course of antifungal treatment for Candida endophthalmitis. 2015 , 21, 687-90		1
884	Pharmacologic and clinical evaluation of posaconazole. 2015 , 8, 321-34		34
883	Antimicrobial Prophylaxis in Hematology. 2015 , 275-296		1
882	Discrimination of Candida species by paper spray mass spectrometry. 2015 , 378, 288-293		20
881	Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!. <i>Clinical Infectious Diseases</i> , 2015 , 61 Suppl 6, S635-42	11.6	13
880	Mechanisms of echinocandin antifungal drug resistance. 2015 , 1354, 1-11		154
879	Endogenous endophthalmitis: diagnosis, management, and prognosis. 2015 , 5, 32		82
878	Potential Microbiological Effects of Higher Dosing of Echinocandins. <i>Clinical Infectious Diseases</i> , 2015 , 61 Suppl 6, S669-77	11.6	33
877	Role of Echinocandins in Fungal Biofilm-Related Disease: Vascular Catheter-Related Infections, Immunomodulation, and Mucosal Surfaces. <i>Clinical Infectious Diseases</i> , 2015 , 61 Suppl 6, S622-9	11.6	24
876	The Role of Echinocandins in Candida Biofilm-Related Vascular Catheter Infections: In Vitro and In Vivo Model Systems. <i>Clinical Infectious Diseases</i> , 2015 , 61 Suppl 6, S618-21	11.6	32
875	Rapid identification of 6328 isolates of pathogenic yeasts using MALDI-ToF MS and a simplified, rapid extraction procedure that is compatible with the Bruker Biotyper platform and database. 2016 , 54, 80-8		49
874	Echinocandin Resistance in Candida. <i>Clinical Infectious Diseases</i> , 2015 , 61 Suppl 6, S612-7	11.6	192
873	Candida glabrata: new tools and technologies-expanding the toolkit. 2015 , 15,		19
872	Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008-2014. 2015 , 2, ofv163		107
871	Old and new pathogenic Nakaseomyces species: epidemiology, biology, identification, pathogenicity and antifungal resistance. 2016 , 16, fov114		22
870	New antifungal and antiviral dosing. 2015 , 42, 177-94, x		5

869	Exogenous fungal endophthalmitis: an analysis of isolates and susceptibilities to antifungal agents over a 20-year period (1990-2010). 2015 , 159, 257-64.e1		33
868	Economic impact of antifungal treatment in IFD by <i>Candida</i> species: anidulafungin administration as a cost-effective alternative for critical care patients. 2015 , 22, 12-17		
867	The epidemiology and diagnosis of invasive candidiasis among premature infants. 2015 , 42, 105-17, viii-ix		57
866	Training should be the first step toward an antifungal stewardship program. 2015 , 33, 221-7		15
865	Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole. 2015 , 35, 208-19		42
864	Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update. 2015 , 16, 693-710		10
863	Echinocandins for Primary Therapy of Candidemia: Time for a Paradigm Shift?. 2015 , 9, 15-22		1
862	Antifungal stewardship in a tertiary-care institution: a bedside intervention. 2015 , 21, 492.e1-9		55
861	Characteristics of vertebral osteomyelitis after liver transplantation. 2015 , 21, 573-7		1
860	Targeted versus universal antifungal prophylaxis among liver transplant recipients. 2015 , 15, 180-9		48
859	Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. <i>Clinical Infectious Diseases</i> , 2015 , 60, 997-1006	11.6	52
858	Successful treatment of <i>Candida</i> osteoarticular infections with limited duration of antifungal therapy and orthopedic surgical intervention. 2015 , 47, 144-9		12
857	<i>Aspergillus flavus</i> endophthalmitis after penetrating keratoplasty combined with cataract phacoemulsification and IOL implantation. 2015 , 35, 145-8		6
856	T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. <i>Clinical Infectious Diseases</i> , 2015 , 60, 892-9	11.6	305
855	The serum glucan level and pathological changes of antifungal treatment for lower respiratory tract infection of <i>Candida albicans</i> . 2015 , 53, 153-9		1
854	Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients. 2015 , 16, 213-26		9
853	Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. 2015 , 59, 1265-72		73
852	The A395T mutation in <i>ERG11</i> gene confers fluconazole resistance in <i>Candida tropicalis</i> causing candidemia. 2015 , 179, 213-8		23

851	Antifungal activity of the essential oil of <i>Angelica major</i> against <i>Candida</i> , <i>Cryptococcus</i> , <i>Aspergillus</i> and dermatophyte species. 2015 , 69, 241-8	30
850	ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. 2015 , 21 Suppl 1, S1-25	406
849	Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseases. 2015 , 34, 951-61	3
848	Fungemia caused by <i>Yarrowia lipolytica</i> . 2015 , 179, 437-45	12
847	Hospital use of systemic antifungal drugs: a multi-center surveillance update from Germany. 2015 , 43, 423-9	20
846	Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs. 2015 , 34, 651-9	45
845	Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients. 2015 , 59, 1004-13	17
844	Evaluation of sulfobutylether- β -cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. 2015 , 19, 32	61
843	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. 2015 , 19, 33	83
842	Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis. 2015 , 13, 1171-83	13
841	<i>Candida quercitrusa</i> Candidemia in a 6-Year-Old Child. 2015 , 53, 2785-7	2
840	Positive Impact of Fungal Histopathology on Immunocompromised Pediatric Patients With Histology-Proven Invasive Fungal Infection. 2015 , 144, 61-7	12
839	Micafungin triggers caspase-dependent apoptosis in <i>Candida albicans</i> and <i>Candida parapsilosis</i> biofilms, including caspofungin non-susceptible isolates. 2015 , 6, 385-94	23
838	Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review. 2015 , 54, 1223-35	28
837	Epidemiology and risk factors for nosocomial Non- <i>Candida albicans</i> candidemia in adult patients at a tertiary care hospital in North China. 2015 , 53, 684-90	35
836	Invasive Fungal Infections and Approaches to Their Diagnosis. 2015 , 42, 219-287	8
835	Utilizing Rapid Diagnostics for Detection of <i>Candida</i> Species. 2015 , 7, 127-141	
834	<i>Candida tropicalis</i> bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance. 2015 , 71, 385-94	28

833	Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant <i>Candida glabrata</i> isolates. 2015 , 59, 5405-12	9
832	A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. 2015 , 59, 1671-9	36
831	Initial serum (1,3)- β -D-glucan as a predictor of mortality in proven candidaemia: findings from a retrospective study in two teaching hospitals in Italy and Brazil. 2015 , 21, 954.e9-17	17
830	Terminal-stage prognostic analysis in candidemia. 2015 , 21, 376-80	2
829	The additional costs of catheter-related bloodstream infections in intensive care units. 2015 , 43, 1046-9	11
828	Antifungal agents use in a French administrative region. 2015 , 45, 279-85	1
827	In the Literature. <i>Clinical Infectious Diseases</i> , 2015 , 61, iii-iv	11.6
826	Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with <i>Candida albicans</i> and non- <i>albicans</i> bloodstream infection. 2015 , 21, 1011-7	21
825	Multidrug Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal Resistance in <i>Candida parapsilosis</i> . 2015 , 59, 5942-50	48
824	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. 2015 , 41, 1601-10	125
823	Evaluation of the predictive indices for candidemia in an adult intensive care unit. 2015 , 48, 77-82	10
822	Usefulness of MALDI-TOF Mass Spectrometry for Routine Identification of <i>Candida</i> Species in a Resource-Poor Setting. 2015 , 180, 173-9	17
821	The Monoterpene Carvacrol Generates Endoplasmic Reticulum Stress in the Pathogenic Fungus <i>Candida albicans</i> . 2015 , 59, 4584-92	43
820	Are prophylactic antifungals in highly colonized patients safe and effective?. 2015 , 41, 1336-9	10
819	Fungal Infections in the Hospitalized Patient. 2015 , 4, 313-327	
818	Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia. 2015 , 49, 1068-74	16
817	Evaluation of species distribution and anti fungal susceptibility profiles of <i>Candida</i> isolates from hospitalized patients. 2015 , 72, 17-26	2
816	Genotoxic effect of photodynamic therapy mediated by curcumin on <i>Candida albicans</i> . 2015 , 15, fov018	16

815	The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. 2015 , 70, 2362-8	55
814	Treatment of invasive candidiasis: between guidelines and daily clinical practice. 2015 , 13, 685-9	10
813	In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. 2015 , 81, 259-63	50
812	[Patients treated with micafungin during their stay in intensive care unit]. 2015 , 39, 467-76	
811	Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection. 2015 , 21, 493.e1-4	19
810	A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis. 2015 , 53, 455-61	11
809	Candida albicans endocarditis in a patient with an implantable cardioverter defibrillator (ICD). 2015 , 33, 213-4	3
808	Risk factors and the clinical and surgical features of fungal prosthetic joint infections: A retrospective analysis of eight cases. 2016 , 12, 991-999	18
807	Antifungal Therapy in Eye Infections: New Drugs, New Trends. 2016 , 217-236	0
806	International guidelines: the need to standardize the management of candidaemia. 2016 , 48, 779-81	5
805	Echinocandin Antifungals. 2016 , 97-107	
804	Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation. 2016 , 35, 1204-1210	23
803	The clinical outcomes and predictive factors for in-hospital mortality in non-neutropenic patients with candidemia. 2016 , 95, e3834	4
802	Updates on Therapeutic Strategies Against Candida (and Aspergillus) Biofilm Related Infections. 2016 , 931, 95-103	4
801	Pulmonary Fungal Diseases in Immunocompetent Hosts: A Single-Center Retrospective Analysis of 35 Subjects. 2016 , 181, 513-21	7
800	Exploring the In Vitro Resistance of Candida parapsilosis to Echinocandins. 2016 , 181, 663-70	5
799	Systematic Analysis of the Lysine Acetylome in Candida albicans. 2016 , 15, 2525-36	24
798	Fungal Endocarditis: Update on Diagnosis and Management. 2016 , 129, 1037-43	44

797	Fungal spine. 2016 , 28, 163-172	2
796	Fluconazole Prophylaxis for the Prevention of Candidiasis in Premature Infants: A Meta-analysis Using Patient-level Data. <i>Clinical Infectious Diseases</i> , 2016 , 63, 604-10	11.6 32
795	Reply. 2016 , 64, 998-9	4
794	Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. 2016 , 56, 143-51	35
793	Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis. 2016 , 22, 427-35	30
792	Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible <i>Candida albicans</i> infections. 2016 , 59, 179-85	10
791	Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. 2016 , 14, 731-46	13
790	Duration and intensity of fluconazole for prophylaxis in preterm neonates: a meta-analysis of randomized controlled trials. 2016 , 16, 312	9
789	Antifungal Lock Therapy with Liposomal Amphotericin B: A Prospective Trial. 2016 , 5, 80-4	9
788	Drug resistance mechanisms and their regulation in non- <i>albicans</i> <i>Candida</i> species. 2016 , 71, 1438-50	49
787	The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary. 2016 , 35, 261-282	110
786	Candidiasis. 2016 , 1261-1267	3
785	Cold atmospheric plasma inhibits the growth of <i>Candida albicans</i> by affecting ergosterol biosynthesis and suppresses the fungal virulence factors in vitro. 2016 , 13, 66-72	15
784	<i>Candida</i> Arthritis: Analysis of 112 Pediatric and Adult Cases. 2016 , 3, ofv207	24
783	Cost-Effectiveness Analysis of Multiplex PCR with Magnetic Resonance Detection versus Empiric or Blood Culture-Directed Therapy for Management of Suspected Candidemia. 2016 , 54, 718-26	26
782	Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study. 2016 , 72, 117-23	21
781	Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. 2016 , 6, 2	55
780	Active immunizations with peptide-DC vaccines and passive transfer with antibodies protect neutropenic mice against disseminated candidiasis. 2016 , 34, 245-251	13

779	The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant <i>Candida glabrata</i> . 2016 , 71, 692-5	24
778	Initial antifungal strategy does not correlate with mortality in patients with candidemia. 2016 , 35, 187-93	21
777	Antifungal susceptibilities of <i>Candida</i> species isolated from the patients with vaginal candidiasis. 2016 , 22, 124-6	20
776	May one-stage exchange for <i>Candida albicans</i> peri-prosthetic infection be successful?. 2016 , 102, 127-9	10
775	Infection in Burns. 2016 , 17, 250-5	126
774	Le changement en un temps est-il une option raisonnable pour traiter une infection pfi-prothétique ^ <i>Candida albicans</i> ?. 2016 , 102, 89-91	
773	<i>Candida</i> growth in urine cultures: a contemporary analysis of species and antifungal susceptibility profiles. 2016 , 109, 325-9	10
772	Spondilodiscite. 2016 , 18, 1-10	
771	Risk factors for candidemia in non-neutropenic critical patients in Colombia. 2016 , 40, 139-44	12
770	A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant <i>Candida albicans</i> Vaginitis. 2016 , 59, 1791-9	77
769	Vertebral osteomyelitis in adults: an update. 2016 , 117, 121-38	92
768	Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by <i>Candida glabrata</i> . 2016 , 47, 286-8	4
767	Delivery of Antifungal Agents from Bone Cement. 2016 , 10, 30-36	1
766	Incidence and Risk Factors of Ocular Infection Caused by <i>Staphylococcus aureus</i> Bacteremia. 2016 , 60, 1212-7	19
765	Esofagitis eosinofílica. Esofagitis infecciosa. Esofagitis tóxicas. Esofagitis clústicas. 2016 , 12, 22-30	
764	Evaluation and Management of Infectious Esophagitis in Immunocompromised and Immunocompetent Individuals. 2016 , 14, 28-38	8
763	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016 , 62, 409-17	11.6 1105
762	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. 2016 , 100, 147-66	92

761	Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. 2016 , 55, 723-33	27
760	Decrease in Candida bloodstream infections in veterans in Atlanta. 2016 , 44, 488-90	4
759	Newer patents in antimycotic therapy. 2016 , 5, 115-34	12
758	Improved detection of deeply invasive candidiasis with DNA aptamers specific binding to (1->3)-D-glucans from Candida albicans. 2016 , 35, 587-95	14
757	Endocarditis. 2016 ,	1
756	Time to overcome fluconazole resistant Candida isolates: Solid lipid nanoparticles as a novel antifungal drug delivery system. 2016 , 142, 400-407	55
755	Oral candidiasis. 2016 , 34, 487-94	131
754	Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection. 2016 , 30, 277-96	23
753	Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications. 2016 , 30, 51-83	182
752	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016 , 62, e1-50	11.6 1655
751	Utility of in-house fluconazole disk diffusion susceptibility testing in the treatment of candidemia. 2016 , 84, 223-6	
750	Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. 2016 , 42, 905-27	239
749	Drug-symptom networking: Linking drug-likeness screening to drug discovery. 2016 , 103, 105-13	8
748	Whole animal HTS of small molecules for antifungal compounds. 2016 , 11, 177-84	12
747	T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. 2016 , 11, 103-17	102
746	Probiotics in Invasive Candidiasis. 2016 , 641-653	
745	Cardiac Effects of Echinocandins in Endotoxemic Rats. 2016 , 60, 301-6	4
744	Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production. 2016 , 54, 155-61	10

743	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. 2016 , 64, 717-35	183
742	Impact of antifungal prescription on relative distribution and susceptibility of <i>Candida</i> spp. - Trends over 10 years. 2016 , 72, 103-11	51
741	Antifungal prophylaxis with liposomal amphotericin B and caspofungin in high-risk patients after liver transplantation: impact on fungal infections and immune system. 2016 , 48, 161-6	14
740	Activity of Isavuconazole and Other Azoles against <i>Candida</i> Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms. 2016 , 60, 229-38	45
739	Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes. 2016 , 42, 813-46	28
738	Growth, biofilm formation, antifungal susceptibility and oxidative stress resistance of <i>Candida glabrata</i> are affected by different glucose concentrations. 2016 , 40, 331-338	19
737	Breakthrough candidaemia in the era of broad-spectrum antifungal therapies. 2016 , 22, 181-188	32
736	Risk Factors and Outcomes for Bloodstream Infections Secondary to <i>Clostridium difficile</i> Infection. 2016 , 60, 252-7	30
735	Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014. 2016 , 44, 205-13	63
734	Voriconazole and posaconazole therapy for experimental <i>Candida lusitanae</i> infection. 2016 , 84, 48-51	6
733	Immune deficiency vs. immune excess in inflammatory bowel diseases-STAT3 as a rheo-STAT of intestinal homeostasis. 2016 , 99, 57-66	8
732	Identification of Azole Resistance Markers in Clinical Isolates of <i>Candida tropicalis</i> Using cDNA-AFLP Method. 2016 , 30, 266-72	5
731	Opportunistic Mycoses. 2016 , 661-681.e16	2
730	Outcomes of Primary Transconjunctival 23-Gauge Vitrectomy in the Diagnosis and Treatment of Presumed Endogenous Fungal Endophthalmitis. 2017 , 25, 239-245	6
729	Antifungal therapy did not improve outcomes including 30-day all-cause mortality in patients suffering community-acquired perforated peptic ulcer-associated peritonitis with <i>Candida</i> species isolated from their peritoneal fluid. 2017 , 50, 370-376	9
728	Combinatorial strategies for combating invasive fungal infections. 2017 , 8, 169-185	94
727	Comparison of Amphotericin B Bladder Irrigations Versus Fluconazole for the Treatment of Candiduria in Intensive Care Unit Patients. 2017 , 30, 347-352	12
726	Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant <i>Candida albicans</i> . 2017 , 23, 215-221	14

725	Epidemiology of Candida isolates from Intensive Care Units in Colombia from 2010 to 2013. 2017 , 34, 17-22		13
724	Micafungin in the treatment of invasive fungal infection in an infant with extracorporeal. 2017 , 35, 466-467		
723	In vitro assessment of the growth and plasma membrane H ⁺ -ATPase inhibitory activity of ebselen and structurally related selenium- and sulfur-containing compounds in Candida albicans. 2017 , 31, e21892		15
722	Answers. 98-133		
721	Early-Onset Invasive Candidiasis in Extremely Low Birth Weight Infants: Perinatal Acquisition Predicts Poor Outcome. <i>Clinical Infectious Diseases</i> , 2017 , 64, 921-927	11.6	20
720	Pattern recognitions receptors in immunodeficiency disorders. 2017 , 808, 49-56		8
719	The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. 2017 , 18, 1-76		242
718	Impact of echinocandin on prognosis of proven invasive candidiasis in ICU: A post-hoc causal inference model using the AmarCAND2 study. 2017 , 74, 408-417		12
717	Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study. 2017 , 17, 93		4
716	Vulvar infections: beyond sexually transmitted infections. 2017 , 56, 361-369		5
715	A mechanistic study of anti-HIV activities of antifungal peptides. 2017 , 95, 633-640		1
714	In Vivo Candida Device Biofilm Models. 2017 , 93-113		
713	Trabeculectomy bleb-associated infections. 2017 , 62, 591-610		23
712	A Risk Score for Fluconazole Failure among Patients with Candidemia. 2017 , 61,		7
711	Structural analyses of sterol 14 α -demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. 2017 , 292, 6728-6743		144
710	Fluoroscopic studies of the upper gastrointestinal tract: techniques and indications. 2017 , 59, 343-354		
709	Usefulness of procalcitonin in differentiating Candida and bacterial blood stream infections in critically ill septic patients outside the intensive care unit. 2017 , 12, 629-635		18
708	Invasive Candidiasis in the Southeast-Asian Region. 2017 , 25-40		4

707	Candida and its dual lifestyle as a commensal and a pathogen. 2017 , 168, 802-810	44
706	Candida Biofilm Tolerance: Comparison of Planktonic and Biofilm Resistance Mechanisms. 2017 , 77-92	3
705	Human Fungal Pathogens and Drug Resistance Against Azole Drugs. 2017 , 387-428	1
704	Gastrointestinal and Hepatic Complications in Cancer Patients. 2017 , 1-16	
703	What Can the Clinical Mycology Laboratory Do for Clinicians Today and Tomorrow?. 2017 , 4, 96-105	1
702	Clinical factors affecting costs in patients receiving systemic antifungal therapy in intensive care units in Greece: Results from the ESTIMATOR study. 2017 , 60, 454-461	
701	Assessment of high-priced systemic antifungal prescriptions. 2017 , 47, 382-388	3
700	The Etest Performed Directly on Blood Culture Bottles Is a Reliable Tool for Detection of Fluconazole-Resistant <i>Candida albicans</i> Isolates. 2017 , 61,	10
699	Activity of Combined Antifungal Agents Against Multidrug-Resistant <i>Candida glabrata</i> Strains. 2017 , 182, 819-828	12
698	Impact of initial empirical antifungal agents on the outcome of critically ill patients with invasive candidiasis: analysis of the China-SCAN study. 2017 , 50, 74-80	6
697	Candiduria: Evidence-based approach to management, are we there yet?. 2017 , 27, 293-302	23
696	Exudative retinal detachment. 2017 , 62, 723-769	27
695	Epidemiology of <i>Candida albicans</i> and non- <i>C. albicans</i> of neonatal candidemia at a tertiary care hospital in western China. 2017 , 17, 329	43
694	Utilization Management in the Clinical Laboratory and Other Ancillary Services. 2017 ,	1
693	Potential of novel drug delivery systems in the management of topical candidiasis. 2017 , 25, 685-703	13
692	The Role of Resistance in <i>Candida</i> Infections: Epidemiology and Treatment. 2017 , 1075-1097	3
691	Biofilm on the tracheoesophageal voice prosthesis: considerations for oral decontamination. 2017 , 274, 405-413	14
690	Solasodine-3-O- β -glucopyranoside kills <i>Candida albicans</i> by disrupting the intracellular vacuole. 2017 , 106, 139-146	14

689	An Immunomodulatory Peptide Confers Protection in an Experimental Candidemia Murine Model. 2017 , 61,	15
688	Emerging Infectious Uveitis. 2017 ,	
687	Emerging Infectious Uveitis: Candida. 2017 , 179-190	
686	Impact of a multifaceted educational intervention including serious games to improve the management of invasive candidiasis in critically ill patients. 2017 , 41, 3-11	
685	The risk and clinical outcome of candidemia depending on underlying malignancy. 2017 , 43, 652-662	66
684	Fungemia due to <i>Saprochaete capitata</i> in a non-neutropenic patient hospitalized in an intensive care unit after cardiac surgery. 2017 , 27, 281-284	8
683	Fungal Infections in Primary and Acquired Immunodeficiencies. 2017 , 1-34	
682	Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal Medicine wards: A multicenter study. 2017 , 41, 33-38	27
681	Oral Fungal Infections: Diagnosis and Management. 2017 , 61, 319-349	43
680	Molecular Confirmation of the Relationship between <i>Candida guilliermondii</i> Fks1p Naturally Occurring Amino Acid Substitutions and Its Intrinsic Reduced Echinocandin Susceptibility. 2017 , 61,	13
679	Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements and challenges. 2017 , 523, 15-32	90
678	Increasing Non-Albicans <i>Candida</i> in Hematological Patients with Fluconazole Prophylaxis: A Case Series. 2017 , 33, 624-625	1
677	[Gastroenterological diseases as triggers of chest pain]. 2017 , 58, 29-38	3
676	Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties. 2017 , 61,	31
675	Fungal Skin Infections. 2017 , 38, 8-22	9
674	Infectious Diseases: Superficial Fungal Infections. 2017 , 253-268	0
673	Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. 2017 , 6, 2918-2931	198
672	Emerging multidrug-resistant <i>Candida</i> species. 2017 , 30, 528-538	83

671	Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis. 2017 , 61,	5
670	Fifty-one cases of fungal arteritis after kidney transplantation: A case report and review of the literature. 2017 , 19, e12781	5
669	The Pitt Bacteremia Score, Charlson Comorbidity Index and Chronic Disease Score are useful tools for the prediction of mortality in patients with Candida bloodstream infection. 2017 , 60, 676-685	22
668	Mediator Tail Module Is Required for Tac1-Activated Expression and Azole Resistance in <i>Candida albicans</i> . 2017 , 61,	24
667	Solasodine-3-O- β -glucopyranoside is hydrolyzed by a membrane glucosidase into active molecule solasodine against <i>Candida albicans</i> . 2017 , 109, 356-362	3
666	AFM combined to ATR-FTIR reveals <i>Candida</i> cell wall changes under caspofungin treatment. 2017 , 9, 13731-13738	13
665	Fungal chorioretinitis with systemic candidiasis in an infant following treatment with broad spectrum antibiotics: A case report. 2017 , 14, 286-288	4
664	The essential oil of <i>Allium sativum</i> as an alternative agent against <i>Candida</i> isolated from dental prostheses. 2017 , 34, 158-164	9
663	Performance evaluation of enzyme immunoassay for voriconazole therapeutic drug monitoring with automated clinical chemistry analyzers. 2017 , 8, 86-94	6
662	Critical care management of the patient with cirrhosis awaiting liver transplant in the intensive care unit. 2017 , 23, 1465-1476	21
661	Contemporary Oral Oncology. 2017 ,	
660	Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model. 2017 , 61,	51
659	Association Between Candiduria and Candidemia: A Clinical and Molecular Analysis of Cases. 2017 , 182, 1045-1052	14
658	Changes in the distribution of colonising and infecting <i>Candida</i> spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: A 10-year study. 2017 , 60, 770-780	18
657	Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in a Clinical Practice Setting in China. 2017 , 39, 1758-1768	2
656	Micafungin in the treatment of invasive fungal infection in an infant with extracorporeal. 2017 , 35, 466-467	
655	Red Rashes of the Vulva. 2017 , 44, 353-370	1
654	<i>Candida</i> vertebral osteomyelitis (CVO) 28 cases from a 10-year retrospective study in France. 2017 , 96, e7525	16

653	Yarrowia lipolytica fungemia in patients with severe polytrauma requiring intensive care admission: analysis of 32 cases. 2017 , 43, 1921-1923	2
652	Recent advances in delivery of antifungal agents for therapeutic management of candidiasis. 2017 , 96, 1478-1490	39
651	Probiotics for vulvovaginal candidiasis in non-pregnant women. 2017 , 11, CD010496	41
650	Antifungal Drugs. 2017 , 29-89	1
649	The Genomic Landscape of the Fungus-Specific SWI/SNF Complex Subunit, Snf6, in. 2017 , 2,	11
648	The carboxylic acid transporters Jen1 and Jen2 affect the architecture and fluconazole susceptibility of Candida albicans biofilm in the presence of lactate. 2017 , 33, 943-954	9
647	Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance. 2017 , 61,	35
646	Candidemia and invasive candidiasis among hospitalized neonates and pediatric patients. 2017 , 33, 1803-1812	22
645	Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. 2017 , 45, 737-779	137
644	Auf Pilzsuche in der Lunge. 2017 , 9, 37-45	
643	Measuring (1,3)- β -D-glucan in tracheal aspirate, bronchoalveolar lavage fluid, and serum for detection of suspected Candida pneumonia in immunocompromised and critically ill patients: a prospective observational study. 2017 , 17, 252	6
642	New facets of antifungal therapy. 2017 , 8, 222-236	73
641	T2 Magnetic Resonance for Fungal Diagnosis. 2017 , 1508, 305-319	24
640	Systemic Antifungal Agents: Current Status and Projected Future Developments. 2017 , 1508, 107-139	32
639	Opportunistic and Systemic Fungi. 2017 , 1681-1709.e3	3
638	Management of destructive Candida albicans spondylodiscitis of the cervical spine: a systematic analysis of literature illustrated by an unusual case. 2017 , 26, 1009-1018	5
637	Chitosan silver nanocomposite (CAGNC) as an antifungal agent against Candida albicans. 2017 , 55, 213-222	18
636	CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility. 2017 , 70, 130-135	54

635	Candida-induced prosthetic joint infection. A literature review including 72 cases and a case report. 2017 , 49, 81-94	23
634	Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology. 2017 , 25, 221-228	19
633	Impact of a multifaceted educational intervention including serious games to improve the management of invasive candidiasis in critically ill patients. 2017 , 41, 3-11	1
632	Systemic Candidiasis. 2017 , 439-445.e1	2
631	Complicated Urinary Infection, Including Postsurgical and Catheter-Related Infections. 2017 , 539-546.e1	
630	Potential clinical and economic outcomes of active beta-D-glucan surveillance with preemptive therapy for invasive candidiasis at intensive care units: a decision model analysis. 2017 , 36, 187-194	3
629	A Comparative Study of the Effects of Intravitreal Anidulafungin, Voriconazole, and Amphotericin B in an Experimental Candida Endophthalmitis Model. 2017 , 42, 225-232	6
628	Antimicrobial Stewardship in the Management of Sepsis. 2017 , 35, 199-217	13
627	Extensive functional redundancy in the regulation of Candida albicans drug resistance and morphogenesis by lysine deacetylases Hos2, Hda1, Rpd3 and Rpd31. 2017 , 103, 635-656	20
626	In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates. 2017 , 61,	23
625	Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints. 2017 , 60, 89-95	8
624	Contemporary In-Hospital and Long-Term Outcomes of Surgical Management for Fungal Endocarditis. 2017 , 58, 516-520	1
623	Invasive Candidiasis in pediatric patients at King Fahad Medical City in Central Saudi Arabia. A 5-year retrospective study. 2017 , 38, 1118-1124	6
622	Identification of the paradoxical effect of caspofungin and micafungin on growth using a growth curve methodology. 2017 , 35, 252-255	1
621	Antifungal activity of caspofungin in experimental infective endocarditis caused by Candida albicans. 2017 , 112, 370-375	3
620	[Epidemiology, species, antifungal resistance and outcome of candidemia in a university hospital in Buenos Aires, Argentina for 16 years]. 2017 , 34, 431-440	5
619	Successful treatment of pulmonary candidiasis and aspergillosis in patient with refractory Hodgkin lymphoma using micafungin - case study and brief literature review. 2017 , 42, 111-115	1
618	Probiotics in the Prevention and Treatment of Postmenopausal Vaginal Infections: Review Article. 2017 , 23, 139-145	30

617	Impact of automatic infectious diseases consultation on the management of fungemia at a large academic medical center. 2017 , 74, 1997-2003	12
616	Strategies to Reduce Mortality in Adult and Neonatal Candidemia in Developing Countries. 2017 , 3,	32
615	Fluconazole Resistance among Oral Candida Isolates from People Living with HIV/AIDS in a Nigerian Tertiary Hospital. 2017 , 3,	8
614	Dermatologic manifestations of endocrine disorders. 2017 , 6, 300-312	47
613	Antifungal Drug Susceptibility of Species Isolated from HIV-Positive Patients Recruited at a Public Hospital in S Lu, Maranh, Brazil. 2017 , 8, 298	19
612	Notable Increasing Trend in Azole Non-susceptible Causing Invasive Candidiasis in China (August 2009 to July 2014): Molecular Epidemiology and Clinical Azole Consumption. 2017 , 8, 464	45
611	A Linear 19-Mer Plant Defensin-Derived Peptide Acts Synergistically with Caspofungin against Biofilms. 2017 , 8, 2051	23
610	Epidemiology and Evolution of Fungal Pathogens in Plants and Animals. 2017 , 71-98	3
609	Fungal Bezoar: A Rare Cause of Ureteral Obstruction. 2017 , 2017, 6454619	2
608	Nephrologists Hate the Dialysis Catheters: A Systemic Review of Dialysis Catheter Associated Infective Endocarditis. 2017 , 2017, 9460671	
607	Nosocomial Infection in Adult Patients Undergoing Veno-Arterial Extracorporeal Membrane Oxygenation. 2017 , 32, 593-598	24
606	Candidemia in the elderly: What does it change?. 2017 , 12, e0176576	41
605	Unexpected effects of azole transporter inhibitors on antifungal susceptibility in Candida glabrata and other pathogenic Candida species. 2017 , 12, e0180990	10
604	A chronic hemodialysis patient with isolated pulmonary valve infective endocarditis caused by non-albicans Candida: a rare case and literature review. 2017 , 18, 286	3
603	A rare case of osteomyelitis: a literature review and proposed treatment algorithm. 2017 , 11, 31	4
602	Prosthetic Joint Infection. A Review of Treatment Methods. 2017 , 2, 114-121	34
601	Elderly versus non-elderly patients with intra-abdominal candidiasis in the ICU. 2017 , 83, 1126-1136	8
600	"De-escalation" strategy using micafungin for the treatment of systemic infections: budget impact in France and Germany. 2017 , 9, 763-774	1

599	Identification and antifungal susceptibility of <i>Candida</i> species isolated from the urine of patients in a university hospital in Brazil. 2017 , 59, e75	3
598	Fungal Biofilms. 2017 , 326-326	
597	Pediatric spinal infections. 2017 , 03, 075-085	
596	Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations. 2018 , 84, 1006-1012	9
595	Chemical composition, antioxidant activity and antifungal effects of five Iranian essential oils against <i>Candida</i> strains isolated from urine samples. 2018 , 28, 355-360	17
594	Structure-activity relationship studies of ultra-short peptides with potent activities against fluconazole-resistant <i>Candida albicans</i> . 2018 , 150, 479-490	14
593	In vitro activity of azole derivatives and griseofulvin against planktonic and biofilm growth of clinical isolates of dermatophytes. 2018 , 61, 449-454	9
592	Neonatal and Pediatric Candidemia: Results From Population-Based Active Laboratory Surveillance in Four US Locations, 2009-2015. 2018 , 7, e78-e85	30
591	Mycotic aneurysm of the hepatic artery in pediatric liver transplantation: A case series and literature review. 2018 , 20, e12861	8
590	Antifungal Activity of Chitosan-Coated Poly(lactic-co-glycolic) Acid Nanoparticles Containing Amphotericin B. 2018 , 183, 659-668	21
589	Antimicrobial stewardship without infectious disease physician for patients with candidemia: A before and after study. 2018 , 19, 82-89	12
588	Routine susceptibility testing for <i>Candida albicans</i> isolated from blood stream infections. 2018 , 50, 462-464	2
587	A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis. 2018 , 37, 992-998	18
586	Sepsis and Infection. 2018 , 455-468	1
585	<i>Candida albicans</i> - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control - An update. 2018 , 117, 128-138	119
584	Diagnosis and management of a fatal case of sepsis caused by in a neonate with omphalocele. 2018 , 20, 10-14	1
583	Yeast species associated with diseased fish: Occurrence, identification, experimental challenges and antifungal susceptibility testing. 2018 , 488, 134-144	13
582	<i>Candida</i> Species. 2018 , 1231-1237.e3	

581	Antifungal Agents. 2018 , 1532-1541.e3	1
580	Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. 2018 , 37, 923-929	11
579	Comprehensive drug utilization review in neonates: liposomal amphotericin B. 2018 , 70, 328-334	10
578	A simplified regimen of targeted antifungal prophylaxis in liver transplant recipients: A single-center experience. 2018 , 20, e12859	12
577	Candiduria in kidney transplant recipients: Is antifungal therapy useful?. 2018 , 61, 298-304	5
576	Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates. 2018 , 62,	13
575	Independent risk factors for mortality in critically ill patients with candidemia on Italian Internal Medicine Wards. 2018 , 13, 199-204	16
574	EQUAL Candida Score: An ECMM score derived from current guidelines to measure QUALity of Clinical Candidaemia Management. 2018 , 61, 326-330	35
573	Use of echinocandin prophylaxis in solid organ transplantation. 2018 , 73, i51-i59	12
572	What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. 2018 , 73, i14-i25	59
571	Intensive Care of Pulmonary Complications Following Liver Transplantation. 2018 , 33, 595-608	6
570	Genital diseases in the mature woman. 2018 , 36, 208-221	6
569	Empirical antifungal treatment for diagnosed and undiagnosed invasive fungal disease in patients with hematologic malignancies. 2018 , 34, 1209-1216	2
568	Development and regulation of single- and multi-species Candida albicans biofilms. 2018 , 16, 19-31	250
567	The role of biofilm forming on mortality in patients with candidemia: a study derived from real world data. 2018 , 50, 214-219	17
566	Significant Publications on Infectious Diseases Pharmacotherapy in 2016. 2018 , 31, 469-480	8
565	Infections in Hematopoietic Stem Cell Transplant Recipients. 2018 , 573-578.e2	
564	Fever and Granulocytopenia. 2018 , 578-586.e4	

563	Infections of the Oral Cavity. 2018 , 193-199.e2	1
562	Focal Suppurative Infections of the Nervous System. 2018 , 329-339.e3	2
561	Peritonitis. 2018 , 423-428.e2	
560	Management of invasive candidiasis and candidaemia in critically ill adults: expert opinion of the European Society of Anaesthesia Intensive Care Scientific Subcommittee. 2018 , 98, 382-390	17
559	Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern. 2018 , 56,	67
558	Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study. 2018 , 62,	16
557	Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro. 2018 , 42, 200-207	10
556	Post-Keratoplasty and Corneal Refractive Surgery Endophthalmitis. 2018 , 173-183	
555	Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?. 2018 , 19, 1152-1158	8
554	The Frequency of Infective Endocarditis in Candida Bloodstream Infections: a Retrospective Study in a Child Hospital. 2018 , 33, 54-58	5
553	Caspofungin resistant disseminated candidiasis in a 7-year-old girl with T cell lymphoma: a case report. 2018 , 7, 63-66	2
552	Epidemiology of Candidemia at a University Hospital in Colombia, 2008-2014. 2018 , 60,	1
551	Clinical Impact of Antifungal Susceptibility, Biofilm Formation and Mannoside Expression of Yeasts on the Outcome of Invasive Candidiasis in ICU: An Ancillary Study on the Prospective AmarCAND2 Cohort. 2018 , 9, 2907	3
550	Candidiasis sistêmica en pacientes críticos, factores predictores de riesgo. 2018 , 18, 75-85	3
549	Micafungin and caspofungin pharmacodynamics in patients with candidemia. 2018 , 10, 36-47	
548	Opciones terapéuticas frente a especies de Candida resistentes a las equinocandinas. 2018 , 59,	1
547	FORMULATION AND EVALUATION OF CHITOSAN NANOPARTICLES FOR IMPROVED EFFICACY OF ITRACONAZOLE ANTIFUNGAL DRUG. 2018 , 11,	1
546	Dementia in Patients with Central Nervous System Infection. 2018 , 77, 303-307	

545	Phenotypic typing and epidemiological survey of antifungal resistance of species detected in clinical samples of Italian patients in a 17 months' period. 2018 , 8, 58-66	4
544	Candida parapsilosis: An Unusual Cause of Infective Endocarditis. 2018 , 10, e3553	6
543	THR1 mediates GCN4 and CDC4 to link morphogenesis with nutrient sensing and the stress response in Candida albicans. 2018 , 42, 3193-3208	6
542	Echinocandin-Induced Microevolution of Candida parapsilosis Influences Virulence and Abiotic Stress Tolerance. 2018 , 3,	9
541	Candidiasis. 2018 , 187-191	
540	The use of oral fosfomycin-trometamol in patients with catheter-associated urinary tract infections (CAUTI): new indications for an old antibiotic?. 2018 , 30, 290-295	7
539	Treatment of candidemia in a nationwide setting: increased survival with primary echinocandin treatment. 2018 , 11, 2449-2459	5
538	Catheter-related candidemia and identification of causative species in patients with cardiovascular disorder. 2018 , 4, 7-13	9
537	Candida albicans biofilm-induced vesicles confer drug resistance through matrix biogenesis. 2018 , 16, e2006872	107
536	Comparative Analysis of the Capacity of the Species To Elicit Vaginal Immunopathology. 2018 , 86,	19
535	Improved potency and reduced toxicity of the antifungal peptoid AEC5 through submonomer modification. 2018 , 28, 3514-3519	6
534	Yeast species-specific, differential inhibition of β 1,3-glucan synthesis by poacic acid and caspofungin. 2018 , 3, 12-25	22
533	Advances in the Treatment of Mycoses in Pediatric Patients. 2018 , 4,	10
532	Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America. 2018 , 18, 501	7
531	Essentials in Candida bloodstream infection. 2018 , 46, 897-899	11
530	Epidemiology of antifungal susceptibility: Review of literature. 2018 , 28, 574-584	13
529	Surveillance of Antibiotic Prescribing in Intensive Care Units in Poland. 2018 , 2018, 5670238	5
528	Caspofungin Modulates Ryanodine Receptor-Mediated Calcium Release in Human Cardiac Myocytes. 2018 , 62,	3

527	Systemic hematogenous dissemination of mouse oral candidiasis is induced by oral mucositis. 2018 , 106, 389-397	8
526	Syndrome-Based Antibiotic Stewardship. 85-110	
525	Outcomes and Predictors of Early Infection after Heart Transplantation. 2018 , 19, 516-522	4
524	Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients. 2018 , 39, 1533-1543	4
523	Complicaciones infecciosas en el paciente con infecci3n por el VIH. 2018 , 12, 3306-3313	0
522	Antifungal Use in Veterinary Practice and Emergence of Resistance. 2018 , 359-402	6
521	Treatment of Infection in Burn Patients. 2018 , 93-113.e4	7
520	Complications After Hematopoietic Cell Transplantation. 2018 , 1669-1684.e2	0
519	Difunctional bacteriophage conjugated with photosensitizers for -targeting photodynamic inactivation. 2018 , 13, 2199-2216	16
518	Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship. 2018 , 37, 1993-2000	14
517	Candidemia in the patient with malignancy. 2018 , 46, 246-252	6
516	A phenotypic small-molecule screen identifies halogenated salicylanilides as inhibitors of fungal morphogenesis, biofilm formation and host cell invasion. 2018 , 8, 11559	21
515	Trends in antifungal use in US hospitals, 2006-12. 2018 , 73, 2867-2875	22
514	Advancements in Regenerative Strategies Through the Continuum of Burn Care. 2018 , 9, 672	38
513	Clinical Approach to Infections in the Compromised Host. 2018 , 1447-1461	
512	Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents. 2018 , 9, 1351	85
511	Bacterial, Fungal, and Parasitic Encephalitis. 2018 , 163-173	
510	Prevention of Invasive Candidiasis in Premature Neonates: Administering Fluconazole or Not?. 2018 , 12, 86-91	

509	De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety. 2018 , 8, 49	8
508	Candidemia in the intensive care unit: A 12-year retrospective cohort study in Reunion Island. 2018 , 48, 414-418	3
507	Fungal infections in pediatric neurosurgery. 2018 , 34, 1973-1988	4
506	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). 2018 , 61, 796-813	35
505	Efficacy of antifungal-impregnated cement spacer against chronic fungal periprosthetic joint infections after total knee arthroplasty. 2018 , 25, 631-637	12
504	Infections of the Skin. 2018 , 1495-1502.e2	
503	Author Reply to the Letter to the Editor: Antimicrobial stewardship without infectious disease physician. 2018 , 19, 148	
502	Combined Surgical and Medical Therapy for Candida Prosthetic Endocarditis in a Patient with Repaired Tetralogy of Fallot. 2018 , 59, 877-880	5
501	Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study. 2018 , 7, 309-325	4
500	D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections. 2018 , 8, 9235	10
499	Recent Advances in Fungal Infections of the Central Nervous System: From Etiology to Diagnosis and Management. 2018 , 215-259	2
498	Drug susceptibility profile of Candida glabrata clinical isolates from Iran and genetic resistant mechanisms to caspofungin. 2018 , 35, 88-91	3
497	Risk Analysis for Invasive Fungal Infection after Living Donor Liver Transplantation: Which Patient Needs Potent Prophylaxis?. 2019 , 36, 59-66	2
496	Frontier in Antifungal Treatments Against Major Human Fungal Opportunistic Pathogen Candida Species and Medically Important Fungi. 2019 , 453-476	1
495	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. 2019 , 74, 3056-3062	29
494	Pathogenesis of Fungal Infections. 2019 , 31-42	3
493	Principles of Antibiotic Prescription in Intensive Care Unit Patients and Patients With Acute Renal Failure. 2019 , 567-573.e1	
492	Adherence to Antifungal Guidelines in Malignant Hematology Patients: A Review of the Literature. 2019 , 35, 270-280	2

491 Candidiasis. **2019**, 107-120

490 The classic azole antifungal drugs are highly potent endocrine disruptors in vitro inhibiting steroidogenic CYP enzymes at concentrations lower than therapeutic Cmax. **2019**, 425, 152247 10

489 Infections in Intestinal and Multivisceral Transplantation. **2019**, 111-139 1

488 Pulmonary Aspergillosis. **2019**,

487 Risk Assessment of Infections in SOT Recipients. **2019**, 13-24

486 The Overlooked Immune State in Candidemia: A Risk Factor for Mortality. **2019**, 8, 6

485 Antimicrobial Stewardship Review of Automated Candidemia Alerts Using the Epic Stewardship Module Improves Bundle-of-Care Adherence. **2019**, 6, ofz412 5

484 Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment. **2019**, 63, 8

483 Clinical manifestations and outcome analysis of invasive pulmonary aspergillosis infection: a retrospective study in 43 nonneutropenic patients. **2019**, 47, 5680-5688 3

482 Importancia de las infecciones por Candida en neonatología. **2019**, 12, 53-57

481 Topical ketoconazole: a systematic review of current dermatological applications and future developments. **2019**, 30, 760-771 21

480 Effects of immune suppression in murine models of disseminated *Candida glabrata* and *Candida tropicalis* infection and utility of a synthetic peptide vaccine. **2019**, 57, 745-756 10

479 Severe Acute Pancreatitis with *Candida* Endophthalmitis. **2019**, 58, 2529-2533 0

478 Infections in Allogeneic Stem Cell Transplantation. **2019**, 209-226 1

477 Antimicrobial Drug Prophylaxis: Challenges and Controversies. **2019**, 1123-1135

476 Native valve endocarditis due to *Candida albicans* in two children: Two new case reports. **2019**, 36, 1401-1404 2

475 Suppression of the pathogenicity of *Candida albicans* by the quorum-sensing molecules farnesol and tryptophol. **2020**, 65, 277-283 13

474 Anti-candidal and anti-virulence efficiency of selected seaweeds against azole resistance *Candida albicans*. **2019**, 20, 101195 3

473	Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol. 2019 , 9, e027489	10
472	Nonreflux Esophagitis. 2019 , 480-489	
471	Antimicrobial Effect of and var. as Raw Extracts and Nanovesicles. 2019 , 11,	19
470	Population Pharmacokinetics of Anidulafungin in Critically Ill Patients. 2019 , 63,	7
469	Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors. 2019 , 38, 1499-1505	2
468	Candida catheter-related bloodstream infection in patients on home parenteral nutrition - Rates, risk factors, outcomes, and management. 2019 , 31, 1-9	16
467	Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. 2019 , 74, 2128-2138	12
466	Health care-associated invasive Candida infections in children. 2019 , 57, 929-936	10
465	Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Species From 1997-2016. 2019 , 6, S79-S94	227
464	Beyond tissue concentrations: antifungal penetration at the site of infection. 2019 , 57, S161-S167	6
463	Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. 2019 , 57, S127-S137	7
462	ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. 2019 , 45, 789-805	70
461	Effect of antifungal exposure on the etiology of candidemia. 2019 , 49, 356	
460	Role of Antifungal Drugs in Combating Invasive Fungal Diseases. 2019 , 103-144	1
459	Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China. 2019 , 184, 413-422	10
458	Defining standards of CARE for invasive fungal diseases in the ICU. 2019 , 74, ii9-ii15	4
457	Genotypic and phenotypic characterization of Candida albicans Lebanese hospital isolates resistant and sensitive to caspofungin. 2019 , 127, 12-22	6
456	Activity of antifungal agents alone and in combination against echinocandin-susceptible and -resistant Candida parapsilosis strains. 2019 , 36, 44-47	2

455	Critically Ill Recipients of Weight-Based Fluconazole Meeting Drug-Induced Liver Injury Network Criteria. 2019 , 54, 378-384	0
454	Chronic Candida osteomyelitis of hard palate and nose: A diagnostic quandary. 2019 , 24, 1-4	2
453	Hepatosplenic Fungal Infections in Children With Leukemia-Risk Factors and Outcome: A Multicentric Study. 2019 , 41, 256-260	3
452	Efficacy of liposomal amphotericin B and anidulafungin using an antifungal lock technique (ALT) for catheter-related Candida albicans and Candida glabrata infections in an experimental model. 2019 , 14, e0212426	8
451	Management of Patients With Fever and Neutropenia Through the Arc of Time: A Narrative Review. 2019 , 170, 389-397	15
450	Depigmentation Disorders of the Vulva, Clinical Management. 2019 ,	
449	Management of Candida Urinary Tract Infection in the Elderly. 2019 , 14, 33	2
448	Diagnosis and Treatment of Esophageal Candidiasis: Current Updates. 2019 , 2019, 3585136	22
447	Explore type and concentration of Indonesian propolis wax in inhibiting Candida albicans: In vitro study anti-candidiasis. 2019 ,	
446	6.1 Septische Entzündungen der Wirbelsäule Wirbelsäulenentzündung, septische. 2019 ,	
445	Implementation and Impact of an Antimicrobial Stewardship Program at a Tertiary Care Center in South India. 2019 , 6, ofy290	20
444	Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis. 2019 , 19, 7	21
443	Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen. 2019 , 102, 331-340	4
442	Antifungal Dosing Considerations for Term and Preterm Infants. 2019 , 185-191	
441	Alternative and complementary therapies for vulvovaginal candidiasis. 2019 , 64, 133-141	15
440	Antifungal Agents. 2019 ,	
439	Fungal and Parasitic CNS Infections. 2019 , 86, 83-90	11
438	Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. 2019 , 57, 52-62	40

437	A Multicenter, Randomized, Open-Label Study to Compare Micafungin with Fluconazole in the Prophylaxis of Invasive Fungal Infections in Living-Donor Liver Transplant Recipients. 2020 , 24, 832-840	10
436	Inflammatory and Infectious Ocular Disorders. 2020 ,	0
435	Invasive Infections in a Pediatric Intensive Care Unit in Turkey: Evaluation of an 11-Year Period. 2020 , 9, 21-26	6
434	Deletion of bem46 retards spore germination and may be related to the polar growth of <i>Aspergillus fumigatus</i> . 2020 , 58, 690-697	
433	Risk factors for fungal infection in extremely low birthweight infants registered in the Korean neonatal network from 2013 to 2015: Male sex and hypotension. 2020 , 62, 477-483	1
432	Uterus Transplantation. 2020 ,	
431	Curative Treatment of Candidiasis by the Live Biotherapeutic Microorganism Lcr35 in the Invertebrate Model : First Mechanistic Insights. 2019 , 8,	6
430	Phytol-Loaded Solid Lipid Nanoparticles as a Novel Anticandidal Nanobiotechnological Approach. 2020 , 12,	5
429	A randomized clinical trial evaluating Photodithazine-mediated Antimicrobial Photodynamic Therapy as a treatment for Denture stomatitis. 2020 , 32, 102041	6
428	Efficacy of a vaginal tablet as a Persian medicine product on vulvovaginal candidiasis: a double-blind, randomised, placebo-controlled trial. 2020 , 58, 574-580	1
427	Caspofungin: a review of its characteristics, activity, and use in intensive care units. 2020 , 18, 1213-1220	9
426	Treatment of invasive fungal infections in intensive care units with micafungin: The MYRIADE study. 2020 , 63, 443-451	1
425	Antifungal drugs: An updated review of central nervous system pharmacokinetics. 2020 , 63, 1047-1059	0
424	Lactoferrin-Derived Peptide Lactofungin Is Potently Synergistic with Amphotericin B. 2020 , 64,	2
423	Triazole Evolution of <i>Candida parapsilosis</i> Results in Cross-Resistance to Other Antifungal Drugs, Influences Stress Responses, and Alters Virulence in an Antifungal Drug-Dependent Manner. 2020 , 5,	7
422	Preventing <i>Candida albicans</i> biofilm formation using aromatic-rich piperazines. 2020 , 28, 115810	
421	adhesion to central venous catheters: Impact of blood plasma-driven germ tube formation and pathogen-derived adhesins. 2020 , 11, 1453-1465	4
420	Functional characterization of <i>Candida glabrata</i> ORF, CAGL0M02233g for its role in stress tolerance and virulence. 2020 , 149, 104469	4

419	Favourable outcome in paediatric endogenous endophthalmitis secondary to following pars plana vitrectomy. 2020 , 13,	0
418	An unusual case of fungal ball on implantable cardioverter defibrillator wire and literature review. 2020 , 10, 340-342	
417	Tobacco Hornworm () caterpillars as a novel host model for the study of fungal virulence and drug efficacy. 2020 , 11, 1075-1089	6
416	Clinical characteristics, risk factors and outcomes of mixed <i>Candida albicans</i> /bacterial bloodstream infections. 2020 , 20, 810	7
415	Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center. 2020 , 22, e13361	7
414	and Mechanisms of Antifungal Resistance. 2020 , 9,	91
413	Fungal endocarditis in transplant recipients: A systematic review. 2020 , 63, 952-963	11
412	Combination therapy against human infections caused by <i>Candida</i> species. 2020 , 81-94	2
411	Management of osteoarticular fungal infections in the setting of immunodeficiency. 2020 , 18, 461-474	4
410	Species distribution and antifungal susceptibilities of bloodstream isolates: a nine-years single center survey. 2020 , 32, 244-250	3
409	Rapid identification of the <i>Candida glabrata</i> species complex by high-resolution melting curve analysis. 2020 , 34, e23226	4
408	species in the urinary tract: is it a fungal infection or not?. 2020 , 15, 81-83	5
407	Candidemia by <i>Candida parapsilosis</i> in a neonatal intensive care unit: human and environmental reservoirs, virulence factors, and antifungal susceptibility. 2020 , 51, 851-860	2
406	Candidemia in Patients with Acute Leukemia: Analysis of 7 Years' Experience at a Single Center in China. 2020 , 12, e2020003	1
405	Oral Candidiasis: A Disease of Opportunity. 2020 , 6,	81
404	Effects and long-term follow-up of using umbilical cord blood-derived mesenchymal stromal cells in pediatric patients with severe BK virus-associated late-onset hemorrhagic cystitis after unrelated cord blood transplantation. 2020 , 24, e13618	4
403	Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal. 2020 , 8,	39
402	Candidemia in Colombia. 2020 , 40, 195-207	4

401	Quantitative analysis of the expression of fluconazole-resistant genes in strains of <i>Candida albicans</i> isolated from elderly people at their admission in an intensive care unit in Manizales, Colombia. 2020 , 40, 153-165	0
400	Development of effective AmB/AmB- β D complex double loaded liposomes using a factorial design for systemic fungal infection treatment. 2021 , 31, 177-188	1
399	Efficacy of antifungal drugs in the treatment of oral candidiasis: A Bayesian network meta-analysis. 2021 , 125, 257-265	10
398	Epidemiology, risk factors, treatment and outcome of <i>Candida</i> bloodstream infections because of <i>Candida albicans</i> and <i>Candida non-albicans</i> in two district general hospitals in the United Kingdom. 2021 , 75, e13655	6
397	Caspofungin suppresses zymosan-induced cytokine and chemokine release in THP-1 cells: possible involvement of the spleen tyrosine kinase pathway. 2021 , 227, 53-63	4
396	Clinical characteristics, management and outcome of patients with invasive candidiasis hospitalized in Internal Medicine Units: findings from a registry by the Italian Scientific Society FADOI. 2021 , 49, 277-285	1
395	European confederation of medical mycology quality of clinical candidaemia management score: A review of the points based best practice recommendations. 2021 , 64, 123-131	0
394	Synthetic antifungal compounds. 2021 , 167-262	0
393	Antifungal therapy. 2021 , 49-66	
392	Chronic, persistent fungal shoulder arthropathy secondary to genetic mutation: a case report. 2021 , 30, e69-e75	
391	A Second-Generation Fungicidal Analog, SCY-247, Shows Potent Activity in a Murine Model of Hematogenously Disseminated <i>Candida albicans</i> . 2021 , 65,	1
390	Post COVID-19 opportunistic candida retinitis: A case report. 2021 , 69, 987-989	8
389	<i>Candida</i> Infections in Solid Organ Transplantation. 2021 , 1045-1075	
388	Clinical Surveillance of Candidemia at Our Hospital. 2021 , 62, 29-34	
387	The role of gut mycobiome in health and diseases. 2021 , 14, 17562848211047130	7
386	[Brazilian Protocol for Sexually Transmitted Infections 2020: infections causing vaginal discharge]. 2021 , 30, e2020593	1
385	Defining Adequate Management in Elderly Patients with Candidaemia. 2021 , 67, 453-454	
384	Review of Fluconazole Treatment and Prophylaxis for Invasive Candidiasis in Neonates. 2021 , 26, 115-122	3

383	Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. 2021 , 40, 1521-1528	1
382	Current and promising pharmacotherapeutic options for candidiasis. 2021 , 22, 867-887	2
381	Candidemia: An Infection Prevention Issue?. <i>Clinical Infectious Diseases</i> , 2021 , 73, 697-698	11.6 1
380	Recurrent Vulvovaginal Candidiasis; a dynamic interkingdom biofilm disease of <i>Candida</i> and <i>Lactobacillus</i> .	
379	High prevalence of asymptomatic nosocomial candiduria due to among hospitalized patients with heart failure: a matter of some concern?. 2020 , 6, 1-8	
378	Phytotherapy in the management of denture stomatitis: A systematic review and meta-analysis of randomized controlled trials. 2021 , 35, 4111-4126	3
377	Effect of LongZhang Gargle on Dual-Species Biofilm of <i>Candida albicans</i> and <i>Streptococcus mutans</i> . 2021 , 2021, 6654793	1
376	Evaluation of Microbiological Contamination of Dummies Used in Cardiopulmonary Resuscitation in Korea. 2021 , 22, 281-287	
375	Acute-on-chronic Liver Failure in a Patient with : A Case Report. 2021 , 9, 447-451	1
374	Impact of Low-Dose Fluconazole on Tacrolimus Dosing in Renal Transplant. 2021 , 8971900211000702	
373	Species as Sources of Active Phytochemicals for Dermatological and Cosmetic Applications. 2021 , 2021, 6643827	3
372	Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization. 2021 , 12, 636097	2
371	<i>Mycoplasma genitalium</i> and Other Reproductive Tract Infections in Pregnant Women, Papua New Guinea, 2015-2017. 2021 , 27, 894-904	4
370	A Pilot Clinical Study on Post-Operative Recurrence Provides Biological Clues for a Role of Yeasts and Fluconazole in Crohn's Disease. 2021 , 7,	2
369	Epidemiology, species distribution, and outcome of nosocomial <i>Candida</i> spp. bloodstream infection in Shanghai: an 11-year retrospective analysis in a tertiary care hospital. 2021 , 20, 34	2
368	Management of patients with digestive diseases during the COVID-19 pandemic. Clinical Practice Guidelines by the Russian scientific medical society of internal medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia (2nd edition). 2021 , 5-82	5
367	<i>Candida</i> Contamination in Kidney and Liver Organ Preservation Solution: Does It Matter?. 2021 , 10,	0
366	Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards. 2021 , 16, e0252165	5

- 365 Computational Drug Repurposing Resources and Approaches for Discovering Novel Antifungal Drugs against *Candida albicans* N-Myristoyl Transferase. **2021**, 15, 556-579
- 364 Treatment Practices for Adults With Candidemia at 9 Active Surveillance Sites-United States, 2017-2018. *Clinical Infectious Diseases*, **2021**, 73, 1609-1616 11.6 2
- 363 Importance of Yeasts in Oral Canine Mucosa.
- 362 Invasive Fungal Infections After Liver Transplantation: A Retrospective Matched Controlled Risk Analysis. **2021**, 26, e930117 0
- 361 Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?. **2021**, 49, 1107-1131 1
- 360 Application of Nanotechnologies in Studying Yeast Structure in *Candida*. **2021**, 16, 450-472 0
- 359 Oral Candidosis: Pathophysiology and Best Practice for Diagnosis, Classification, and Successful Management. **2021**, 7, 4
- 358 Top 10 Pearls for the Recognition, Evaluation, and Management of Maternal Sepsis. **2021**, 138, 289-304 3
- 357 Mixed bacterial-fungal infection following total hip arthroplasty: A case report. **2021**, 25, 32-32 0
- 356 Development of a Method of Measuring β -D-Glucan and Its Use in Preemptive Therapy for Invasive Fungal Infections. **2021**, 22, 0
- 355 Recurrent Vulvovaginal Candidiasis: a Dynamic Interkingdom Biofilm Disease of and. **2021**, 6, e0062221 9
- 354 Hospital-Acquired Infections in Critically Ill Patients With COVID-19. **2021**, 160, 454-465 64
- 353 Gene expression of *Candida albicans* strains isolates from patients with denture stomatitis submitted to treatments with photodynamic therapy and nystatin. **2021**, 35, 102292 2
- 352 Effect of Cold Atmospheric Plasma Jet Associated to Polyene Antifungals on Biofilms. **2021**, 26, 1
- 351 Participation of the ABC Transporter in Azole Resistance of. **2021**, 7, 1
- 350 Evaluation for Metastatic *Candida* Focus and Mortality at *Candida*-associated Catheter-related Bloodstream Infections at the Pediatric Hematology-oncology Patients. **2021**, 1
- 349 Echinocandins Accelerate Particle Transport Velocity in the Murine Tracheal Epithelium: Dependency on Intracellular Ca Stores. **2021**, 65, e0066921
- 348 Infections in hematopoietic stem cell transplant patients admitted to Hematology intensive care unit: a single-center study. **2021**, 26, 328-339 1

347	Bloodstream Infections: Changes in Epidemiology and Increase in Drug Resistance. 2021 , 14, 11786337211026927	2
346	Adherence to National Consensus Guidelines and Association with Clinical Outcomes in Patients with Candidemia. 2021 , 14, 11786337211018722	0
345	Brazilian Protocol for Sexually Transmitted Infections, 2020: infections causing vaginal discharge. 2021 , 54, e2020593	1
344	Cutaneous Diseases and the Esophagus. 763-781	1
343	Flucytosine. 2011 , 57-60	1
342	Azoles. 2011 , 61-93	1
341	Rational approach to pediatric antifungal therapy. 2011 , 697, 231-42	2
340	Infectious Complications. 2010 , 143-165	2
339	Fungal Infection of the CNS. 2014 , 119-137	1
338	Management of shunt related infections. 2011 , 719, 105-15	3
337	Anti-infectives. 2013 , 429-464	1
336	Utility of Antifungal Susceptibility Testing and Clinical Correlations. 2012 , 131-158	5
335	Emergence of Invasive Fungal Infection: Diagnosis and Treatment in Humans. 2019 , 131-148	1
334	Antimicrobial agents, drug adverse reactions and interactions, and cancer. 2014 , 161, 413-62	4
333	Fungal infections in cancer patients. 2014 , 161, 129-55	14
332	Pediatric Infective Endocarditis and Congenital Heart Disease. 2016 , 333-355	1
331	Clinical Syndromes: Candida and Candidosis. 2019 , 45-75	2
330	Antifungal Resistance: Cellular and Molecular Mechanisms. 2010 , 125-145	2

329	Antiinfektive Therapie. 2016 , 131-142	0
328	Infections in Patients with Acute Leukemia. 2015 , 3-23	4
327	Fungal arthritis of the wrist caused by <i>Candida parapsilosis</i> during infliximab therapy for rheumatoid arthritis. 2012 , 22, 903-6	4
326	Fungal Infections of the Eye. 2020 , 7, 39-50	5
325	Osteomyelitis. 2010 , 1457-1467	8
324	Endophthalmitis. 2010 , 1553-1559	2
323	<i>Candida</i> Species. 2010 , 3225-3240	10
322	Nosocomial Urinary Tract Infections. 2010 , 3725-3737	3
321	Urinary Tract Infection in Adults. 2012 , 1356-1382	1
320	Surgical Infections and Antibiotic Use. 2012 , 240-280	3
319	Risk Factors for Endogenous Endophthalmitis in Hospitalized Patients with <i>Candida</i> Fungemia. 2021 , 5, 687-695	1
318	Clinical Characteristics and Outcomes of Breakthrough Candidemia in 71 Hematologic Malignancy Patients and/or Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Single-center Retrospective Study From China, 2011-2018. <i>Clinical Infectious Diseases</i> , 2020 , 71, S394-S399	11.6 5
317	Dose escalation studies with caspofungin against <i>Candida glabrata</i> . 2015 , 64, 998-1007	11
316	Overexpression and mutation as a genetic mechanism of fluconazole resistance in <i>Candida albicans</i> isolated from human immunodeficiency virus patients in Indonesia. 2015 , 64, 1046-1052	19
315	The effects of human lactoferrin in experimentally induced systemic candidiasis. 2019 , 68, 1802-1812	6
314	High burden of <i>Mycoplasma genitalium</i> and other reproductive tract infections among pregnant women in Papua New Guinea.	1
313	<i>Candida</i> , <i>Cryptococcus</i> , and Other Yeasts of Medical Importance. 2011 , 1793-1821	12
312	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. 343-371	3

311	The Impact of Antifungal Drug Resistance in the Clinic. 373-385	1
310	Insights in Antifungal Drug Discovery. 387-401	2
309	Mucosal Candidiasis. 417-427	1
308	Systemic Candidiasis: Candidemia and Deep-Organ Infections. 429-441	1
307	The Epidemiology of Invasive Candidiasis. 449-480	5
306	Candida, Cryptococcus, and Other Yeasts of Medical Importance. 1984-2014	10
305	Susceptibility Test Methods: Yeasts and Filamentous Fungi. 2255-2281	5
304	Candida albicans osteomyelitis as a cause of chest pain and visual loss. 2015 , 2015,	3
303	Mediastinitis: Could your case be a candidate for candida?. 2012 , 13, 86-8	5
302	Treatment of Renal Fungal Ball with Fluconazole Instillation Through a Nephrostomy Tube: Case Report and Literature Review. 2018 , 19, 1179-1183	5
301	Success Rate of Fungal Peri-Prosthetic Joint Infection Treated by 2-Stage Revision and Potential Risk Factors of Treatment Failure: A Retrospective Study. 2018 , 24, 5549-5557	9
300	Invasive fungal infection of the central nervous system in a patient with acute myeloid leukaemia. 2012 , 77, 54-7	2
299	Rifampicin induced virulence determinants increase Candida albicans biofilm formation. 2, 106	3
298	ED-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. 2012 , 7, e42282	96
297	Factors associated with esophageal candidiasis and its endoscopic severity in the era of antiretroviral therapy. 2013 , 8, e58217	18
296	Effect of statin use on outcomes of adults with candidemia. 2013 , 8, e77317	11
295	Inhibitors of the glyoxylate cycle enzyme ICL1 in Candida albicans for potential use as antifungal agents. 2014 , 9, e95951	60
294	Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. 2014 , 9, e101510	257

293	Resistance Surveillance in <i>Candida albicans</i> : A Five-Year Antifungal Susceptibility Evaluation in a Brazilian University Hospital. 2016 , 11, e0158126	15
292	An Optimized Lock Solution Containing Micafungin, Ethanol and Doxycycline Inhibits <i>Candida albicans</i> and Mixed <i>C. albicans</i> - <i>Staphylococcus aureus</i> Biofilms. 2016 , 11, e0159225	12
291	The Efficacy and Safety of Miconazole Nitrate Mucoadhesive Tablets versus Itraconazole Capsules in the Treatment of Oral Candidiasis: An Open-Label, Randomized, Multicenter Trial. 2016 , 11, e0167880	7
290	A retrospective study of 606 cases of nasopharyngeal carcinoma with or without oropharyngeal candidiasis during radiotherapy. 2017 , 12, e0182963	3
289	SPECIES DISTRIBUTION AND ANTIFUNGAL SUSCEPTIBILITY PROFILE OF CANDIDA SPECIES ISOLATED FROM BLOOD STREAM INFECTIONS. 2012 , 1, 241-249	4
288	An unusual case of <i>Candida</i> infection producing a fungus ball in the left atrial cavity. 2013 , 16, E276-8	3
287	In Vitro Antifungal-Antibacterial Combinations are Effective Against MRSA in <i>Candida albicans</i> - <i>Staphylococcus aureus</i> Polymicrobial Biofilms. 2016 , 3,	2
286	Population-Based Active Surveillance for Culture-Confirmed Candidemia - Four Sites, United States, 2012-2016. 2019 , 68, 1-15	57
285	Study of Inhibitory Effect of <i>Echinops cephalotes</i> on <i>Candida</i> Spp. Isolated from Vulvovaginal Candidiasis Patients in Isfahan. 2016 , In Press,	1
284	Plant Antifungal Lectins: Mechanism of Action and Targets on Human Pathogenic Fungi. 2020 , 21, 284-294	1
283	Emerging Complexity and the Need for Advanced Drug Delivery in Targeting <i>Candida</i> Species. 2019 , 19, 2593-2609	21
282	Gingerol Derivatives as 14 α -demethylase Inhibitors: Design and Development of Natural, Safe Antifungals for Immune-compromised Patients. 2020 , 17, 918-928	3
281	Antifungal Activity Directed Toward the Cell Wall by 2-Cyclohexylidenhydrazo- 4-Phenyl-Thiazole Against <i>Candida albicans</i> . 2019 , 19, 428-438	2
280	Effect of Denture-Related Stomatitis Fluconazole Treatment on Oral <i>Candida albicans</i> Susceptibility Profile and Genotypic Variability. 2015 , 9, 46-51	17
279	Chronic candidal bronchitis: a consecutive series. 2012 , 6, 145-9	11
278	Management of Resistant, Atypical and Culture-negative Periprosthetic Joint Infections after Hip and Knee Arthroplasty. 2016 , 10, 615-632	31
277	Endocarditis infecciosa debida a <i>candida lusitanae</i> en un lactante menor: Reporte de caso. 2020 , 24, 266	1
276	Fluconazole and Ibuprofen Combination: A Potential Treatment for Mucosal Candidiasis. 2020 , 14, 25-29	1

275	Correspondence (letter to the editor): Non-albicans Candida species. 2011 , 108, 320	1
274	Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data. 2020 , 6,	8
273	Prospective observational multicenter study to define a diagnostic algorithm for biliary candidiasis. 2014 , 20, 12260-8	12
272	[A clinical study of fungal esophagitis in 13 patients with hematologic malignancies]. 2016 , 37, 507-11	2
271	Common Infections in Solid Organ Transplant Recipients. 2013 , 84, 145	2
270	Common Infectious Diseases in Hematopoietic Stem Cell Transplant Recipients. 2013 , 84, 158	7
269	Ophthalmology Consultation to Detect Endogenous Endophthalmitis: Clinical Characteristics in Consulted Versus Diagnosed Cases Among At-Risk Inpatients. 2020 , 51, 159-A3	4
268	A Case ofCandida pelliculosaProsthetic Valve Endocarditis Treated with Anidulafungin and Valve Replacement. 2012 , 44, 499	1
267	Septic shock due to candidemia: outcomes and predictors of shock development. 2011 , 3, 65-71	27
266	Use of matrix-assisted laser desorption/ionisation-time of flight mass spectrometry analyser in a diagnostic microbiology laboratory in a developing country. 2017 , 6, 598	3
265	Invasive candidiasis in non neutropenic critically ill - need for region-specific management guidelines. 2015 , 19, 333-9	7
264	Identification and Antifungal Susceptibility Testing of Species: A Comparison of Vitek-2 System with Conventional and Molecular Methods. 2016 , 8, 139-146	21
263	Fungal infections in intensive care unit: challenges in diagnosis and management. 2013 , 3, 238-44	39
262	Identification of Candida species in patients with oral lesion undergoing chemotherapy along with minimum inhibitory concentration to fluconazole. 2016 , 5, 132	13
261	Identification of Candida Species and Antifungal Susceptibility in Cancer Patients with Oral Lesions in Ahvaz, Southern West of Iran. 2020 , 9, 50	2
260	Management of a case of endogenous endophthalmitis with intravitreal caspofungin. 2017 , 65, 529-531	10
259	The Interesting of Antifungal Effects of Novel <i>In Vitro</i> Fabrics of Stabilized ZnO Nanofluids. 2016 , 05, 206-223	4
258	Vertebral Osteomyelitis Due to <i>Candida</i> Species: A Cohort Study and Review of the Literature. 2013 , 03, 81-89	5

- 257 Antifungal activity of chemotype essential oils from rosemary against *Candida albicans*. **2013**, 03, 176-182 17
- 256 Bacterial infections post-living-donor liver transplantation in Egyptian hepatitis C virus-cirrhotic patients: A single-center study. **2017**, 9, 896-904 4
- 255 Antifungal Effects of Common Mouthwashes on *Candida* Strains Colonized in the Oral Cavities of Liver Transplant Recipients in South Iran in 2014. **2016**, 16, e31245 13
- 254 In Vitro Activities of Six Antifungal Drugs Against *Candida glabrata* Isolates: An Emerging Pathogen. **2016**, 9, e36638 7
- 253 The Inhibitory Effect of Probiotic Bacteria against Drug - Resistant *Candida* Species Isolated from the Oral Cavity of the Elderly. **2018**, 19, 1
- 252 Amphotericin B-Deoxycholate is as Effective and Safe as the Costly Amphotericin B Colloidal Dispersion in the Treatment of Paediatric Invasive Fungal Infections. **2014**, 4, 228-237 2
- 251 Hepatosplenic Candidiasis Detected by (18)F-FDG-PET/CT. **2016**, 4, 106-8 8
- 250 Treatment of vulvovaginal candidiasis in preparation programs for in vitro fertilization. **2021**, 77-83
- 249 Neonatal invasive candidiasis: updates on clinical management and prevention. **2021**, 1
- 248 Voice rehabilitation with voice prosthesis: Long term results, complications and risk factors. **2021**, 1
- 247 Synergistic effect of thymoquinone and nystatin in the treatment of oral candidiasis; an in vitro study. **2021**, 1 1
- 246 Fungal Infections. **2009**, 347-366 O
- 245 Antifungal Susceptibility Testing and Therapy. **2010**, 311-326
- 244 Echinocandins for Prevention and Treatment of Invasive Fungal Infections. **2009**, 219-242
- 243 Novel Administrations of Antifungals. **2009**, 243-257
- 242 Invasive Candidiasis. **2009**, 278-292 1
- 241 Flucytosine. **2009**, 184-198
- 240 Polyenes for Prevention and Treatment of Invasive Fungal Infections. **2009**, 163-183

- 239 Systemic fungal infections. **2010**, 777-796 0
- 238 Uvôtes secondaires aux endophtalmies endogènes fongiques. **2010**, 233-243
- 237 Opportunistic and systemic fungi. **2010**, 1823-1852 2
- 236 Vaginal Infections. **2010**, 76-93 1
- 235 Role of De-Escalation and Combination Therapy Strategies in the Management of Invasive Fungal Infection: A Multidisciplinary Point of View. **2010**, 241-272
- 234 Liver Transplantation: Prevention and Treatment of Infection. **2010**, 724-739
- 233 Combination Antifungal Therapy. **2011**, 153-163
- 232 Fungal Infections Among Patients with AIDS. **2011**, 525-536
- 231 Fungal Infections in Neutropenic Patients. **2011**, 465-496
- 230 Antifungal Therapy in Patients with Hematological Malignancies. **2011**, 569-588
- 229 Candida Pneumonia in Patients with Hematological Neoplasia. **2011**, 349-356 1
- 228 Pharmakotherapie. **2011**, 105-141
- 227 Fungal Infections. **2011**, 617-622
- 226 A CASE OF ETHANOL-LOCK THERAPY FOR CANDIDA PARAPSILOSIS IN CATHETER-RELATED BLOOD STREAM INFECTION. **2011**, 72, 1374-1377
- 225 Antifungal Therapy in The ICU: The Bug, the Drug, and the Mug. **2011**, 516-530 1
- 224 Prävention und Antibiotikatherapie postoperativer Komplikationen. **2011**, 223-232
- 223 Therapie mit Antiinfektiva. **2011**, 371-389
- 222 Invasive Candidiasis in Management of Infections in Cancer Patients. **2011**, 273-281

221 Endocarditis in Oncology Patients. **2011**, 219-232

220 Mycotic Diseases. **2011**, 1155-1187

219 Spezielle Infektionen. **2011**, 295-321

218 Antifungal Agents *. **2011**, 1995-2007

217 CANDIDA SPONDYLITIS FOLLOWING SURGERY FOR RECTAL PERFORATION-A CASE REPORT-. **2011**, 72, 2718-2722

216 A Case of Laryngeal Fungal Infection Requiring an Urgent Tracheotomy. **2011**, 23, 36-39

215 Antibiotika, Prophylaxe und Antimykotika. **2011**, 781-787

214 Fungal Infections. **2011**, 1050-1060

213 Principles of Antifungal Therapy. **2011**, 1053-1053.e5

212 Candidemia in a Regional Hospital without Infectious Diseases Department. **2011**, 60, 18-23

211 Perioperative Infections: Prevention and Therapeutic Options. 235-260

210 Steroid-Induced Side Effects Affecting Diet and Nutrition in Palliative Care. **2011**, 403-415

209 Antimykotika. **2011**, 74-76

208 Infections in Leukemia and Hematopoietic Stem Cell Transplantation. **2012**, 309-365

207 Early Recognition of Invasive Candidiasis in the ICU. **2012**, 311-323

1

206 Spezielle nosokomiale Infektionen auf der Intensivstation. **2012**, 141-297

1

205 Clinical Syndromes of Device-Associated Infections. **2012**, 588-599.e9

0

204 Candida Species. **2012**, 1196-1202.e4

203 Infections in Hematopoietic Stem Cell Transplant Recipients. **2012**, 562-566.e2

202 Gynecology. **2012**, 455-467

201 Infectious and Inflammatory Arthritis. **2012**, 477-483.e4

3

200 Fungal, Rickettsial, and Parasitic Diseases of the Nervous System. **2012**, 1291-1338

199 Case 36. **2012**, 73-74

198 Fungal Infections. **2012**, 1061-1069

o

197 Candida Arthritis Presenting as a Huge Popliteal Cyst in a Patient with Rheumatoid Arthritis: A Case Report and Review of the Literature. **2012**, 82, 119

196 Neonatal infection. **2012**, 993-1064

195 Infections of the Oral Cavity. **2012**, 190-196.e2

194 ?????????????????????????????????CT????????????2012, 27, 8-12

o

193 Invasive fungal diseases in solid organ transplant recipients: recent progress in diagnosis and treatment. **2012**, 31, 1361-1365

192 Esophagitis in the Immunocompromised Host. 724-741

1

191 Mouth care. **2012**, 124-135

190 Superficial Candidosis. 121-137

189 Invasive Candidosis. 201-235

188 AIDS and the Gut. 865-872

187 Vulvovaginal Candidiasis, Desquamative Inflammatory Vaginitis, and Atrophic Vaginitis. 72-84

1

186 Infectious Esophagitis. **2013**, 657-670

1

185 Premature newborn with intracardiac fungus balls and endocarditis which is curable only with anti-fungal therapy: Case presentation. **2013**, 02, 315-317

184 Prinzipien der Chemotherapie. **2013**, 13-45

183 A Case of a Deep Neck Space Candidial Abscess in an Immunocompetent Woman. **2013**, 84, 101

182 A Case of Fungal Peritonitis after Duodenal Diverticulum Perforation Prolonged High Level of (1 α ,25-(OH) $_2$ -D-glucan. **2013**, 74, 1382-1387 1

181 Invasive Candidal Infections in Extremely Preterm Infants. **2013**, 20, 369 1

180 Skin Disorders. 22-78

179 Superficial Fungal Infections. **2014**, 141-147

178 Infective Endocarditis, Device Infections, and Cardiac Manifestations of HIV. **2014**, 486-504

177 Postoperative Management of Periprosthetic Joint Infection. **2014**, 237-247

176 Care and Prevention of Infection. **2014**, 73-90

175 Invasive Candidiasis in the Intensive Care Setting. **2014**, 235-259

174 Renal Imaging: Infection. **2014**, 251-276 1

173 Histone Deacetylase Inhibitors, Proteasome Inhibitors, Demethylating Agents, Arsenicals, and Retinoids. 215-223

172 Dermatologic Infections. 319-336

171 Infections of the Liver. **2014**, 285-312

170 Oral Lesions: Poor Markers of Virologic Failure in HIV-Infected Patients on Antiretroviral Therapy. **2013**, 2013, 1-7 1

169 Diagnosis and Management of Central Venous Catheter-Related Infections. **2014**, 86, 282 1

168 Systemische Pilzinfektionen. **2014**, 329-334

167 Spezielle Infektionen. **2014**, 299-333

166 Etiology of Fungemia in Neonates: Four Decades of Case Reports. **2014**, 04, 97-105

165 Candidaemia in a tertiary hospital in Nigeria. **2014**, 3, 89

0

164 Multidrug Resistance Transcriptional Regulatory Networks in Candida. 403-416

163 Vaccines and Passive Immunity against Candidiasis. 171-184

162 Candida: What Should Clinicians and Scientists Be Talking About?. 1-8

1

161 Candida Arthritis in a Hemodialysis Patient. **2014**, 18, 93-97

160 Febrile Neutropenia. **2015**, 1-25

159 Antiinfektive Therapie. **2015**, 939-947

158 Biomaterials (Vol. 18, No. 12, Full Issue). **2014**, 18,

157 Entzündliche Erkrankungen der Speiseröhre. **2015**, 191-204

156 Infectious Complications. **2015**, 201-222

155 Peritonitis and Intraperitoneal Abscesses. **2015**, 935-959.e4

1

154 [Factors influencing recovery in patients with hemoblastoses and candidemia]. **2015**, 87, 77-87

1

153 Infektionen. **2015**, 653-674

152 Revisions in the 2015 Japanese guidelines for the management of acute pancreatitis: 1. Medical treatments. **2015**, 30, 733-740

151 Chapter 33. Infectious Disease. **2015**,

150 Endophthalmitis. **2015**, 1415-1422.e2

1

- 149 Clinical Study of the Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Fungal Infections in Non-neutropenic Patients. **2015**, 27, 147-153
- 148 Antimykotische Therapie. **2015**, 1-15
- 147 Infections in Injection Drug Users. **2015**, 3475-3491.e5
- 146 Invasive Fungal Infections in the Era of Antifungal Resistance. **2015**, 88, 518 1
- 145 Antibiotika, Antibiotikaphylaxe und Antimykotika in der Intensivmedizin. **2015**, 1-15
- 144 Candidiasis. **2015**, III-1-14-III-1-17
- 143 Mechanisms of Resistance to Antifungal Agents. 2236-2254 0
- 142 Antifungal Agents. 2221-2235
- 141 MALDI-TOF MS: A Rapid and New Approach in Fungal Diagnosis and Susceptibility Testing. **2015**, 337-355
- 140 Otorhinolaryngology-Related Fungal Diseases: A Convenient Classification for Better Clinical Practice. **2015**, 102-117 1
- 139 Infectious Esophagitis. **2016**, 87-92
- 138 Liposomal Amphotericin B Usefulness in Critical Care Unit: A Review Study. **2016**, 2,
- 137 Yeast Infections After Solid Organ Transplantation. **2016**, 693-706
- 136 Liposomal Amphotericin B Usefulness in Critical Care Unit: A Review Study. **2016**, 2,
- 135 Candidiasis Treatment Should Pay Attention to the Immune Changing Patients. **2016**, 06, 31-36
- 134 Utilization Management in a Large Community Hospital. **2017**, 151-170
- 133 Obstructive Renal Failure Caused by Bilateral Renal Candidiasis and Hypoplastic Renal Pelvises in a Preterm Infant: Case Presentation and Review of the Literature. **2016**, 5,
- 132 Harnwegsinfektionen auf der ITS. **2017**, 631-636

131 Holistic Supportive Care in Oral Cancer: Principles and Practice. **2017**, 121-231

130 Flucytosine Treatment and Resistance Mechanisms. **2017**, 407-413

2

129 Brief report: Fungal balls in the urinary tract of an infant. **2017**, 27, 165-166

1

128 Urosepsis. **2017**, 453-456

127 Echinocandin Resistance. **2017**, 415-428

126 Common superficial fungal infections in the pediatric age group. **2017**, 18, 77

125 Effect of Systemic Illness, Medication, Radiation, and Infection on the Esophagus. **2017**, 749-764

124 Bone and Joint Infections. **2017**,

123 Vaginal biocoenosis examining comparing to exfoliative cervical cytology. **2017**, 7, 36-42

122 Topical Clotrimazole/Betamethasone use in Oral Erosive Lichen Planus. **2017**, 4, 142-144

121 Late Onset Candida albicans Spondylodiscitis Following Candidemia: A Case Report. **2017**, 22, 117-121

120 Management of Fungal Keratitis in Pediatric Patients. **2017**, In Press,

1

119 ANTIFUNGAL SUSCEPTIBILITY TESTING OF CANDIDA SPECIES ISOLATED FROM BLOOD STREAM INFECTION BY USE OF VITEK 2 SYSTEM. **2017**, 4, 5874-5877

118 Infektionen. **2018**, 697-719

117 Vulvovaginitis in pre-pubertal and adolescent girls (a review). **2018**, 24, 49

1

116 Treating endocarditis: A protocol of an antimicrobial treatment from a middle-income country. 2, 38

115 A phenotypic small-molecule screen identifies halogenated salicylanilides as inhibitors of fungal morphogenesis, biofilm formation and host cell invasion.

114 Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China. **2018**, 24, 5258-5270

1

- 113 The Effect of Use of Anidulafungin on Failure of Weaning Due to Ventilator-associated Pneumonia which Complicate Contused Lungs. **2018**, 12, 73-84
- 112 Antifungal Effects of *Silybum marianum* Extract Individually and in Combination with Fluconazole on Clinical *Candida* Isolates in Northern Iran. **2018**, In Press, 0
- 111 Pulmonary Aspergillosis with Presenting Symptom of Hemoptysis. **2019**, 165-244
- 110 Pulmonary Aspergillosis Resembling to Pulmonary Tuberculosis. **2019**, 27-79
- 109 Catheter-Associated Bacteria Urinary Tract Infection and Antibiotic Susceptibility Pattern in a Tertiary Hospital, in Ghana. **2019**, 09, 140-151 2
- 108 In Vitro Susceptibilities of Vitreous *Candida* Endophthalmitis Isolates to Newer and Traditional Antifungal Agents. **2019**, 50, S13-S17 1
- 107 Manifestaciones dermatológicas de la infección por el virus de la inmunodeficiencia humana. **2019**, 53, 1-14
- 106 Tobacco Hornworm (*Manduca sexta*) caterpillars as a novel host model for the study of fungal virulence and drug efficacy. 2
- 105 Isolation of *Candida* in the blood cultures of patients admitted to the Emergency Room in a tertiary care hospital. **2019**, 36, 142-146
- 104 Infections in Critically Ill Cirrhosis Patients. **2020**, 105-122
- 103 Fungal Infection. **2020**, 163-171
- 102 High prevalence of itraconazole resistance among isolated from Iran. **2019**, 5, 43-46 2
- 101 Infections After Uterus Transplantation. **2020**, 189-207
- 100 Optimization of Dosage Regimen of Rezafungin against *Candida* spp. Based on Pharmacokinetic/Pharmacodynamic Analysis. **2020**, 11, 79-84
- 99 Clavicular Osteomyelitis Secondary to *Candida* Parapsilosis Infection. **2020**, 12, e8699 1
- 98 Antifungal effects of PC945, a novel inhaled triazole, on *Candida albicans*-infected immunocompromised mice.
- 97 Retrospective Evaluation of The Cases with Newborn *Candida* Sepsis.
- 96 Text Processing for Detection of Fungal Ocular Involvement in Critical Care Patients: Cross-Sectional Study. **2020**, 22, e18855 1

95	Candidalysin: From Mechanism of Action to Biomarker Development and Therapeutic Response. 2021 , 1, 41-44	0
94	Highly conserved gene of in patients with or without prior exposure to Echinocandins. 2021 , AAC0156321	
93	Management of Candidemia. 2020 , 35, 1-6	1
92	Urosepsis. 2020 , 445-448	
91	Vaginitis and Vulvar Conditions. 2020 , 165-186	
90	Candida Infections in Solid Organ Transplantation. 2020 , 1-32	
89	Invasive Fungal Infections With Good Survival Following Liver Transplant: A Single-Center Experience From a Developing Country. 2020 , 18, 196-200	0
88	[Evaluation and management of infectious esophagitis in immunocompromised patients and immunocompetent individuals]. 2020 , 92, 108-117	
87	Infective Endocarditis and Device Infections. 2021 , 467-482	
86	Fungal Endophthalmitis. Literature Review. 2020 , 17, 556-565	
85	Liver Transplantation in Acute-on-chronic Liver Failure. 2021 , 105, 1471-1481	6
84	Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. 2013 , 14, 193-202	12
83	Comparison of adverse events and hospital length of stay associated with various amphotericin B formulations: sequential conventional amphotericin b/lipid versus lipid-only therapy for the treatment of invasive fungal infections in hospitalized patients. 2013 , 38, 278-87	6
82	Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries. 2014 , 6, 134-42	10
81	Epidemiology of Oropharyngeal Candidiasis in Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patients and CD4+ Counts. 2015 , 7, 20-3	18
80	An experience of liver transplantation in Latin America: a medical center in Colombia. 2015 , 46, 8-13	1
79	Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients. 2015 , 8, 11794-802	1
78	Species identification of invasive yeasts including Candida in Pakistan: limitations of phenotypic methods. 2012 , 62, 995-8	2

77	[Not Available]. 2015 , 28, 21-8	2
76	Infectious Complications After Liver Transplantation. 2015 , 11, 741-53	13
75	Giant Cardiac Mass Detected to an Infant with Normal Fetal Echography and No Systolic Murmur in Early Postnatal Evolution. 2015 , 10, 123-126	
74	Adherence to clinical practice guidelines for the treatment of candidemia at a Veterans Affairs Medical Center. 2017 , 11, 18-23	2
73	Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit. 2017 , 49, 150-159	10
72	Candidemia in Febrile Neutropenic Patients; a Brief Report. 2018 , 6, e39	2
71	[The clinical value of diagnostic-driven therapy of invasive fungal disease (IFD) type unclassified CIIgroup in multiple myeloma patients during inducing chemotherapy]. 2018 , 39, 435-437	
70	[Clinical features of invasive candidiasis and risk factors for Candida bloodstream infection in children: a multicenter study in Urumqi, China]. 2017 , 19, 414-418	
69	A meta-analysis of fluconazole for the prevention of invasive fungal infection in preterm infants. 2021 , 13, 434-447	1
68	Organmykosen. 2015 , 1-20	
67	Oral Candidiasis in Infants and Children. 2022 , 489-501	
66	Successful treatment of chronic hyperplastic candidiasis with 5-aminolevulinic acid photodynamic therapy: A case report. 2021 , 37, 102633	0
65	Infectious Esophagitis. 2022 , 103-109	
64	Efficacy of antimicrobial photodynamic therapy compared to nystatin therapy in reducing Candida colony count in patients with Candida-associated denture stomatitis: a systematic review and meta-analysis. 2021 ,	1
63	Organmykosen.	
62	Mono-/Bis-Alkenoic Acid Derivatives From an Endophytic Fungus and Their Antifungal Activity.. 2021 , 9, 812564	1
61	Increased Activities against Biofilms of the Pathogenic Yeast of Optimized Pom-1 Derivatives.. 2022 , 14,	1
60	The Association between COVID-19-Related Wellbeing with Materialism and Perceived Threat.. 2022 , 19,	1

- 59 Antibiofilm Activities of Biogenic Silver Nanoparticles Against .. **2021**, 12, 741493 1
- 58 T2 Candida Panel: A Game Changer in Diagnosis of Fungal Infections. **2022**, 4, 24-25
- 57 Filament Negative Regulator Suppresses Glycogen Phosphorylase Encoded That Impacts the Cell Wall-Associated Features in .. **2022**, 8,
- 56 Molecular Identification and Caspofungin Susceptibility Profile in Comparison to Oregano Antifungal Effects on Oral Candida Isolates. **2022**, In Press,
- 55 Candidemia in Internal Medicine: Facing the New Challenge.. **2022**, 1 2
- 54 Fungal Infections in Critically Ill COVID-19 Patients: Inevitable Malum.. **2022**, 11, 1
- 53 Determination of Resistance Rates of C.albicans Species Isolated from Sterile Body Fluids to Triazoles by Microdilution Method.
- 52 Sepsis and the Inflammatory Response to Injury. **2022**, 45-53
- 51 Systemic anti-fungal therapy for esophageal candidiasis - systematic review and meta-analysis of randomized controlled trials.. **2022**, 106590
- 50 Data_Sheet_1.PDF. **2018**,
- 49 Brain abscess: A narrative review. **2022**, 0
- 48 Development and Validation of a Risk Score for Predicting Invasive Candidiasis in Intensive Care Unit Patients by Incorporating Clinical Risk Factors and Lymphocyte Subtyping.. **2022**, 12, 829066 1
- 47 De-escalation from Echinocandins to Azole Treatment in Critically Ill Patients with Candidemia.. **2022**,
- 46 Oral mucosal therapeutics. **2013**, 666-676.e1
- 45 Current concept of the diagnostics and treatment of vulvovaginal candidosis. **2015**, 91, 111-115
- 44 L-Se-methylselenocysteine loaded mucoadhesive thermogel for effective treatment of Vulvar candidiasis. **2022**, 622, 121851 0
- 43 Nosocomial Infections During Extracorporeal Membrane Oxygenation in Pediatric Patients: A Multicenter Retrospective Study. 10,
- 42 Continuing Shifts in Epidemiology and Antifungal Susceptibility Highlight the Need for Improved Disease Management of Invasive Candidiasis. **2022**, 10, 1208 1

- 41 Salivary Gland Dysfunction Secondary to Cancer Treatment. 3, 1
- 40 The Edge of Unknown: Postoperative Critical Care in Liver Transplantation. **2022**, 11, 4036
- 39 An Epidemiologic Analysis of Vulvovaginal Candidiasis and Antifungal Susceptibilities. Publish Ahead of Print,
- 38 Talus osteomyelitis by *Candida krusei* with multiple huge cystic lesions: a case report and review of literatures. **2022**, 23,
- 37 Intestinal Flora-Derived Kynurenic Acid Protects Against Intestinal Damage Caused by *Candida albicans* Infection via Activation of Aryl Hydrocarbon Receptor. 13, o
- 36 Voice rehabilitation with voice prosthesis: Long term results, complications and risk factors. **2022**, 73, 219-224 o
- 35 Incidence of Endogenous Fungal Endophthalmitis in Screening Dilated Exams in Patients with Elevated Beta-D-Glucan Levels versus Positive Fungal Blood Cultures. Volume 16, 2743-2750 o
- 34 Antifungal activity of vitamin D3 against *Candida albicans* in vitro and in vivo. **2022**, 265, 127200 o
- 33 Clinical Management of Fungal Biofilm Infections. **2022**, 441-465 o
- 32 Epidemiology of Invasive Fungal Infections in Solid Organ Transplant Recipients: a North American Perspective. o
- 31 Post-Operative Infections Following Glaucoma Drainage Surgery. o
- 30 Incidence and risk factors of bacterial sepsis and invasive fungal infection (IFI) in neonates and infants requiring major surgery: an Italian multicenter prospective study. **2022**, o
- 29 Synthesis and Characterization of Derivatives of the Antifungal Peptoid RMG8-8. o
- 28 Expert group opinion for diagnosis and management of fungal infections in solid organ transplant recipients in South Asia. **2022**, 16, 41 o
- 27 Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases. **2022**, 13, 204209862211275 o
- 26 Evolution of Fluconazole Resistance Mechanisms and Clonal Types of *Candida parapsilosis* Isolates from a Tertiary Care Hospital in South Korea. o
- 25 Nystatin Effectiveness in Oral Candidiasis Treatment: A Systematic Review & Meta-Analysis of Clinical Trials. **2022**, 12, 1677 2
- 24 The recommended dosage regimen for caspofungin in patients with higher body weight or hypoalbuminaemia will result in low exposure: Five years of data based on a population pharmacokinetic model and Monte-Carlo simulations. 13, o

23	Incidence, clinical characteristics, risk factors and outcomes of patients with mixed Candida/bacterial bloodstream infections: a retrospective study. 2022 , 21,	0
22	In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.	1
21	Antifungal Agents. 2023 , 1564-1573.e4	0
20	Infections of the Oral Cavity. 2023 , 197-203.e2	0
19	Clinical Syndromes of Infection in Children With Cancer. 2023 , 604-610.e3	0
18	Isolation of moderately halotolerant bacterial strains, associated with coral <i>Porites lutea</i> from Gulf of Kachchh: Antibacterial activity and PHB production. 2023 , 218, 115006	0
17	Antifungal Stewardship Task Shifting Required of Pharmacists. 2022 , 63, 109-117	1
16	Kaempferol: Antimicrobial Properties, Sources, Clinical, and Traditional Applications. 2022 , 23, 15054	2
15	Distribution of candida species and risk factors for invasive candidiasis. 616-625	0
14	Osteoarticular Mycoses. 2022 , 35,	1
13	Copper- and Iodine-Doped Nanozymes with Simulated Enzyme Activity and Efficient Antifungal Activity against <i>Candida albicans</i> . 2022 , 108791	0
12	Cerebral infarction and thrombotic meningoencephalitis in a calf due to candidiasis. 2023 , 53,	0
11	Evaluation of candidemia in children at a university hospital: A retrospective cohort.	0
10	Prophylaxis of Antifungal Drugs against Systemic Fungemia induced by Oral Candidiasis in Mice. 2023 , 45, 1306-1313	0
9	Metal Chelation as a Promising Strategy to Combat Fungal Drug Resistance. 2023 , 271-280	0
8	Should Preventive Antifungal Treatment Be Given to Patients With Abdominal Contamination in the Intensive Care Unit?. 2023 ,	0
7	<i>Candida</i> Bezoar of the Bladder Resulting in Obstructive Uropathy: A Case Report. 2023 ,	0
6	Chemotherapy-Induced Oral Complications and Prophylaxis Strategies. 1-24	0

- 5 Oral Candidiasis: Pathogenesis, Clinical Presentation, Diagnosis and Treatment Strategies. **2013**, 41, 263-268 1
- 4 Fungal Infections. **2013**, 1483-1490.e1 o
- 3 Urinary tract infection in children: A narrative review of clinical practice guidelines. **2023**, 15, 113 o
- 2 Thymoquinone Antifungal Activity against *Candida glabrata* Oral Isolates from Patients in Intensive Care Units: An In Vitro Study. **2023**, 13, 580 o
- 1 Species Distribution and Antifungal Susceptibilities of *Candida* Species Isolated From Blood Culture. **2023**, o